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ABSTRACT OF DISSERTATION

AGING AND THE DYNORPHINERGIC SYSTEM:
EVALUATION OF MEMORY AND MOTOR SYSTEMS
IN PRODYNORPHIN KNOCKOUT MICE
Dynorphins, endogenous peptide neurotransmitters expressed in the central
nervous system, have been implicated in diverse pathophysiological processes, including
excitotoxicity, chronic inflammation, traumatic injury, cognitive impairment, and motor
dysfunction, with significant changes with aging or age-related disease processes. This
has led to the hypothesis that the suppression of dynorphin expression would produce
beneficial effects on learning and memory and motor function.
To assess the phenotypic manifestations of chronic suppression of endogenous
dynorphin, knockout (KO) mice lacking the coding exons of the gene encoding the
prodynorphin (Pdyn) precursor protein, were tested in a series of behavioral, biochemical,
and molecular biological studies. Moderately aged Pdyn KO perform comparatively
better than similarly aged wild-type (WT) mice in the water maze task, although no Pdyn
effect was seen among young adult mice. In addition, young adult Pdyn KO mice show
mildly improved performance on a passive avoidance task. Minimal baseline differences
were noted in spontaneous locomotor activity in an open-field assay, but Pdyn deletion
produced a relative sparing of motor dysfunction induced by the neurotoxin 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP).
To investigate the relationship between aging and brain dynorphin expression in
mice, we examined dynorphin peptide levels at varying ages in hippocampus, striatum,
and frontal cortex of WT mice by quantitative radioimmunoassay. While aging produces
progressive decline in Dyn B in striatum and frontal cortex, Dyn A shows an upward
trend in frontal cortex without significant change in striatum. Systemic MPTP produces
significant short-term elevations in dynorphin peptides that regress to below baseline by 7
days. HPLC analysis of striatal dopamine shows an age-dependent increase in basal
dopamine levels in Pdyn KO mice, an effect that is abolished after MPTP. Western

blotting experiments demonstrate that Pdyn deletion is associated with greater
phosphorylation at the serine-40 site of tyrosine hydroxylase (TH) despite relatively less
total TH immunoreactivity, suggesting a suppressive effect of dynorphins on dopamine
synthesis. Microarray analysis of hippocampal tissue from young and aged WT and Pdyn
KO mice reveals a number of functional groups of genes demonstrating altered
expression. The results of this dissertation support a role of endogenous dynorphins in
age-associated cognitive and motor dysfunction.
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CHAPTER 1:

Introduction

Dynorphins, endogenous opioid peptides found in specific pathways in the brain, have
recently received increased attention for their roles in a variety of physiological and
pathological processes. This dissertation will seek to examine the role of these peptides
in the brain during aging with regard to two major behavioral functionalities that are
compromised in normal aging and in age-related disorders. The first is learning and
memory, a major aspect of cognition that has been exensively studied across multiple
species and technical disciplines, but for which little is known about mechanisms
contributing to age-related impairment.

The second is motor function, a prominent

feature of both normal aging and pathological states such as Parkinson's disease. In both
these areas, dynorphin peptides have been suggested to influence behavioral endpoints.
This chapter will summarize the existing literature on the known properties and actions of
dynorphins, with particular attention to their roles in the above functional domains, and
establish the rationale for studies described in subsequent chapters.

Introduction to dynorphins
First isolated in 1979 (Goldstein et al., 1979), the dynorphins were described originally in
terms of their opiate properties, namely as

opioid receptor (KOR) agonists. Numerous

other studies since have identified other mechanisms by which these peptides influence
the many neurobiological processes in which they have been implicated.

Historically,

when these peptides were first identified, they were given the name “dynorphin” to
indicate their relatively high potency in an ileal tissue contractility inhibition assay when
compared to morphine (Goldstein et al., 1979). The term dynorphin generally refers to
peptides obtained by proteolytical cleavage of a polypeptide precursor encoded by the
prodynorphin (Pdyn) gene and most commonly refer to dynorphin A (Dyn A 1-17) or
dynorphin B (Dyn B 1-16) [reviewed in (Simonato and Romualdi, 1996; Hauser et al.,
2005)].

Other peptides obtained from this prodynorphin precursor include alpha-

neoendorphin (α-NE), "Big Dynorphin" (Dyn-32), leumorphin (Dyn B 1-29), Leucineenkephalin-arginine (Leu-Enk-Arg), and Leucine-enkephalin (Leu-Enk) (Hauser et al.,
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2005). Biochemically, dynorphin peptides are C-terminal extensions of Leu-Enk in that
they share the same five amino-terminal residues as Leu-Enk, thereby explaining some
the pharmacologic similarities between these classes of opiate peptides. Table 1.1 details
the amino acid composition of selected prodynorphin-derived peptides. Notably, these
peptides have a relatively high proportion of the basic amino acid residues lysine and
arginine, resulting in their high positive charge, which imparts certain biophysical
properties that can affect their biochemical interactions (Naqvi et al., 1998; Tan-No et al.,
2001; Marinova et al., 2005).
Table 1.1. Amino acid composition of selected prodynorphin-derived peptides.
Peptide

Sequence

Dynorphin A (1-17)
Dynorphin A (2-17)
Dynorphin A (1-13)
Dynorphin B
Dynorphin 32 (Big Dynorphin)
-neo-endorphin
-neo-endorphin

YGGFLRRIRPKLKWDNQ
GGFLRRIRPKLKWDNQ
YGGFLRRIRPKLK
YGGFLRRQFKVVT
(Dyn A)-KR-(Dyn B)
YGGFLRKYP
YGGFLRKYPK

Anatomical distribution of dynorphin peptides
Immununohistochemistry and in situ hybridization studies have demonstrated that
dynorphin peptides are widely distributed in the central nervous system (CNS)
(Khachaturian et al., 1982; Watson et al., 1982a; Watson et al., 1982b; Hurd et al., 1999).
High Pdyn mRNA levels have been noted in hypothalamus, nucleus accumbens,
neostriatum, dentate gyrus, hippocampus, cerebral cortex, and spinal cord (Khachaturian
et al., 1993; Yakovleva et al., 2006b). One particular area of interest is the hippocampal
formation, where dynorphins are prominent in mossy fiber terminals (McGinty et al.,
1983; Zamir et al., 1985). Prodynorphin precursors are synthesized in granule cells of the
dentate gyrus and transported along the axons of the mossy fiber pathway to terminate at
synapses in the CA3 region of the hippocampus. In addition to the mossy fiber-CA3
pyramidal cell synapses, dynorphins have also been identified at perforant path-granule
cell synapses and mossy fiber recurrent synapses in the dentate gyrus (Wagner et al.,
1993; Terman et al., 1994; Terman et al., 2000).

2

Dynorphins are also distributed in the striatonigral system. Within the striatum,
dynorphins are found predominantly colocalized with substance P and GABA within
dopamine D1-receptor (D1R)-expressing striatonigral projection neurons [reviewed in
(Steiner and Gerfen, 1998)]. Striatal dynorphinergic neurons project to the substantia
nigra (SN) and contact tyrosine hydroxylase (TH)-positive dopaminergic neurons (Pickel
et al., 1993). Since

opioid receptors are found on presynaptic terminals in striatum and

on glutamatergic neurons projecting from the subthalamic nucleus to the globus pallidus
(Abou-Khalil et al., 1984), the neuroanatomical distribution of dynorphins favors a
opioid-mediated mechanism by which dynorphins can regulate dopamine (DA) release
and/or function in the striatum. A recent study employing electron microscopy with dual
labeling of prodynorphin and either D1R or TH in the rat nucleus accumbens showed that
a majority (63%) of prodynorphin-containing dendrites colocalized with the D1R (Hara
et al., 2006).

Moreover, axon terminals containing Pdyn frequently made synaptic

connections with D1R-containing dendrites and TH-containing axon terminals. The
ultrastructural evidence thus supports a mechanism whereby dynorphin peptides can
readily modulate

dopamine

release

or

its

postsynaptic

effects.

Similarly,

neuroanatomical colocalization of dynorphins with gonadotropins (Knepel et al., 1985)
and with vasopressin (Sherman et al., 1986) has also been reported in the anterior
pituitary and hypothalamus, respectively.
Outside of the CNS, dynorphin peptides are found in a wide range of tissue and
organ types, including adrenal glands, heart, lung, and reproductive organs (Simonato
and Romualdi, 1996). Additionally, dynorphin-responsive opioid receptors have been
found on dendritic cells of mice (Kirst et al., 2002), and dynorphin is found in
sympathetic neurons in the liver in close approximation to

-receptor-expressing

lymphocytes (Kaiser et al., 2003), suggesting a role in neuroimmunomodulation.

Regulation of dynorphin expression
The control of dynorphin expression occurs at a number of levels. The molecular biology
of the Pdyn gene shows the presence of various sites that may be modulated by
transcription factor binding (Simonato and Romualdi, 1996). Its promoter contains a
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functional AP-1 element (Naranjo et al., 1991; Bronstein et al., 1994), and antisense c-fos
mRNA has been found to reduce Pdyn mRNA levels in vitro (Hunter et al., 1995), which
suggests that basal expression of dynorphins are at least partially mediated via the AP-1
site. The rat Pdyn promoter contains four distinct cAMP response elements (CREs), and
when bound by CREB, these elements suppress Pdyn transcription (Collins-Hicok et al.,
1994) and can potentially enhance memory processes (Josselyn et al., 2001; Nguyen,
2001). In the nucleus accumbens, CREB has been shown to increase Pdyn mRNA
expression (Carlezon et al., 1998). The Downstream Regulatory Element Antagonistic
Modulator (DREAM) transcription factor has been shown to block Pdyn expression in
spinal cord (Cheng et al., 2002), and this inhibition also occurs in pancreatic islet cells
during low-calcium states (Jacobson et al., 2006). Nitric oxide and cyclic GMP (cGMP)
have also been implicated in suppressing Pdyn gene expression. In the hippocampus,
injection of the nitric oxide donor Sin-1 or the cGMP analogue 8-bromo-cGMP reduced
Pdyn mRNA levels (Johnston and Morris, 1994, 1995), as did injection of NMDA
(Johnston and Morris, 1995). Moreover, the nitric oxide synthase inhibitor L-NAME can
block the amphetamine-induced increase in Pdyn mRNA expression in the striatum and
amygdala (Przewlocka et al., 1996). Dynorphin gene expression is also enhanced in
embryonic stem cell nuclei by exposure to Dyn B, suggesting the presence of a
feedforward control system via nuclear

receptors (Ventura et al., 2003).

Environmental and biological factors that are associated with Pdyn gene
expression have also been identified. Dynorphin peptides are increased by various types
of cellular stressors. Traumatic spinal cord injury causes localized increases in spinal
cord dynorphins beginning within hours of the insult and lasting weeks, without a
corresponding change in enkephalin (Faden et al., 1985a, b). Inoculation of mycobacteria
to induce joint swelling and inflammation in rats as a model for chronic pain resulted in
increased dynorphin levels in anterior pituitary, hypothalamus, and spinal cord (Millan et
al., 1985), as does a Freund’s adjuvant model of peripheral inflammation (Iadarola et al.,
1986).

The increase in dynorphin expression in spinal cord following peripheral

inflammation is enhanced in aged animals (Zhang et al., 2004a). In addition, dynorphin
expression in the hippocampus increases following systemic administration of kainic
acid, particularly during the process of mossy fiber sprouting (Simpson et al., 1997).
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Surgical lesioning of the perforant path also mimics this effect (Thai et al., 1996).
Normal aging is also associated with changes in the dynorphinergic system. Age-related
changes in Dyn peptide or Pdyn mRNA expression have been noted in the rodent
hippocampus and cortex (Jiang et al., 1989; Zhang et al., 1991; Gallagher and Nicolle,
1993). Alterations in CREB expression (Collins-Hicok et al., 1994) or binding at the AP1 site in the Pdyn promoter (Naranjo et al., 1991; Collins-Hicok et al., 1994; Hunter et al.,
1995; Kitamura et al., 1995) could increase transcription and thus represent feasible
molecular mechanisms for increased Pdyn with age. Prior studies had shown significant
increases of approximately 50% in dynorphin immunoreactivity in the hippocampus and
frontal cortex of aged rats, especially aged rats who were also memory-impaired (Jiang et
al., 1989; Gallagher and Nicolle, 1993). Elevated levels of dynorphin A(1-8) in the
hippocampus and frontal cortex were correlated with deficits in Morris water maze
performance (Jiang et al., 1989) and with decreased glutamate release (Zhang et al.,
1991). Increased dynorphin immunoreactivity was also observed in the supragranular
layer and mossy fiber system of amyloid precursor protein (APP)-overexpressing mice
(Diez et al., 2000). In humans, dynorphin A is markedly elevated in the frontal cortex of
patients with Down syndrome or Alzheimer’s disease (AD) (Risser et al., 1996). In
models of PD, several studies have observed decreases in Dyn following experimental
manipulations that lesion the nigrostriatal dopaminergic pathway (Gerfen et al., 1991),
produce dopamine depletion as in suppression of the vesicular monoamine transporter
type 2 (VMAT2) gene (Colebrooke et al., 2007), or cause decreased dopamine receptor
activity as in D1-receptor knockout mice (Wong et al., 2003).

Pharmacology of dynorphins
Because the known pharmacological activity of dynorphins is not limited to their
interaction with the KOR, their effects in vivo have been difficult to fully characterize,
and many effects of the prodynorphin-derived peptides may vary from one organ system
to the next [reviewed in (Hauser et al., 2005)]. The interaction at the

opioid receptor

was the first effect of dynorphins to be characterized, with their particularly high affinity
for the κ opioid receptor (Goldstein et al., 1979; Chavkin et al., 1982) (Goldstein and
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Naidu, 1989) that requires the N-terminal tyrosine residue. Although the affinity of
dynorphin for κ opioid receptors is within the picomolar range, physiological
concentrations of dynorphins are still capable of binding to μ and δ opioid receptors
(Garzon et al., 1984).
Interestingly, dynorphins at supraphysiological levels demonstrate significant
interactions with the NMDA receptor (Chen et al., 1995a, b; Chen and Huang, 1998;
Tang et al., 1999), presumed to be mediated by C-terminal residues. Depending on the
particular experimental conditions, the dynorphin peptides can bind to the NMDA
receptor and either block or potentiate NMDA receptor activation (Brauneis et al., 1996;
Shukla et al., 1997; Zhang et al., 1997; Caudle and Dubner, 1998; Tang et al., 1999).
Mass spectrometry studies have confirmed that the positively charged residues of
dynorphin A 1-17 and its non-opioid counterpart dynorphin A 2-17 allow the peptides to
form stable complexes with a conserved epitope on the NR1 subunit of the NMDA
receptor that consists of five adjacent glutamate residues and an aspartate residue (Woods
et al., 2006). Dynorphins have also been reported to act at sites that are not affected by
either opioid or NMDA antagonists (Tang et al., 2000), including direct non-covalent
interactions with the excitatory amino acids glutamate and aspartate (Woods and Zangen,
2001), likely a result of their highly basic amino acid constituency.

Additionally,

dynorphin peptides have also been observed to possess cell-penetrating capabilities and
interact directly with phospholipid membranes (Lind et al., 2006).

The complex

pharmacologic activity of dynorphin peptides presents a difficulty when using specific
pharmacological antagonists to evaluate the role of dynorphins in a particular
experimental system, since the use of even highly selective opioid agonists or antagonists
may not be sufficient to distinguish clearly the extent to which dynorphins contribute to a
given physiological effect.

Review of physiological and pathological processes involving dynorphins
The fairly broad interactions of dynorphins across multiple receptor and organ systems
have hindered attempts to elucidate fully the functional significance of dynorphinergic
activity in vivo. The literature, however, does support a role of dynorphin peptides in
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certain neurobiological functions, which include learning and memory, motivation, pain
and nociception, modulation of seizure threshold, motor activity, and a variety of other
physiological processes. Regarding the role of dynorphins in learning and memory,
several behavioral studies point toward a detrimental effect of excess dynorphin. Aged
rats, for instance, exhibit increases in hippocampal dynorphin that correlate with spatial
memory impairment (Jiang et al., 1989; Gallagher and Nicolle, 1993). Microinjection of
dynorphin B into the rat hippocampus similarly showed impaired performance in the
Morris water maze task (Sandin et al., 1998), and this effect was blocked by the selective
κ opioid antagonist nor-binaltorphimine, while nor-binaltorphimine alone had no effect
(Sandin et al., 1998). Dynorphin was also found to dose-dependently impair retention in
an inhibitory avoidance task in mice (Introini-Collison et al., 1987), and direct infusion of
dynorphin A(1-8) into the hippocampus dose-dependently impairs spatial memory in rats
(McDaniel et al., 1990). Electrophysiological studies support an ability of dynorphin to
inhibit neural plasticity by blocking long-term potentiation (LTP), by mechanisms that
may include presynaptic inhibition of glutamate release via κ opioid receptors or
postsynaptic modulation of LTP as a retrograde inhibitory neurotransmitter (Wagner et
al., 1992; Wagner et al., 1993; Weisskopf et al., 1993). From human studies, AD patients
have been noted to exhibit large increases in κ opioid receptor levels (Hiller et al., 1987)
and Dyn A (Yakovleva et al., 2006a), and cognitive performance in AD patients can be
improved by the nonselective opioid antagonist naloxone (Reisberg et al., 1983). On the
other hand, dynorphin activity in the cholinergic system has been noted to be more
favorable to learning in memory, as it reduces passive avoidance task deficits induced by
mecamylamine (Hiramatsu et al., 1997; Hiramatsu and Watanabe, 2006) or galanin
(Hiramatsu et al., 1996).
Pain control is a common clinical indication for opiate use in general, although
the

opioid receptor is seldom specifically targeted. In contrast to other classes of

opioids, dynorphins have minimal analgesic effects in the brain (Friedman et al., 1981).
While dynorphin peptides can antagonize analgesic effects in opiate-naïve subjects, they
may also potentiate analgesia in morphine-tolerant animals [reviewed in (Smith and Lee,
1988)] while exhibiting minimal withdrawal effects (Khazan et al., 1983), suggesting a
modulatory role of dynorphins in the pain processing in the brain.
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In spinal cord,

intrathecal dynorphin administration at low concentrations produces analgesia mediated
by opioid receptors, but at higher concentratrions can cause allodynia (Vanderah et al.,
1996; Laughlin et al., 1997), flaccid hindlimb paralysis (Faden and Jacobs, 1984; Stevens
and Yaksh, 1986; Long et al., 1988a; Long et al., 1988b), and neuronal and axonal injury
(Caudle and Isaac, 1987; Long et al., 1988a; Long et al., 1988b; Hauser et al., 2001). In
fact, a growing body of literature supports a role of dynorphins in exacerbating
neuropathic pain, particularly in spinal cord injury models (Lai et al., 2001).

Moreover,

these latter effects are not mitigated by an opioid antagonist nor by substituting peptides
lacking the N-terminal tyrosine residue needed for opiate receptor interactions. This
implicates the involvement of non-opioid-mediated mechanisms (Bakshi and Faden,
1990; Vanderah et al., 1996; Shukla et al., 1997; Hauser et al., 2001), such as those
involving the NMDA receptor (Caudle and Isaac, 1988; Bakshi and Faden, 1990).
Blocking dynorphin by administering synthetic peptides containing the NR1 epitope of
the NMDA receptor prevents neurotoxicity in cell culture experiments and in in vivo
models of dynorphin-induced allodynia and paralysis (Woods et al., 2006).
Additionally, the effects of dynorphins on glutamate and aspartate release are believed to
contribute to excitotoxic mechanisms that may exacerbate cellular injury under
appropriate circumstances. Intrahippocampal dynorphin injections produce elevations in
excitatory amino acids in a non-opioid-dependent manner (Faden, 1992).

Potential

mechanisms include dynorphin-induced increases in intracellular calcium, as previously
observed in cultured cortical neurons and dorsal root ganglion cells (Tang et al., 2000;
Lai et al., 2001).
In contrast to the excitotoxicity roles noted above, dynorphins also have known
anticonvulsant actions (Przewlocka et al., 1983; Siggins et al., 1986) and inhibitory
effects on neuronal activity and neurotransmission (Chavkin, 2000). Dynorphins can
block glutamate release via κ opioid receptors and post-synaptically modulate LTP
(Wagner et al., 1992; Wagner et al., 1993; Weisskopf et al., 1993). Pdyn deletion
decreases seizure threshold in the kainic acid model (Loacker et al., 2007).
Dynorphins have also been implicated in inflammation, with in vitro
administration producing a non-opioid-dependent histamine release from rat mast cells
(Sydbom and Terenius, 1985) and in vivo experiments showing dynorphin-induced
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plasma extravasation in rat skin (Chahl and Chahl, 1986). In models of chronic pain and
peripheral inflammation, dynorphin immunoreactivity increases in conjunction with
appearance of chronic nociceptive behavioral patterns and immediate-early gene
expression (Noguchi et al., 1991; Gillardon et al., 1994; Zhang et al., 2005), and these
changes can be suppressed by anti-sense oligonucleotides against c-fos (Gillardon et al.,
1994; Zhang et al., 2005). While Pdyn-derived peptides are not required for initiation of
neuropathic pain in a spinal nerve ligation model, they are elevated by approximately 10
days post-ligation and are needed for maintenance of chronic neuropathic pain (Wang et
al., 2001). In models of spinal cord hyperalgesia, intrathecal dynorphin injection causes
release of prostaglandin and excitatory amino acids in cyclooxygenase-dependent and
opiate-independent mechanisms (Koetzner et al., 2004).
The role of dynorphin peptides in the motor system, including the dopaminergic
nigrostriatal pathway, has also begun to receive increased attention in the literature. In
the striatum and nucleus accumbens, dynorphins and exogenous

agonists have clearly

been shown to inhibit dopamine release (Mulder et al., 1984; Herrera-Marschitz et al.,
1986; Di Chiara and Imperato, 1988; Reid et al., 1988; Spanagel et al., 1992; Ronken et
al., 1993; Schlosser et al., 1995), while

antagonists can elevate basal DA release

(Spanagel et al., 1992). Dynorphins also reduce glutamate release in output regions of
basal ganglia (Maneuf et al., 1995). Striatal neurons are also susceptible to dynorphininduced apoptosis in cell culture models (Tan-No et al., 2001).

Moreover, striatal

neurons transfected with Dyn-32 (a.k.a. “big dynorphin”) exhibit cytotoxic effects (TanNo et al., 2001). In terms of functional behavioral manifestations, administration of high
doses of dynorphin peptides into brain regions were demonstrated in early studies to
induce barrel rotation in rats in a naloxone-independent manner (Smith and Lee, 1988),
while intrathecal dynorphin administration induces flaccid paralysis (Smith and Lee,
1988). More recent studies have shown that activation of the
suppress locomotion; for instance, in rats, the

opioid receptor tends to

agonist CI-977 decreased locomotion in a

naloxone-reversible manner (Fernandez et al., 1999).

-opiate receptor deficient mice

show similar spontaneous locomotor activity compared to WT but are resistant to the
decreased locomotor activity that accompanies administration of
al., 1998).
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agonists (Simonin et

The endocrine system is also affected by endogenous dynorphins. Dynorphin
elevates serum prolactin presumably by lowering dopaminergic tone in the
tuberoinfundibular system (Kreek et al., 1999), thereby removing the inhibitory effect of
dopamine on prolactin release. Estrogens also appear to control Pdyn expression in the
anterior pituitary (Spampinato et al., 1995).

Also, dynorphin A(1-17), via a

opioid

receptor mechanism, can stimulate glucagon release from pancreatic alpha cells
(Jacobson et al., 2006). Dynorphin in the hypothalamus colocalizes with vasopressin
(Sherman et al., 1986), and

opioid agonists and dynorphin analogues have been

demonstrated to induce water diuresis via negative regulation of antidiuretic hormone in a
opioid-dependent manner (Currie et al., 1994; Ohnishi et al., 1994). Furthermore,
dynorphins increase serum levels of adrenocorticotropic hormone (ACTH) in both ovine
and murine models (Cheng et al., 2000; Nardo et al., 2002).

A putative role of

dynorphins in negative feedback of gonoadotropin acticvity has also been proposed, as
progesterone increases Dyn A in cerebrospinal fluid and Pdyn mRNA in hypothalamus,
with resultant inhibition of pulsatile gonatotropin-releasing hormone activity (Goodman
et al., 2004; Foradori et al., 2005). Other effects of dynorphin peptides that have been
reported include decreased blood pressure and heart rate, respiratory depression, body
temperature regulation, and appetite stimulation (Smith and Lee, 1988).

Fasting

increases Pdyn expression, while Pdyn suppression increases fatty acid oxidation and
weight loss (Sainsbury et al., 2007).

Aging and the dynorphinergic system
Since dynorphins have been implicated in aging, the neurobiology of aging will be briefly
reviewed here. Aging is associated with a number of physical and behavioral alterations,
often with distinct neurobiological and neurochemical changes in the CNS and
commonly associated with functional declines in nervous system function that lead to
sensory, motor, cognitive, and numerous other types of deficits. Cognitive changes
represent an important component of brain aging that has clear relevance to an
individual’s functional status. Rat behavioral studies in particular have documented
significant aging declines in cognitive tasks (Barnes, 1987; Greene and Naranjo, 1987).
Recent evidence suggests that cognitive decline in most cases cannot be explained solely
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by decreased neuronal numbers in the aged brain. Age-related deficits in learning and
memory are typically attributed not only to varying degrees of degenerative neuronal loss
but also to functional decreases in neurotransmission or neural plasticity. One of the
most widely studied regions related to cognition is the hippocampus. Numerous studies
have attempted to assess whether hippocampal size, volume, or neuronal number is
altered with age (Miller and O'Callaghan, 2003).

While earlier studies concluded

widespread decreases in neuronal density in hippocampus, more recent unbiased
stereological counting techniques revealed only small or nonsignificant declines. For
instance, one study found stereological estimates of hippocampal volume to decrease
only 2.16% compared to normal adult mice (von Bohlen und Halbach and Unsicker,
2002). Neuronal density in hippocampus in this study was found to demonstrate a
nonsignificant decrease of 4-7%.

While studies in humans have noted progressive

decline in certain tasks beginning in early young adulthood, the mechanisms underlying
these changes have been difficult to identify.
Motor impairments with normal aging have been found across multiple species
and are likely due to impairments in the dopamine neurotransmitter system in basal
ganglia motor pathways (Ingram, 2000). Dopamine, synthesized by neurons in the SN
projecting to the striatum, has been strongly implicated in aging (Reeves et al., 2002).
For instance, some early studies have reported substantial declines in normal aged
humans from young adult levels (Kish et al., 1992). One study (Kish et al., 1992)
observed a statistically significant 60% loss of dopamine in human postmortem striatal
specimens in normal 84-year-olds compared to normal 22-year-olds. However, recent
studies have concluded that the decreases typically attributed to aging are of much
smaller magnitude (Friedemann and Gerhardt, 1992; Burwell et al., 1995; Hebert and
Gerhardt, 1998; Stanford et al., 2003). One study in mice (Greenwood et al., 1991) found
no age-related change in DA and its metabolite 3,4-dihydroxyphenylacetic acid
(DOPAC) relative to striatal wet weight.

However, these monoamine levels were

increased 5- to 7-fold at 21 months of age compared to at 2 months when expressed
relative to the proportion of remaining TH-positive neurons, suggesting the existence of
compensatory effects.

In pathological states such as Parkinson’s disease, clinically

manifested by symptoms of bradykinesia, gait and posture disturbances, rigidity, and
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resting tremor (Hornykiewicz and Kish, 1987; Forno, 1996), severe dopaminergic
neuronal loss in SN is observed (Graybiel et al., 1990), with age as the most identifiable
risk factor for sporadic cases of PD. In addition, dopamine dysfunction may also affect
cognition as well (Nieoullon, 2002; Marie and Defer, 2003; Nieoullon and Coquerel,
2003; Pillon et al., 2003; Remy and Samson, 2003). The mechanisms by which
dopaminergic neuron loss occurs either in normal aging or in pathological conditions are
currently unknown.
The role of dynorphin peptides in Parkinson’s disease is controversial with at least
one study reporting decreased dynorphins in SN of PD patients (Waters et al., 1988) and
some reporting no change (Taquet et al., 1985; Baronti et al., 1991). Although

agonists

have been evaluated for therapy in a small clinical trial of PD patients based on
hypothesized effects on glutamatergic neurons, they were not found to have any
discernable effects of motor performance and in fact exhibited dose-limiting adverse
effects, including behavioral aberrations (Giuffra et al., 1993).

Overview of experimental aims
The experimental studies described in this dissertation primarily involve behavioral,
biochemical, and molecular biological studies in mice. Specifically, we make use of a
strain of knockout (KO) mice lacking the coding exons of the Pdyn gene (Sharifi et al.,
2001). These mice do not exhibit any gross developmental, morphological, or overt
behavioral deficits (Sharifi et al., 2001).

To minimize effects related to genetic

background variation, these mice were maintained within the 129SvEv background and
compared to 129SvEv WT mice as controls.

The use of Pdyn KO mice offers several

distinct advantages over studies employing exogenously administered agents. First, acute
stresses related to experimental manipulations are minimized.

Second, complexities

associated with the pharmacodynamics and pharmacokinetics of peptide agents, including
limitations on in vivo half-lives and distribution or delivery issues, are circumvented.
Third, because potential dynorphin interactions include more than the

opioid receptor,

the approach of employing knockout mice enables analysis of effects of Pdyn suppression
at the gene expression level without necessitating assumptions regarding the types of
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receptors involved. In addition, long-term effects and compensatory mechanisms, such
as those associated with aging, can be more readily evaluated.

The experiments

described in this dissertation therefore represent novel approaches that would
complement and enhance existing knowledge of dynorphin peptides in cognition and
motor function.
To address the effect of Pdyn deletion on learning and memory impairment with
age, a series of behavioral experiments will be described in which WT and Pdyn KO
mice are tested in both spatial and nonspatial learning tasks.

Spatial learning and

memory was assessed using a Morris water maze paradigm (Morris et al., 1982), and
non-spatial tasks include both a passive avoidance task, which uses an aversive footshock stimulus, and a paired object recognition assay. The role of dynorphins in motor
function was evaluated using open-field analysis of spontaneous locomotion and
quantitation of striatal content of dopamine and related monoamines under basal
conditions and following systemic administration of the neurotoxin 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP).

Next, we will discuss quantitaion of dynorphin

peptides in varying regions of the aging or MPTP-treated mouse brain using
radioimmunological methods. Finally, gene expression changes with aging and Pdyn
deletion were systematically analyzed to identify patterns of upregualted or
downregulated genes that may shed light on potential mechanisms to explain the
behavioral and neurochemical findings reported in this dissertation.

Copyright © Xuan V. Nguyen 2007
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CHAPTER 2:

Prodynorphin knockout mice demonstrate diminished age-

associated impairment in spatial water maze performance

Introduction
The endogenous opioid peptide dynorphin, expressed widely in the central nervous
system (Khachaturian et al., 1982; Watson et al., 1982a; Watson et al., 1982b; Hurd et al.,
1999) and particularly prominent in mossy fiber terminals of the hippocampal formation
(McGinty et al., 1983; Zamir et al., 1985), has been implicated in modulating learning
and memory. Dynorphin peptides are pharmacological agonists at
(Chavkin et al., 1982), and to a lesser extent

and

opioid receptors

receptors (Garzon et al., 1984), but

have been observed to interact with other non-opioid targets like the NMDA receptor
(Chen et al., 1995a, b; Chen and Huang, 1998; Tang et al., 1999) and even the excitatory
amino acids themselves (Woods and Zangen, 2001).

The effects of endogenous

dynorphins in learning and memory are supported by reports of their ability to inhibit
neural plasticity by blocking long-term potentiation (LTP) at mossy fiber-CA3 pyramidal
cell synapses, perforant path-granule cell synapses, and mossy fiber recurrent synapses in
the dentate gyrus (Wagner et al., 1993; Terman et al., 1994; Terman et al., 2000). The
mechanisms involved include presynaptic inhibition of glutamate release via κ opioid
receptors and postsynaptic modulation of LTP as a retrograde inhibitory neurotransmitter
(Wagner et al., 1992; Wagner et al., 1993; Weisskopf et al., 1993).
Behavioral studies have documented an inhibitory effect of this neuropeptide on
learning and memory. In vivo approaches in rats have demonstrated impairment of
spatial memory upon intrahippocampal injection of dynorphin A(1-8) (McDaniel et al.,
1990) or dynorphin B (Sandin et al., 1998).

Dynorphin was also found to dose-

dependently impair retention in an inhibitory avoidance task in mice (Introini-Collison et
al., 1987). The findings that dynorphin is elevated in hippocampus and frontal cortex of
aged rats, especially memory-impaired rats (Jiang et al., 1989; Gallagher and Nicolle,
1993), further suggested a possible involvement of dynorphins in age-related memory
deficits. Of particular relevance to human disease, dynorphin A is markedly elevated in
the frontal cortex of patients with Down syndrome or Alzheimer’s disease (AD) (Risser
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et al., 1996) and in mice overexpressing human amyloid precursor protein (Diez et al.,
2000). Large increases in κ opioid receptor levels have also been noted in brains of AD
patients (Hiller et al., 1987), and cognitive performance in AD patients can be improved
by the nonselective opioid antagonist naloxone (Reisberg et al., 1983).
A definitive causative role of increases in dynorphin in producing memory
deficits associated with normal aging has not been clearly established, and cellular and
genetic mechanisms related to its effect in the hippocampus and other parts of the brain
have not been carefully explored.

To investigate the mechanisms underlying age-

dependent changes in spatial learning and memory and the potential role of dynorphins in
mediating these changes, we examine in this study the effects of aging in knockout mice
lacking the coding exons for the precursor prodynorphin (Pdyn) (Sharifi et al., 2001).

Materials and Methods
Animal subjects
All animals in this study were wild-type (WT) or Pdyn KO mice that were maintained in
an approved animal facility at the University of Kentucky. WT mice were derived from
the 129SvEv-Tac line, and Pdyn KO mice were originally obtained by targeted deletion
of the coding exons of the prodynorphin gene and bred into a 129SvEv-Tac background
as previously described (Sharifi et al., 2001). These KO mice demonstrate no serious
structural, developmental, or behavioral phenotypic impairment (Sharifi et al., 2001). To
minimize effects of genetic background variation, the WT and Pdyn KO mice used in this
study were obtained from offspring of multiple matings between Pdyn KO and WT mice.
The aged mice included in this analysis ranged from 13 to 17 months at the time of
testing, averaging 15.8 ± 2.0 (mean ± S.D.) months for WT and 15.2 ± 1.8 months for
KO. Young mice were 3 to 6 months, averaging 4.1 ± 1.8 months for WT and 3.9 ± 1.5
months for KO. Animals were housed in groups of up to 4 per cage with food and water
ad libitum in a well-ventilated room with a 12 h: 12 h light: dark cycle. Prior to weaning,
tail specimens were collected from each animal, and DNA was extracted for subsequent
genotyping to confirm the identity of the Pdyn locus by the polymerase chain reaction
(PCR) using primer pairs specific for each genotype as described previously (Sharifi et
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al., 2001). The following primers were used in the PCR assay to detect deletion of the
coding

exons

of

Pdyn:

5'-ATCCAGGAAACCAGCAGCGGCTAT-3'

and

5'-

ATTCAGACACATCCCACATAAGGACA-3'. The primers used to detect WT alleles at
the

Pdyn

locus

were

5'-CAGGACCTGGTGCCGCCCTCAGAG-3'

and

5'-

CGCTTCTGGTTGTCCCACTTCAGC-3'. The products were amplified in a PerkinElmer thermal cycler at 94°C for 5 min, followed by 30 cycles of 94°C for 30 sec, 65°C
for 30 sec, and 72°C for 30 sec. Samples were then incubated at 72°C for 5 min,
followed by electrophoresis on 1% agarose gels containing ethidium bromide and
visualization under ultraviolet (UV) lighting.
behavioral experiments.

Only male mice were used in the

All procedures involving animals are approved by the

Institutional Animal Care and Use Committee at the University of Kentucky.

Water maze spatial navigation testing
The Morris water maze protocol used in this study was an adaptation of that used
previously in the detection of subtle spatial learning and memory differences (Fugger et
al., 1998). Water maze tests were conducted in a 1-m-diameter circular pool within an
isolated well-lit room containing a number of two- and three-dimensional cues external to
pool. The water was opacified by toxic white powdered paint and held at a constant
temperature of 27±2oC. The water maze testing procedure involves one day of the cued
phase of the water maze task, followed by three consecutive days of the spatial (hidden
platform) phase. Twelve trials were performed per day, grouped into four blocks of three
trials each. An interval of 20 sec was placed between trials of the same block, with a 15to 20-minute interval between blocks. During the cued phase, a visible rod was affixed to
the platform, and the platform location and release points were varied across trials to
ensure that the vector from the release point to the platform changes between each
successive pair of trials. Animals that did not escape more than three times during the
last six trials of cue discrimination training were considered to have deficits in motivation
or sensorimotor function and were removed from the study. During spatial water maze
testing, the platform location was fixed at a constant position 23 cm from the perimeter of
the pool in the center of a predetermined quadrant, and the release points were selected
according to a predetermined pseudorandom schedule from the three non-target
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quadrants. In both the cued and spatial tasks, the mouse was allowed to search for the
platform for a maximum of 60 seconds, after which it was guided to the platform and
allowed to remain on the platform for 10 seconds. Video monitoring and tracking were
performed for each trial using Water Maze v3.44 software interfaced with a Videomex
recording system (Columbus Instruments, Columbus, Ohio) to record swim distances,
quadrant preferences, platform crossings, and average proximity to platform.

The

penultimate trial of each day of spatial water maze testing was an acquisition probe trial
to assess intra-day spatial learning, and the first trial of Days 2 and 3 of the spatial phase
served as 24-hour retention probe trials to record how accurately the mice retain the
correct location of the target platform from the previous day of training.

Latency and path length analysis
Latency to platform was recorded using a stopwatch or digital timer to assess the total
time from release of the subject into the pool until the subject successfully climbed onto
the platform. Mice failing to locate the platform within the allotted minute were assigned
a latency of 60 sec. Path length was recorded automatically by the video monitoring
software based on the visual contrast between the mouse and the surrounding water.
Occasional light artifacts were automatically removed by the video processing software,
and additionally, all trajectories were screened manually in a blinded fashion to eliminate
path length values for trials containing an unacceptably high content of light artifacts that
were not removed by the automated artifact removal algorithm.

Probe trial analysis
The total time of each 60-second probe trial spent in each of the four quadrants was
recorded by the video processing software and was used to calculate the percentage of
time the subject spent in the target or opposite quadrants. During each probe trial, the
number of platform crossings during the 60-second interval was also recorded
automatically by the video processing software as detailed below. A circular area 10 cm
in diameter was defined in the center of the target quadrant at the position of the target
platform, and an automated counter recorded the number of times the animal subject
traversed the defined area. To minimize the effects of differences in motor activity or of
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random search strategies, equivalent areas were similarly defined in each of the other
three quadrants, and the number of these non-target crossings were averaged and
subtracted from the number of target platform crossings to obtain a net platform crossings
index. The expected value of this index in the absence of a spatial memory-dependent
search strategy is therefore taken to be zero. Average proximity to platform for each
probe trial was also similarly recorded by the water maze analysis software.

Swim speed measurement
Average swim speed was estimated for each mouse by taking the mean swim distances
recorded by the tracking software in each of the five probe trials and dividing by 60 sec,
the probe trial duration.

Dynorphin A extraction and radioimmunoassay (RIA)
Frontal cortical and hippocampal tissue were isolated from 3-month (n = 8) and 12-month
(n = 5) male WT mice following rapid asphyxiation by CO2 and were frozen in liquid
nitrogen prior to being processed for radioimmunoassay as previously described
(Christensson-Nylander et al., 1985; Christensson-Nylander and Terenius, 1985;
Nylander et al., 1991). Briefly, tissues were incubated in 1 M hot acetic acid containing
0.01% mercaptoethanol, homogenized by sonication, heated again to 95°C, and
subsequently centrifuged. The resulting supernatant was applied onto ion exchange
columns, and the resulting fractions dried using a vacuum centrifuge and redissolved in
methanol/0.1 M HCl prior to radioimmunoassay. Dynorphin A (Dyn A) was radiolabeled
with 125I using chloramine T, and the labeled peptide was purified by high pressure liquid
chromatography (HPLC).

Samples or standards were incubated with antiserum

overnight, and antibody-bound peptide was separated from free peptide by the nonimmune globulin precipitation method prior to quantitation. One hippocampal specimen
in the 3-month group was lost due to technical reasons.

Statistical analysis
Statistical analyses were performed using Systat 10 software (SPSS Inc., Chicago,
Illinois). Three-way ANOVA with repeated measures was used in conjunction with
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selected a priori comparisons to determine statistical significance between groups and
across trials or days in the behavioral experiments. To determine whether the distribution
of a particular measured variable, such as net platform crossings index, differs from that
expected by chance, a one-sample Student’s t-test was used for comparison with the
appropriate reference mean. The effect of age on dynorphin levels as measured by
radioimmunoassay was analyzed by the Student’s t-test. Statistical significance was
determined based on a p-value less than 0.05.

Results
Water maze
A total of 18 aged Pdyn KO mice, 17 aged WT mice, 11 young Pdyn KO mice, and 13
young WT mice were initially tested on the cue discrimination task to assess visual
acuity, sensorimotor function, and general motivation. Two animals, both aged Pdyn KO
mice, failed to consistently locate the visible platform and were removed from the study.
Based on the remaining mice, all four groups showed significant learning effects across
the four blocks of the cued task (Figure 2.1), as determined by a repeated-measures
ANOVA on either block-averaged latencies [F(3, 159) = 53.3, p<0.0005] or path lengths
to platform [F(3, 132) = 40.2, p<0.0005]. Not unexpectedly, latencies for the younger
groups approached optimal values earlier than for the aged groups, resulting in a
significant age effect [F(1, 53) = 9.90, p<0.003] and learning-age interaction [F(3, 159) =
5.19, p<0.002] (Figure 2.1). Individual contrasts revealed that aged mice reached the
platform more slowly among both Pdyn KO (p<0.003 in Block 2; p<0.05 in Block 3) and
WT (p<0.02 in Blocks 2 and 3) mice. However, age effects between groups vanish when
analyzing path length [F(1, 44) = 3.59, NS] (Figure 2.1), suggesting that the higher
latencies in the aged groups are largely attributable to differences in swim speed. Indeed,
average swim speeds recorded during the five probe trials were significantly higher in
young mice than aged mice [F(1, 53) = 24.7, p<0.0005], and this effect was apparent
among both the Pdyn KO (p<0.0005) and WT (p<0.004) genotypes.

Significant

genotype effects were not observed in either swim speed [F(1, 53) = 1.59, NS] or cued
task performance [latency: F(1, 53) = 0.007, NS; path length: F(1, 44) = 0.596, NS].
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Figure 2.1. Cued water maze task performance and swim speed.
Left: Latency measurements during the cue discrimination task show a highly significant
trend of learning across trials and a significant age effect during blocks 2 and 3, but no
Pdyn genotype effect. Right: The age effect is absent in the analysis of cued task path
length, and all four groups demonstrate comparably strong learning across trials. Far
right: Young mice swim significantly faster than aged mice, but no significant Pdyn
genotype effect is seen. *p<0.05, **p<0.02, ***p<0.005 relative to young controls.

To test whether the mice show increased efficiency in locating the submerged
platform across time, the spatial water maze swim task was performed across three
consecutive days. Daily averages for latency to platform showed a monotonic decrease
across the three days of spatial testing for all groups tested (Figure 2.2). When analyzing
individual group performance by repeated-measures ANOVA on daily mean latencies,
significant learning effects were seen across days for young Pdyn KO and young WT
groups (p<0.0005) and for the aged Pdyn KO group (p<0.05), but not for the aged WT
group (p=0.11). However, ANOVA found no genotype effect [F(1, 53) = 0.376, NS]
even though a significant aging effect [F(1, 53) = 28.2, p<0.0005], learning effect [F(2,
106) = 34.6, p<0.0005], and age-learning interaction [F(2, 106) = 5.81, p<0.004] were
observed. Significantly higher latencies to platform were evident in aged mouse groups
compared to young mice within both the WT (p<0.03 on Day 1; p<0.0005 on Days 2 and
3) and Pdyn KO (p<0.001 on Day 2; p<0.004 on Day 3) genotypes.
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Because individual differences in swim speed may account for some of the
variance in latencies, the mean path lengths for non-probe trials in each day were also
analyzed by repeated measures ANOVA to obtain a speed-independent measure of
spatial memory task performance. A linear trend across days is clearly evident in the
daily averages for swim distance (Figure 2.2). The young Pdyn KO, young WT, and
aged Pdyn KO groups all demonstrated highly significant learning effects across days
p<0.0005), as did the aged WT group (p<0.004). As observed in the latency analysis,
ANOVA showed a significant age effect [F(1, 53) = 15.7, p<0.0005], learning effect
[F(2, 106) = 56.2, p<0.0005], and age-learning interaction [F(2, 106) = 3.74, p<0.03], but
no significant main effect of Pdyn genotype [F(1, 53) = 0.380, NS]. Aged Pdyn KO mice
on average use a consistently shorter path to the platform than for the aged WT mice, and
the difference reaches significance on Day 3 (p<0.05). Average latencies for the aged
Pdyn KO mice were also less than for aged WT mice but failed to reach significance.
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Figure 2.2. Spatial water maze navigation performance.
Left: Daily means of latency to platform show a monotonically decreasing pattern for all
four groups with significant age effects. *p<0.025, **p<0.005, ***p<0.001 relative to
respective young controls. Right: Mean path lengths similarly show significant age
differences on Days 2 and 3, but in addition, a significant difference between aged Pdyn
KO and WT mice is observed on Day 3. *p<0.05, **p<0.02, ***p<0.001 relative to young
controls; #p<0.05 between Pdyn KO and WT.
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Age effects on path length were also significant for WT mice (p<0.001 on Day 2;
p<0.005 on Day 3) and for Pdyn KO mice (p<0.02 on Day 2).
To detect differences among groups in the extent of learning accomplished during
each day or in the amount of spatial information retained from the previous day’s
training, three acquisition and two retention probe trials were performed over the course
of the spatial phase of water maze testing. Quadrant dwell times, platform crossings, and
average proximity to target platform were measured. ANOVA of percent time spent in
the target quadrant during acquisition probes (Figure 2.3) showed a significant age effect
[F(1, 53) = 23.4, p<0.0005], learning effect across days [F(2, 106) = 18.3, p<0.0005],
learning-genotype interaction [F(2, 106) = 4.32, p<0.02], and learning-age interaction
[F(2, 106) = 3.15, p<0.05]. Target quadrant dwell times for retention probe trials also
showed a significant age effect [F(1, 53) = 13.7, p<0.001) and learning effect [F(1, 53) =
14.7). p<0.0005] but no Pdyn genotype effect [F(1, 53) = 0.174, NS]. An analogous
analysis of opposite quadrant dwell times revealed a significant age effect [F(1, 53) =
13.6, p<0.001], learning effect [F(2, 106) = 7.79, p<0.001], and learning-genotype
interaction [F(2, 106) = 3.14, p<0.05] during acquisition and only an age effect [F(1, 53)
= 10.5, p<0.002] and a learning effect [F(1, 53) = 7.77, p<0.007] during retention.
Measured averages for target quadrant dwell times were higher in the aged Pdyn
KO mice than aged WT mice on all three acquisition probe trials, but the difference as
indicated by ANOVA was significant only at the end of Day 1 (p<0.02). The acquisition
trial on Day 1 also indicated the time spent in the opposite quadrant was significantly
lower for the aged Pdyn KO compared to aged WT mice (p<0.03). Interestingly, young
Pdyn KO mice performed approximately as well as young WT mice on most days;
however, a significant difference (p<0.03) was noted for the Day 3 acquisition probe trial
with young WT exhibiting relatively increased goal quadrant search behavior. Genotype
differences within the young age group were not observed when analyzing opposite
quadrant dwell times. Aged WT mice spent significantly less time in the target quadrant
than young WT mice on all three acquisition trials (p<0.001 on Day 1; p<0.001 on Days
2 and 3) and on both retention trials (p<0.005 on Day 2; p<0.001 on Day 3). The age
effect on target quadrant dwell times within the Pdyn KO mice was not significant on
either of the retention probes and was significant only on the acquisition probe trial on
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Day 2 (p<0.02).

Analysis of opposite quadrant dwell times also failed to show

significant age effects within the Pdyn KO genotype except on Day 3 of acquisition
(p<0.03), whereas aged WT mice consistently spend significantly more time in the
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Figure 2.3. Quadrant analysis of probe trial performance in the water maze task.
Left: Acquisition probe trial analysis suggests aged Pdyn KO mice spend significantly
more time in the correct quadrant and less time in the opposite quadrant at the end of Day
1 than aged WT mice. Moreover, the age effect for the WT mice is quite pronounced all
three days, whereas the Pdyn KO mice show a significant age effect only on Day 2.
Interestingly, young Pdyn KO mice perform more poorly than young WT mice on Day 3.
Right: Retention probe trials demonstrated an age difference only within the WT mice
when examining either the target or opposite quadrant. *p<0.03; **p<0.005; ***p<0.001.
The dashed line denotes the reference value expected by chance.
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opposite quadrant than young WT mice on all acquisition (p<0.02 on Day 1; p<0.03 on
Day 2; p<0.003 on Day 3) and both retention (p<0.02 on Day 2; p<0.03 on Day 3)
probes.
While quadrant dwell times provide crude indications of spatial learning and
memory, platform crossings and proximity measures were also recorded to offer a more
refined assessment. The net platform crossings index during the probe trials (Figure 2.4)
showed a significant overall age effect [F(1, 53) = 42.7, p<0.0005 for acquisition; F(1,
53) = 36.2, p<0.0005 for retention] and a significant repeated measures effect across days
[F(2, 106) = 4.33, p<0.02 for acquisition; F(1, 53) = 4.09, p<0.05 for retention]. WT
mice showed highly significant declines in platform crossings with age in acquisition
(p<0.003 on Day 1; p<0.0005 on Days 2 and 3) and retention (p<0.001 on Day 2;
p<0.0005 on Day 3) probes. For Pdyn KO mice, the age differences were smaller but
still significant during both acquisition (p<0.004 on Days 1 and 2; p<0.04 on Day 3) and
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Figure 2.4. Platform crossings in water maze probe trials.
Left: The number of times aged Pdyn KO mice cross the target platform location during
the acquisition probe trials is significantly different from chance as early as the end of
Day 2, whereas aged WT mice achieve a comparable level of significance much later.
Right: In the retention probe trials, although aged Pdyn KO mice have on average more
platform crossings than aged WT mice, the difference fails to reach statistical
significance. In both acquisition and retention, age effects are significant, but for clarity,
age differences are not depicted on these graphs. *p<0.025, **p<0.01, ***p<0.005,
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p<0.0005 relative to chance.
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retention (p<0.04 on Days 2 and 3). While no explicit genotype effect was seen in the
ANOVA model for platform crossings in either the acquisition or retention probes,
acquisition probe performance for aged WT mice attained levels significantly different
from chance one day later than aged Pdyn KO mice. The higher swim speeds observed
for the younger mice could partially account for a higher number of platform crossings
especially for mice showing strong preferences for the target quadrant.
When analyzing average proximity to the target platform location during the
acquisition probe trials (Figure 2.5), a significant learning effect [F(2, 106) = 13.3,
p<0.0005], learning-genotype interaction [F(2, 106) = 4.34, p<0.02], and learning-age
interaction [F(2, 106) = 3.85, p<0.03] were observed, with no significant main effect of
age [F(1, 53) = 1.40, NS] or Pdyn genotype [F(1, 53) = 0.00, NS]. Aged Pdyn KO mice
young WT
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Figure 2.5. Average proximity measurements during water maze probe trials.
Left: Average proximity to the target platform location during the acquisition probe
trials was slightly but not significantly lower in aged Pdyn KO compared to aged WT.
However, young WT mice performed better than aged WT mice on Day 3. *p<0.02.
Right: No significant differences were detected in average proximity measures during
retention trials.
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were on average closer to the target platform location than aged WT mice on each day,
with the largest difference at the end of Day 1 approaching statistical significance
(p=0.057). The only significant age difference was observed on Day 3 between young
WT and aged WT mice (p<0.02). During retention probes, however, the proximity
measurements were not found to demonstrate any significant effects.

Measurement of Dyn A in brain
To test whether dynorphin levels are altered with aging in normal mice, Dyn A in frontal
cortex and hippocampus was measured by radioimmunoassay in young and aged male
WT mice. A two-tailed t-test detected quantitatively higher Dyn A levels in frontal
cortex [t(11) = 2.83, p<0.02] but not in hippocampus [t(12) = 0.051, NS] of 12-month
WT mice compared to 3-month controls (Figure 2.6). To assess whether additional
elevations in dynorphin may occur at more advanced ages, Dyn A was also measured in a
small number (n = 3) of 24-month male WT mice. Dyn A levels for the 24-month age
point [9.20 ± 1.22 fmol/mg (mean ± S.E.M.)] were comparable to the 12-month group
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Figure 2.6. Dyn A quantitation by RIA in mouse brain.
Dynorphin A levels show significant age-dependent increases in frontal cortex but not
hippocampus of WT mice. *p<0.02 relative to 3-mo. mice.
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and were also significantly different from the 3-month controls [t(9) = 5.34, p<0.0005].
In hippocampus, Dyn A levels were relatively unchanged across all three age groups.
Dyn A was also measured in females aged 12 months (n = 4) and was found to be present
in the same amount as in 12-month males in both frontal cortex and hippocampus (data
not shown).

Discussion
The present study confirms a significant impairment with aging in the spatial water maze
task (Gage et al., 1984; Rapp et al., 1987; Magnusson et al., 2003). The age-related
impairment is clearly observable for the 13- to 16-month mice used in this study as
demonstrated by the significant differences shown in the vast majority of the quantitative
indicators of learning and memory. Although aging confers an approximately 15 to 20%
decrease in swim speed in our study, motor activity by itself is unlikely to account for
most of the age-associated decline in performance since speed-independent
measurements, such as path length and target quadrant preference, also exhibit highly
significant differences with age.

Differences in general sensorimotor function,

motivation to escape the pool, and visual acuity, all of which could potentially be affected
by age, can be excluded because all groups performed equally well in the cued version of
the water maze. In addition, swim stress-induced immobility, in which dynorphins have
been implicated (Pliakas et al., 2001), cannot account for the variations in water maze
performance since the trials do not reveal significant reductions in mean trajectory length
in poorly performing animals.
The data also suggest that the age-related impairment is partially alleviated by the
absence of dynorphin.

In most of the indices recorded, young mice show little or no

Pdyn genotype differences, whereas among aged mice, the absence of dynorphin was
associated with superior learning and memory scores. Compared to WT mice, aged
knockout mice attained modestly greater proficiency in locating the hidden platform and
appeared to employ spatial search strategies earlier and with greater accuracy than aged
WT mice. The results imply that prodynorphin-derived peptides are contributing in part
to age-related impairment in performance on a spatial memory task, but it is not clear
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whether this effect is attributable to an effect of dynorphin on cognition or alternatively to
differences in stress or reward responses that can influence cognitive outcome. It is
possible that the differences in water maze performance may be related to a hypothesized
role of dynorphin in mediating stress responses and the fact that aged animals are more
susceptible to the effects of stress in disrupting performance in the water maze (Foster,
1999). Indeed, disruption of dynorphin transmission is associated with interference of
stress-induced behavioral responses (McLaughlin et al., 2003). Moreover, treatments
such as neonatal handling, which reduce neuroendocrine stress responses, are able to
decrease dynorphin in the frontal cortex and facilitate performance on the water escape
task in aged animals (Meaney et al., 1988; Ploj et al., 2001). Thus, a reduction in stress
influences could explain why differences emerged with age and were more apparent early
in training when stress effects would be expected to be greatest. Although markers of
stress were not explicitly assayed in animals performing the water maze task, it seems
plausible that stress itself or the effects of stress on cognition could account for some of
the observed effects.
A detrimental role of dynorphins in disrupting spatial learning is consistent with a
number of studies (Jiang et al., 1989; McDaniel et al., 1990; Sandin et al., 1998; Hauser
et al., 1999; Tan-No et al., 2001); however, other recent publications have concluded
that a rise in dynorphin following brain injury may be beneficial for recovery following
various insults (Heron et al., 1996; Redell et al., 2003). Interestingly, young Pdyn KO
mice perform somewhat more poorly than young WT mice during later probe trials for
reasons that are not immediately clear.

On the final day of spatial testing, young Pdyn

KO mice performed significantly worse than young WT mice in the probe trial quadrant
preference assessment, despite appearing to have shown strong preference for the target
quadrant on Days 1 and 2, and despite showing latency and path length measures
quantitatively indistinguishable from young WT mice on all three days. The present
data suggest that dynorphins may potentiate the extent of spatial learning at later time
points.
The ability of normal aging to unmask the cognitive functional differences
between Pdyn KO and WT mice can be explained by the findings that dynorphin peptides
in WT mice increases over 2-fold with aging in the present study. However, it is not
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possible to conclude from the data that dynorphin is exerting a direct detrimental effect
on cognition, since the poorer performance in aged WT mice could in theory be due to
other mechanisms that independently lead to increased dynorphin levels.
The significant increases in Dyn A observed in the frontal cortex of both 12- and
24-month mice suggest that abnormal expression of endogenous dynorphin peptides may
at least partially contribute to spatial learning and memory with age but not in younger
animals, in which endogenous dynorphins are present at substantially lower quantities.
This hypothesis is consistent with earlier published data showing increased dynorphins in
both frontal cortex and hippocampus of aged memory-impaired rats (Jiang et al., 1989)
and a more recent study showing elevated Pdyn mRNA in aged rats (Kotz et al., 2004). In
contrast to the above studies, our results in hippocampus do not show increased
dynorphin expression with age.

Interestingly, another immunohistochemical study

reported a slight decrease in dynorphin immunoreactivity in age-impaired rats (Croll et
al., 1999). However, the lack of an age-associated increase in hippocampal dynorphins
does not preclude a possible harmful effect of these neuropeptides on hippocampal
function with aging, since other age-related changes may alter susceptibility to
endogenous dynorphins in the absence of overt changes in dynorphin expression.
Nonetheless, the results in frontal cortex showing the marked age-related increase in
dynorphin, in combination with the finding that aged prodynorphin knockout mice appear
relatively spared in a spatial memory task, are compellingly suggestive of a more
prominent role of frontal cortical dynorphin in learning and memory impairment.
Despite the fact that the water maze task has long been regarded as a
hippocampal-dependent task based on studies documenting spatial impairment upon
selective lesioning of the hippocampus (Jarrard, 1978; Morris et al., 1982), a growing
body of literature now supports the claim that spatial learning may also be critically
dependent on other regions of the brain, such as frontal cortex (Owen et al., 1995;
Kessels et al., 2000).

In fact, in frontal cortex of Alzheimer’s disease or Down’s

syndrome patients, dynorphin A is increased more than 2-fold compared to elderly
controls (Risser et al., 1996). The increases in dynorphin immunoreactivity in aged mice
could therefore reasonably underlie some of the cognitive deficits observed in water maze
performance in aged WT mice. Further experiments, e.g., those involving κ-selective
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agonists and antagonists, are needed, however, to determine causality and to elucidate the
mechanistic basis of the apparent adverse effects of elevated endogenous dynorphins.

Copyright © Xuan V. Nguyen 2007
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CHAPTER 3:

Effects of aging and Pdyn deletion on nonspatial learning and
memory and spontaneous locomotion in mice

Introduction
As detailed in preceding chapters, aging is associated with neurobiological and
neurochemical changes in the brain and is commonly associated with functional declines
in neuronal function that lead to sensory, motor, cognitive, and numerous other types of
deficits. The mechanisms by which the aging process contributes to these deficits have
not been elucidated. Opiate neuropeptides derived from the prodynorphin (Pdyn) gene
and expressed in hypothalamus, nucleus accumbens, neostriatum, dentate gyrus,
hippocampus cerebral cortex, and spinal cord (Khachaturian et al., 1993), have been
implicated in age-related cognitive dysfunction (Jiang et al., 1989; Zhang et al., 1991;
Nguyen et al., 2005).

Findings of increased dynorphin peptides in hippocampus of

normal aged rats (Jiang et al., 1989; Zhang et al., 1991; Gallagher and Nicolle, 1993;
Kotz et al., 2004), in cortex and hippocampus of amyloid precursor proteinoverexpressing mice (Diez et al., 2000), in frontal cortex of Down’s syndrome patients
(Risser et al., 1996), and in frontal and parietal cortex of Alzheimer’s disease patients
(Risser et al., 1996; Yakovleva et al., 2006a) strongly implicate dynorphin dysregulation
in age-related pathophysiological processes.
The existing literature contains conflicting reports regarding the role of dynorphin
peptides in learning and memory. While impairment in spatial learning and memory is
seen upon intrahippocampal administration of Dyn A(1-8) (McDaniel et al., 1990) or
dynorphin B (Sandin et al., 1998), some studies have reported that Dyn A(1-13) can
ameliorate cognitive impairment induced by anticholinergic agents (Itoh et al., 1993a, b;
Hiramatsu et al., 1996; Hiramatsu et al., 1997; Ukai et al., 1997) through mechanisms
involving the

opioid receptor, though recent studies have also reported non-opioid-

dependent beneficial effects on memory (Hiramatsu and Watanabe, 2006). Dynorphin
was also found to dose-dependently impair retention in an inhibitory avoidance task in
mice (Introini-Collison et al., 1987). We have already shown that aging Pdyn knockout
(KO) mice demonstrate improved performance in the water maze task (Nguyen, 2001).
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We therefore hypothesize that Pdyn deletion similarly ameliorates age-related
impairment in other forms of learning and memory. In the present study, we examine
two additional learning and memory assays, the passive avoidance test and the paired
object recognition test.

To evaluate the possibility of differences in nociception

potentially confounding interpretation of these studies, a tail-flick assay was performed
on moderately aged Pdyn KO and WT mice. In addition, because the interpretation of
these tests also depends on general exploratory activity in the animal subjects, we also
examine open-field activity to examine effects of both aging and Pdyn deletion.
Moreover, because of the clinical importance of the dopaminergic system in pathological
motor dysfunction and given the reported dopamine-inhibitory effects of dynorphins and
exogenous

agonists in striatum and nucleus accumbens (Mulder et al., 1984; Herrera-

Marschitz et al., 1986; Di Chiara and Imperato, 1988; Reid et al., 1988; Spanagel et al.,
1992; Ronken et al., 1993; Schlosser et al., 1995), we also evaluated open-field activity
following systemic administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP). The resulting selective loss of dopaminergic neurons (Arai
et al., 1990; Sundstrom et al., 1990) is expected to produce functional impairments in
locomotor activity in these mice, which are hypothesized to be alleviated by Pdyn
deletion.

Methods
Animal subjects
All animals in this study were wild-type (WT) or Pdyn KO mice that were maintained in
an approved animal facility at the University of Kentucky. WT mice were derived from
the 129SvEv-Tac line, and Pdyn KO mice were originally obtained by targeted deletion
of the coding exons of the prodynorphin gene and bred into a 129SvEv-Tac background
as described previously (Sharifi et al., 2001). Animals were housed in groups of up to 4
per cage with food and water ad libitum in a well-ventilated room with a 12 h: 12 h light:
dark cycle. Prior to weaning, tail specimens were collected from each animal, and DNA
was extracted for subsequent genotyping to confirm the identity of the Pdyn locus by the
polymerase chain reaction (PCR) using primer pairs specific for each genotype. All
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procedures involving animals are approved by the Institutional Animal Care and Use
Committee at the University of Kentucky.

Inhibitory avoidance
An inhibitory avoidance paradigm was used to evaluate passive recall of an aversive
stimulus in male 3-month WT (n = 4), 3-month Pdyn KO (n = 4), 13-month WT (n = 8),
13-month Pdyn KO (n = 8), 24-month WT (n = 6), and 24-month Pdyn KO (n = 6) mice.
The task tests the mouse subject's ability to employ situational recall to passively avoid
entry into a dark chamber that is associated with an aversive electrical stimulus. A
WinLinc software program (Coulbourn Instruments, Allentown, PA) was used to
automate the sequence of events during each trial. In the acquisition trial, the subject is
placed in the brightly lit environment of the first chamber for 90 seconds, followed by
automated opening of a door leading to a dark chamber. If the mouse traverses the
threshold into the dark chamber, an automated trigger is activated leading to closure of
the door mechanism, and after a 10-second delay, a 3-second electrical shock at 0.1
mAmp, which was confirmed to produce visible but not excessive discomfort to the
mouse, is applied via the conducting medium of the floor of the dark chamber. A
retention trial was performed 72 hours after the acquisition trial in a similar manner,
except that the door to the dark compartment remained open for the duration of the trial
and no electrical shock was applied in the retention trials. In both trials, the step-through
latency, defined as the time from door-opening until the animal crosses into the dark
chamber, was recorded manually using a stopwatch to a maximum of 900 seconds.

Tail flick assay
Tail withdrawal to a heat stimulus was assessed using a tail-flick assay in 16-month WT
(n = 5) and Pdyn KO (n = 5) mice. The mouse was placed in a restraining device, and the
tail was positioned within a groove of the heating mechanism. Trials were performed in
triplicate to determine the latency from the time of initiation of heat application until the
animal voluntarily withdraws its tail from the heating mechanism.
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Open-field assay
Spontaneous open-field behavioral activity was recorded using an apparatus of four
activity chambers (Model RXYZCM-8, Accuscan Instruments, Columbus, OH), each
consisting of a 41 × 41 × 31-cm Plexiglas box with two grids of infrared beams mounted
at horizontal intervals of 2.5 cm and at a vertical interval of 4.5 cm. Monitors were
connected to a Digiscan Analyzer (Model DCM-8, Accuscan Instruments) that converts
the number and pattern of beam breaks to generate various data parameters, including
horizontal activity, distance traveled, vertical activity, movement time, and stereotypy
counts. During operation, the data were recorded separately for each of six contiguous 5min intervals during each 30-minute trial. Horizontal activity was determined by the
number of photobeam breaks in a horizontal grid, and vertical activity was quantified as
number of photobeam interruptions in a more superiorly positioned grid.

Distance

traveled and movement time was also calculated by the Accuscan software. Stereotypy
counts were detected as a set of repeated breaks in the same photobeam or array of
photobeams. Movement speed was calculated as distance traveled divided by movement
time to provide an estimate of speed during periods of active locomotion. Animals that
yielded a movement time of zero were excluded from the movement speed analysis, as
were two speed outliers that were unrealistically high due to aberrantly low movement
times recorded.
Mice used in this study include 3-month WT (n = 20), 3-month Pdyn KO (n =
30), 3-month Pdyn HET (n = 22), and 10-month WT (n = 6) mice. The 3-month WT
group contains 10 males and 10 females, and the 3-month Pdyn KO group has 11 males
and 19 females. The HET group consists of 11 males and 11 females. Among 10-month
WT mice, there are 2 males and 4 females. The group sizes listed above include mice
pooled from saline controls from the MPTP experiments that were tested prior to any
intervention. In the experiments evaluating effects of MPTP, a regimen of four saline or
15 mg/kg MPTP intraperitoneal injections at 2-hour intervals was administered to mixed
male and female 3-month mice, and behavioral testing performed 7 days later. The saline
control group contains 2 WT, 4 HET, and 3 KO mice, while the MPTP group contains 3
WT, 4 HET, and 5 KO mice. These sample sizes reflect the removal of 4 saline controls
due to failure of the automated recording system during a post-injection trial.
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For

analysis, logarithmic transformation of the post- to pre-injection ratios of the relevant
behavioral parameters was applied to preserve linearity of the underlying distribution.

Object recognition
A paired visual object recognition assay was used to test the animal subject's inclination
to preferentially explore novel objects and to recognize familiar objects in an enclosed
environment. The objects used in this experiment were non-noxious inanimate objects
typically found in a laboratory setting and of a size similar to the mouse subject. Animals
were habituated to the empty testing chamber for 15 minutes one day prior to testing.
During each trial, two objects are positioned at predetermined locations equidistant from
the site at which the mouse is to be placed, and the subject's spontaneous exploratory
activity is monitored for 15 minutes either by real-time video transmission to an
investigator located in a different room or by videotape recording. An investigator
blinded to the identity of the mice recorded the total number of seconds during each trial
the subject expends on active exploration of each object as demonstrated by specific
behavior patterns such as facing the object in close proximity, moving from side to side
while facing the object, placing one or more forelimbs on the object, or encircling the
object in close proximity. Between trials, the testing chamber is cleaned to remove any
odor cues that may influence subsequent exploratory activity. Results are expressed as a
proportion of total exploration time spent on the novel object. To account for individual
differences in baseline exploratory activity, total novel object exploration time is also
presented as a ratio to total cumulative exploration time. Two different protocols were
used in implementing the timing of the testing trials. In the Protocol 1, 6-month WT (n =
12), 6-month Pdyn KO (n = 3), 12-month WT (n = 8), 12-month KO (n = 8), 24-month
WT (n = 5), and 24-month KO (n = 6) male mice were monitored in three acquisition
trials before new target objects are successively introduced in two retention trials 4 and
24 hours later.

In Protocol 2, testing consists of an acquisition trial, a retention trial

immediately afterward, and a second retention trial with a different novel object 4 hours
after the start of the first trial. Animal subjects in Protocol 2 include 4-month WT (n =
3), 14-month WT (n = 7), 14-month Pdyn KO (n = 10), 24-month WT (n = 5), and 24month KO (n = 5) male mice. These protocols differ in that Protocol 1 permits a greater
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amount of time to be spent in the acquisition phase prior to introduction of the first novel
object, which is thought to enhance the distinction between novel and familiar objects in
subsequent trials. The shorter acquisition phase of Protocol 2, on the other hand, may
enable more subtle differences in object recognition to become manifest.

Results
Inhibitory avoidance
An inhibitory avoidance assay was performed on WT and Pdyn KO mice of varying ages

Step-through latency (sec)

(Figure 3.1). Acquisition step-through latencies were recorded in experimentally naïve
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Figure 3.1. Inhibitory avoidance assay results in mice.
Effects of age and Pdyn deletion on step-through latency before and 72 hours after an
electrical foot-shock stimulus were measured in the passive avoidance task. Significant
learning effects are seen independently of age and Pdyn genotype. Acquisition stepthrough latencies, which may reflect exploratory activity in naïve animals, are significantly
increased in Pdyn KO mice, but only at 3 months. Retention latencies in the 3-month Pdyn
KO group are also increased, consistent with improved recall of the aversive stimulus.
Note the ceiling effect in which all four young Pdyn KO mice achieved the predetermined
maximum latency of 900 sec.
*p<0.05, ***p<0.001 compared to respective 3-month
#
###
controls; p<0.05, p<0.001 compared to corresponding WT mice; ‡p<0.01, ††p<0.001
compared to the corresponding acquisition trial.
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Figure 3.2. Tail-flick latencies as a function of Pdyn genotype.
This assay demonstrates no effect of Pdyn deletion on nociception or subsequent reflex
withdrawal to painful stimuli.
mice, while retention latencies at 72 hours were obtained to indicate the subject's ability
to demonstrate situational recall of the aversive stimulus. Three-way ANOVA with
repeated measures was used to evaluate age, Pdyn, and training effects. An overall
training effect was highly significant [F(1, 30) = 64.08, p<0.0005], and an age-Pdyn
interaction was also significant [F(2, 30) = 3.93, p<0.03]. Acquisition scores showed a
significant effect of age [F(2, 30) = 6.75, p<0.004], Pdyn [F(1, 30) = 6.12, p<0.019], and
age-Pdyn interaction [F(2, 30) = 5.94, p<0.007].
The 3-month Pdyn KO mice latencies exhibit a ceiling effect due to all four mice
in the group achieving the predetermined maximum latency of 900 sec.

With the

exception of 3-month Pdyn KO mice showing only a mild tendency toward a significant
learning effect [F(1, 30) = 3.29, p<0.08] as a result of the elevated pre-stimulus stepthrough latency, step-through latencies 72 hours after the initial stimulus were
consistently increased in all other groups, including 3-month Pdyn KO [F(1, 30) = 14.21,
p<0.001], 13-month WT [F(1, 30) = 12.79, p<0.001], 13-month Pdyn KO [F(1, 30) =
15.53, p<0.0005], 24-month WT [F(1, 30) = 17.99, p<0.0005], and 24-month Pdyn KO
mice [F(1, 30) = 7.93, p<0.009].

Among 3-month mice, Pdyn KO mice show

significantly higher acquisition [F(1, 30) = 14.62, p<0.001] and retention [F(1, 30) =
4.51, p<0.042] scores.

The 3-month Pdyn KO retention latency was also significantly
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elevated when compared to that of 24-month Pdyn KO mice [F(1, 30) = 4.21, p<0.049],
and the acquisition latency means were similarly higher than those of both 13-month
Pdyn KO [F(1, 30) = 19.29, p<0.0005] and 24-month Pdyn KO mice [F(1, 30) = 21.70,
p<0.0005].

Beyond the findings associated with the 3-month Pdyn KO mice, no clear

age-associated trend in retention latencies were observed in this passive avoidance task at
72 hours.

Because interpretation of the passive avoidance task as an indication of

memory function assumes the subjects exhibit comparable perception of and response to
the inciting stimulus, potential effects of dynorphin on pain modulation or perception
were evaluated by the tail-flick assay.

Tail-flick response measurements show no

differences between Pdyn KO and WT mice (Figure 3.2).
Open-field analysis
Spontaneous exploratory and locomotor behavior patterns were analyzed by open-field
analysis in young adult (3-month) WT, Pdyn KO, and HET mice, with automated
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Figure 3.3. Horizontal activity measurements during open-field analysis as a function of
Pdyn genotype.
Left: The vertical axis depicts the number of interruptions in the horizontal photobeam
grid of the activity chamber. Intra-trial changes in horizontal activity show a gradual
habituation effect across recording intervals. Right: Summed totals of horizontal
activity show no effect of Pdyn genotype.
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recording of a series of measured variables during a trial consisting of 6 contiguous 5minute intervals (Figure 3.3 through Figure 3.8). Two-factor repeated measures ANOVA
shows a significant intra-trial habituation effect as manifested in a significant decline
across intervals in horizontal activity [F(5, 345) = 36.44, p<0.0005], distance traveled
[F(5, 345) = 36.58, p<0.0005], movement time [F(5, 345) = 29.76, p<0.0005], stereotypy
[F(5, 345) = 14.63, p<0.0005], and movement speed [F(5, 165) = 3.90, p<0.005]. The
one variable analyzed that did not show such an effect was vertical activity, which also
showed substantial intra-group variability likely related to limited sample size (Figure
3.6). No significant effects of Pdyn or Pdyn-habituation interactions were observed for
any of these variables. One-way ANOVA performed on the average trial movement
speed and the summed intra-trial total for all the other variables found no significant
effects of Pdyn deletion.
To determine effects of aging on these parameters, a similar analysis was applied
in 3-month and 10-month WT mice (Figure 3.9 through Figure 3.14).

Similar to the

preceding ANOVA results, habituation effects were again seen in horizontal activity
2500

800
3-mo. WT
3-mo. Pdyn HET

600

2000

Distance (cm)

3-mo. Pdyn KO

500
400
300

1500

1000

500

200
100

3

4

5

6

Recording Interval

KO

HE
T

o.
Pd
yn

2

3m

1

o.
Pd
yn

0

3m

o.
W

T

0

3m

Distance (cm)

700

Figure 3.4. Distance measurements during open-field analysis as a function of Pdyn
genotype.
Left: Intra-trial changes in distance traveled show a gradual habituation effect across
recording intervals. Right: Summed totals of distance measurements show no effect of
Pdyn genotype.
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[F(5, 120) = 14.18, p<0.0005], distance traveled [F(5, 120) = 19.39, p<0.0005],
movement time [F(5, 120) = 15.83, p<0.0005], and stereotypy [F(5, 120) = 13.74,
p<0.0005]. Additionally, vertical activity showed a significant habituation effect in this
analysis [F(5, 120) = 2.29, p<0.05], while movement speed showed no significant intratrial changes. Increased stereotypy counts were observed in older mice [F(1, 24) = 8.95,
p<0.006] with an age-interval interaction [F(5, 120) = 3.81, p<0.003]. Total stereotypy
activity during the 30-minute trial was significantly higher in 10-month WT mice
compared to 3-month WT mice [F(1, 24) = 8.95, p<0.006]. Only a minor age-associated
decline in average movement speed was observed with aging [F(1, 24) = 5.28, p<0.031],
with a significant intra-interval age effect noted only near the end of the trial [F(1, 9) =
7.66, p<0.022]. No other age effects or age-interval interactions were seen in the other
variables analyzed.
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Figure 3.5. Movement time during open-field analysis as a function of Pdyn genotype.
Left: The vertical axis depicts the amount of time spent in active locomotion. Intra-trial
changes in movement time show a gradual habituation effect across recording intervals.
Right: Summed totals of movement time show no effect of Pdyn genotype.

40

3-mo. WT

8

3-mo. Pdyn HET

7

25

3

15
10
5

1

0

2

3

4

5

6

3m

1

3m

0

o.
Pd
yn

o.
W

T

2

Recording Interval

KO

4

o.
Pd
yn

5

20

HE
T

6

3m

3-mo. Pdyn KO

Vertical activity

Vertical activity

30

Figure 3.6. Vertical activity during open-field analysis as a function of Pdyn genotype.
Left: The vertical axis depicts the number of occurrences of breaks in the more
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intervals. Right: Summed totals of vertical activity show no effect of Pdyn genotype.
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Figure 3.7. Stereotypy during open-field analysis as a function of Pdyn genotype.
Left: The vertical axis depicts the number of occurrences of stereotyped behavior as
recorded by repeated breaks in the same photobeam or array of photobeams. Intra-trial
changes in stereotypy show a gradual habituation effect across recording intervals.
Right: Summed totals of stereotypy events show no effect of Pdyn genotype.
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Figure 3.8. Movement speed during open-field analysis as a function of Pdyn genotype.
Left: Movement speed is minimally altered across recording intervals. Right: Average
movement speed shows no effect of Pdyn genotype.

As the above results were performed on groups containing both male and female
mice, a subsequent analysis was performed to assess effects of gender on spontaneous
open-field activity (Figure 3.15 through Figure 3.20).

ANOVA on summed data from

the entire 30-minute trial period reveals significant main effects of gender on movement
time [F(1, 64) = 6.92, p<0.011] and movement speed [F(1, 64)=16.28], p<0.0005], with
gender-Pdyn interactions observed in horizontal activity [F(2, 64) = 4.14, p<0.02],
distance traveled [F(2, 64) = 5.85, p<0.005], and movement time [F(2, 64) = 6.19,
p<0.003]. Extending a similar approach to the aging comparisons in WT mice finds sex
effects in horizontal activity [F(1, 22) = 10.08, p<0.004], distance traveled [F(1, 22) –
24.97, p<0.0005], movement time [F(1, 22) = 27.82, p<0.0005], and vertical activity
[F(1, 22) = 6.41, p<0.019]. Significant interactions between gender and Pdyn genotype
were noted in recorded distance [F(1, 22) = 11.45, p<0.003] and movement time [F(1,
22) = 10.46, p<0.004].
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Figure 3.9. Horizontal activity measurements during open-field analysis as a function of
aging.
Left: The vertical axis depicts the number of interruptions in the horizontal photobeam
grid of the activity chamber. Habituation effects are seen across recording intervals,
with minimal aging effect. Right: Total horizontal activity is unchanged with age.
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Figure 3.10. Distance traveled during open-field analysis as a function of aging.
Left: Habituation effects are seen across recording intervals, with minimal aging effect.
Right: Total distance traveled is unchanged with age.
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Figure 3.11. Movement time during open-field analysis as a function of aging.
Left: The vertical axis depicts the amount of time spent in active locomotion.
Habituation effects are seen across recording intervals, with minimal aging effect. Right:
Total movement time is unchanged with age.
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Figure 3.12. Vertical activity during open-field analysis as a function of aging.
Left:
The vertical axis depicts the number of occurrences of breaks in the more
superiorly placed photobeams. Minimal habituation effects are seen across recording
intervals. Right: Total vertical activity is unchanged with age.
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Figure 3.13. Stereotypy during open-field analysis as a function of aging.
Left: The vertical axis depicts the number of occurrences of stereotyped behavior as
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Figure 3.14. Movement speed during open-field analysis as a function of aging.
Left: Movement speed is decreased in 10-month mice across recording intervals. Right:
Mean speeds are mildly decreased with age. *p<0.05 compared to 3-month mice.
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Figure 3.15. Gender analysis of horizontal activity in open-field task.
Left: The vertical axis depicts the number of interruptions in the horizontal photobeam
grid of the activity chamber. Aging analysis shows increased horizontal activity in 10month male mice compared to 10-month females. Right: Pdyn analysis shows male
Pdyn HET mice exhibit less activity than female HET mice or male Pdyn KO mice.
†
p<0.05, ‡p<0.01 compared to corresponding male mice. #p<0.05 Pdyn genotype effect.

Horizontal activity in 3-month mice (Figure 3.15) was mildly decreased in male
Pdyn HET mice compared to either female Pdyn HET mice [F(1, 64) = 4.68, p<0.034] or
male Pdyn KO mice [F(1, 64) = 5.17, p<0.026]. Female 10-month WT mice also showed
less horizontal activity than male 10-month WT mice [F(1, 22) = 8.58, p<0.008], but a
similar gender difference among 3-month WT mice failed to reach significance [F(1, 22)
= 4.15, p<0.054]. Similar findings were noted in distance (Figure 3.16) and movement
time (Figure 3.17), with 10-month male WT mice accumulating more distance [F(1,22) =
17.02, p<0.0005] and spending more time in motion [F(1, 22) = 18.62, p<0.0005] than 3month male WT mice. Ten-month female WT mice showed comparatively less distance
traveled [F(1, 22) = 22.25, p<0.0005] and movement time [F(1, 22) = 22.92, p<0.0005]
than their male WT counterparts. Movement time was also significantly less in female 3month mice than males [F(1, 22) = 4.95, p<0.037]. Distance traveled by male Pdyn KO
mice were significantly higher than for male Pdyn HET mice [F(1, 64) = 10.73, p<0.002]
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Figure 3.16. Gender analysis of distance traveled in open-field task.
Left: Aging analysis shows significantly increased distance traveled in 10-month males.
Right: Pdyn analysis shows male Pdyn KO mice exhibit greater traversed distance than
male HET mice or female Pdyn KO mice. ***p<0.001 compared to corresponding 3month mice. ‡p<0.01, ††p<0.001 compared to corresponding male mice. ##p<0.01 Pdyn
genotype effect.

or female Pdyn KO mice [F(1, 64) = 10.29, p<0.002]. Similarly time in motion was
significantly higher in Pdyn KO males than Pdyn HET males [F(1, 64) = 14.15,
p<0.0005] or Pdyn KO females [F(1, 64) = 16.44, p<0.0005].
No significant contrasts were found in vertical activity (Figure 3.18). Stereotypy
assessments were not significantly different among 3-month mice (Figure 3.19), but
increased stereotypy behavior was noted at 10 months age in both male [F(1, 22) = 4.57,
p<0.044] and female [F(1, 22) = 5.37, p<0.03] WT mice. Movement speed calculations
(Figure 3.20) were consistently higher in females than males for WT [F(1, 64) = 5.40,
p<0.023], Pdyn HET [F(1, 64) = 6.02, p<0.017], and Pdyn KO mice [F(1, 64) = 4.90,
p<0.03].

In the aging analysis, 3-month female WT showed significantly higher

movement speed than 3-month male WT [F(1, 22) = 8.62, p<0.008] or 10-month female
WT mice [F(1, 22) = 12.55, p<0.002].
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Figure 3.17. Gender analysis of movement time in open-field task.
Left: The vertical axis depicts the amount of time spent in active locomotion. Aging
analysis shows decreased activity in female mice compared to males at each age point,
with 10-month males showing significantly increased time in active motion. Right:
Pdyn analysis shows male Pdyn KO mice exhibit greater movement time than male HET
mice or female Pdyn KO mice. ***p<0.001 compared to corresponding 3-month mice.
††
p<0.001 compared to corresponding male mice. ###p<0.001 Pdyn genotype effect.

Effects of systemic MPTP or saline on open-field behavior in 3-month mice were
also examined by calculating intrasubject log-ratios of post-injection to pre-injection
values of each analyzed variable. ANOVA found an MPTP effect on average speed [F(1,
15) = 6.97, p<0.019] and significant Pdyn-MPTP interactions in movement time [F(2,
15) = 4.15, p<0.037] and movement speed [F(2, 15) = 5.73, p<0.014]. While most mice
showed mild habituation-related decreases in horizontal activity, distance, and movement
times upon re-exposure to the open-field environment (Figure 3.21), WT mice show
substantial post-MPTP reduction in exploratory activity, with statistical significance
demonstrated in the amount of time spent in active locomotion [F(1, 15) = 7.23,
p<0.017]. WT mice also exhibit a greater post-MPTP decline in traversed distance
compared to Pdyn KO [F(1, 15) = 5.15, p<0.038] and Pdyn HET mice [F(1, 15) = 6.32,
p<0.024]. Time spent actively moving was also reduced to a greater extent in post-MPTP
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WT mice compared to post-MPTP Pdyn KO [F(1, 15) = 9.90, p<0.007] or HET mice
[F(1, 15) = 12.89, p<0.003]. Stereotypy assessments revealed mild differences (Figure
3.22), primarily in the saline-treated Pdyn HET group, which demosntrated significantly
less stereotypic behavior in comparison to either WT saline controls [F(1, 15) = 4.99,
p<0.041] or MPTP-treated HET mice [F(1, 15) = 4.97, p<0.041]. Estimates of average
movement speed were mildly increased in the post-injection trial for most groups (Figure
3.22), but MPTP-injected WT mice demonstrate a significantly larger increase in speed
compared to saline-injected WT mice [F(1, 15) = 13.94, p<0.002], MPTP-injected Pdyn
KO mice [F(1, 15) = 9.47, p<0.008] and to MPTP-injected HET mice [F(1, 15) = 14.74,
p<0.002], although this apparent increase in the calculated average speed of MPTPinjected WT mice is likely artifactual due to the markedly lower amount of time spent in

Vertical activity

Vertical activity

active locomotion.

Figure 3.18. Gender analysis of vertical activity in open-field task.
Left: The vertical axis depicts the number of occurrences of breaks in the more
superiorly placed photobeams. Aging analysis shows similar trends as other variables
but with substantial intra-group variability. No significant effects are seen. Right: Pdyn
analysis shows no significant effects in vertical activity.
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Figure 3.19. Gender analysis of stereotypy in open-field task.
Left: The vertical axis depicts the number of occurrences of stereotyped behavior as
recorded by repeated breaks in the same photobeam or array of photobeams. Aging
analysis shows increased stereotypy with age in both male and female mice. Right: Pdyn
analysis shows no significant effects. *p<0.05 relative to corresponding 3-month mice.
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Figure 3.20. Gender analysis of movement speed in open-field task.
Left: Aging analysis shows mild increase in movement speed of female mice at 3
months but a decrease at 10 months. Right: Pdyn analysis shows consistently elevated
movement speed in females of all three Pdyn genotypes. **p<0.01 compared to
corresponding 3-month mice. †p<0.05, ‡p<0.01 compared to corresponding male mice.
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Figure 3.21. Effects of MPTP and Pdyn deletion on locomotor activity.
Open-field data were obtained from 3-month mice before and 7 days after intraperitoneal
injection of saline or MPTP. Within-subject log-ratios of post-injection to pre-injection
horizontal activity, distance, and movement time are shown. WT mice show substantial
decreases in post-MPTP locomotor indices, while Pdyn KO and HET mice are minimally
changed. #p<0.05, ##p<0.01 compared to corresponding WT mice. †p<0.05 compared to
saline controls.
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Figure 3.22. Effects of MPTP and Pdyn deletion on stereotyped behavior and motor
speed.
Open-field data were obtained from 3-month mice before and 7 days after intraperitoneal
injection of saline or MPTP. Within-subject log-ratios of post-injection to pre-injection
stereotypy counts and movement speed are shown. #p<0.05, ##p<0.01 compared to
corresponding WT mice.
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Object recognition assay
Performance in a paired object recognition task was evaluated by measuring the amount
of time spent by the mouse exploring each of two different objects during a series of 5minute trials. Two sets of experiments were performed using slightly different protocols.
In the first set of experiments, animals were monitored in three habituation trials before
new target objects are introduced in retention trials 4 and 24 hours later (Figure 3.23).
The proportion of time spent exploring the new target object was recorded as ratios to
total intra-trial exploratory time and to total cumulative exploratory time. While the
former ratio represents the relative changes in object exploration time during each trial,
the latter ratio was selected to provide an indication of absolute time spent on the novel
object while controlling for baseline differences in general exploratory activity. The
proportion of time in each trial spent exploring the novel object is found by ANOVA to
demonstrate significant effects of Pdyn genotype [F(1, 31) = 4.80, p<0.036], trial number

Figure 3.23. Effects of age and Pdyn deletion on object recognition using Protocol 1.
Left: Novel object preference is expressed as the fraction of total trial exploration time
spent interacting with the novel object or, in the case of Trials 1-3, the object in the
position where the novel object of the subsequent trial is to be placed. Aged Pdyn KO
mice spend a decreased proportion of exploration time interacting with the novel object
in the 24-hour retention trial (Trial 5) compared to similarly aged WT mice. Right: Total
time spent on the novel object is expressed relative to total cumulative object exploration
time to control for individual differences in baseline exploratory tendencies. Total time
spent on the novel object relative to cumulative exploratory activity is increased in 24month Pdyn KO mice. #p<0.05, ##p<0.01 compared to corresponding WT mice.
*p<0.05 compared to corresponding 6-month mice. **p<0.01 compared to
corresponding 12-month mice.
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[F(2, 62) = 9.36, p<0.0005], and a trial-Pdyn interaction [F(2, 62) = 4.30, p<0.029]. The
almost equal division in the amount of time spent on each of the two objects during these
acquisition trials indicates that the mice show no baseline preference for either object
location. While there were no significant aging contrasts in this analysis, significantly
decreased novel object exploration at 24 hours was noted in Pdyn KO mice aged 12
months [F(1, 31) = 7.64, p<0.01] or 24 months [F(1, 31) = 5.10, p<0.031]. When novel
object exploration is expressed relative to cumulative exploratory activity, ANOVA
reveals significant trial effects [F(1, 36) = 16.09, p<0.0005], a trial-Pdyn interaction
[F(1, 36) = 5.19, p<0.029], and a trial-age interaction [F(2, 36) = 3.58, p<0.038].
Significant contrasts are seen only at the 4-hour retention trial, in which 24-month Pdyn
KO mice show elevated novel-object exploratory activity, which was significantly
different from 24-month WT [F(1, 36) = 5.12, p<0.03], 6-month Pdyn KO [F(1, 36) =
6.18, p<0.018], and 12-month Pdyn KO mice [F(1, 36) = 7.60, p<0.009].

Total

exploratory times were also recorded during each trial and analyzed by ANOVA (Figure
3.24), with significant Pdyn effects [F(1, 36) = 4.62, p<0.038], trial effects [F(4, 144) =
13.92, p<0.0005], and trial-Pdyn-age interactions [F(8, 144) = 2.49, p<0.015]. In the first
trial, exploration time in young adult Pdyn KO mice is markedly elevated, resulting in
significant differences in comparison to 6-month WT [F(1, 36) = 8.77, p<0.005] and 24month Pdyn KO mice [F(1, 36) = 5.46, p<0.025]. In contrast, total exploratory time in
Trial 1 is increased at 24 months in WT mice [F(1, 36) = 7.05, p<0.012]. In Trials 2 and
3, exploration times in most groups show progressive decline due to habituation effects,
but 6-month Pdyn KO mice continued to exhibit increased exploratory behavior that is
statistically significant compared to 6-month WT [F(1, 36) = 20.86, p<0.0005], 12-month
Pdyn KO [F(1, 36) = 10.90, p<0.002], and 24-month Pdyn KO mice [F(1, 36) = 19.20,
p<0.0005]. In Trials 4 and 5, with addition of the novel stimulus, most groups show
increased or unchanged exploration times; however, the only significant inter-group
difference was found in 24-month Pdyn KO mice, which showed increased total
exploratory activity in Trial 4 compared to 12-month Pdyn KO mice [F(1, 36) = 5.60,
p<0.023].
In the second object recognition protocol, only three trials were used, with Trials
2 and 3 serving as retention trials at 1 and 4 hours, respectively (Figure 3.25). Young
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Figure 3.24. Effects of age and Pdyn deletion on total exploration time during object
recognition assay using Protocol 1.
Pdyn KO mice demonstrate greater exploratory activity that WT mice, especially among
young adult mice. *p<0.05, **p<0.01, ***p<0.001 compared to corresponding 6-month
mice, or where indicated, to corresponding 12-month mice. ##p<0.01, ###p<0.001
compared to corresponding WT mice.

WT mice appear to show decreased baseline preference for one of the objects during the
acquisition trial, resulting in a significant age effect compared to 14-month [F(1, 12 =
7.86, p<0.016] and 24-month WT mice [F(1, 12) = 12.17, p<0.004]. In Trial 2, the
proportion of exploratory time on the target object is increased in all groups without any
between-group differences.

However, in Trial 3, the 4-month WT group shows a

diminished response to the novel stimulus, resulting in a statistically significant
difference compared to 14-month WT mice [F(1, 12) = 7.87, p<0.016]. Additionally, 24month Pdyn KO mice in Trial 3 also show diminished novel object exploratory activity,
with findings of statistical significance in comparison to 14-month Pdyn KO mice [F(1,
23) = 4.425, p<0.047]. Assessment of ratios of novel object exploration times to
cumulative exploration time under Protocol 2 revealed no significant effects of either
Pdyn deletion or age.
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Discussion
The above results show that multiple behavioral endpoints are affected by Pdyn deletion
with some effects showing significant age dependence. First, in the inhibitory avoidance
assay, which applies Pavlovian fear conditioning in an operative learning paradigm, Pdyn
KO and WT mice of varying ages were assessed to determine whether the animal
subject's motivation to exit a brightly lit chamber exceeds the adverse reaction to a
negatively reinforcing stimulus. Our results show that young adult mice lacking Pdyn
exhibit increased step-through latencies during both acquisition and retention passive
avoidance trials. The increased retention step-through latency in Pdyn KO mice may
signify relatively improved 72-hour recall of the aversive stimulus compared to WT
counterparts. Since none of the mice in the 3-month Pdyn KO group traversed into the
dark chamber in the retention trial, the ceiling effect imposed by the 15-mnute maximum
likely underestimates the magnitude of this Pdyn genotype effect, and it is plausible that
longer retention intervals may elicit differences in maximal recall interval.

Figure 3.25. Effects of age and Pdyn deletion on object recognition using Protocol 2.
Left: Novel object preference is expressed as a fraction of total object exploration time
spent interacting with the novel object or, in the case of Trial 1, the object in the position
where the novel object of the subsequent trial is to be placed. An age-related decline in
novel object interaction is seen in Pdyn KO mice in Trial 3. Right: Total time spent on
the novel object is expressed relative to total cumulative object exploration time to
control for individual differences in baseline exploratory tendencies. *p<0.05, **p<0.01
compared to corresponding 4-month mice, or where indicated, to corresponding 14month mice.
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Dynorphins have been found to dose-dependently impair retention in an inhibitory
avoidance task in mice (Introini-Collison et al., 1987). It is plausible that unknown
compensatory effects in Pdyn KO mice may render such effects less evident in the
present study. However, other studies using the passive avoidance task have found Dyn
A, Dyn B, and Dyn-32 to facilitate retention (Kuzmin et al., 2006) or to prevent
impairment induced by other pharmacologic agents (Hiramatsu et al., 1996; Ukai et al.,
1997). The significance of increased acquisition latency in 3-month Pdyn KO mice is
unclear, given the lack of similar findings in other age groups in this study.

One

interpretation is that Pdyn KO mice used in the assay have less basal exploratory
behavior, which may explain the increased step-through latencies both before and after
the negatively reinforcing stimulus. However, the open-field data do not support this
assertion, since young male Pdyn KO mice showed mildly increased basal exploratory
behavior. Alternatively a delayed latency may also suggest increased anxiety in Pdyn
KO mice, as

agonists have been reported to show anxiolytic properties in rodents

(Privette and Terrian, 1995).
While the passive avoidance task is often interpreted in the context of operant
learning, the role of opiates in pain processing pathways may potentially undermine the
internal validity of studies assuming uniform nociceptive response to adverse stimuli.
For instance, intrathecal Dyn B and Dyn-32 can induce nociceptive behavior (Tan-No et
al., 2002).

However, infusion of exogenous Dyn A and B into cerebrospinal fluid

increases nociceptive latencies in a hot-plate assay (Kuzmin et al., 2006), indicating
potential analgesic effects of these peptides.

The absence of a Pdyn deletion effect on

the tail flick assay in the present study decreases the likelihood of altered perception of
painful stimuli influencing the animals' performance in the passive avoidance task. This
absent pronociceptive effect of dynorphins has been replicated by other investigators
using Pdyn KO mice (Wang et al., 2001).
Open-field activity was used in this study to measure spontaneous locomotion as a
function of age and Pdyn genotype. While our results show a reproducible intra-trial
habituation effect, significant Pdyn effects were observed only when analyzing groups
subclassified by gender.

Male young adult Pdyn KO mice show mild increases in

markers of baseline exploratory activity, with significant gender differences manifested
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primarily among KO mice. An inhibitory action of dynorphins on exploratory behavior
has been previously documented in rats (Tilson et al., 1986). While the existing literature
contains few studies on a gender interaction with Pdyn, anti-estrogen agents have been
noted to enhance Pdyn expression (Spampinato et al., 1995). Females may be more
responsive to dynorphins, since at least one human study found that basal prolactin levels
and dynorphin-induced prolactin release are significantly higher in females (Kreek et al.,
1999). Since prolactin release is under tonic inhibition by dopamine, these findings
suggest a potential mechanism whereby gender effects contribute to differences in motor
activity. Interestingly, female mice consistently demonstrated increased movement speed
across all three Pdyn genotypes in this study.
Aging in this study yielded a significant but mild decrease in motor speed and an
increase in stereotyped behavior. This is consistent with previous studies that have
shown age-associated decreases in open-field locomotor activity and increases in
susceptibility to stimulant-induced stereotypic motor behaviors in rats (Dorce and
Palermo-Neto, 1994).

Interestingly, aging male mice show increases in multiple

indicators of exploratory behavior that are not evident in aged females. Some of these
measures may be attributable to anxiety, based on associated increases in stereotypy
counts.
Open-field indicators of locomotor activity are significantly reduced in WT mice
systemically injected with MPTP, while MPTP-injected Pdyn KO and HET mice show
no substantial declines in motor activity beyond the habituation effect that is also seen in
saline controls. The hypokinetic effect of MPTP, which induces dopaminergic cell loss
as a model of parkinsonism (Heikkila et al., 1984), is similar to that observed previously
in C57BL mice (Sedelis et al., 2001; Vijitruth et al., 2006), other mouse strains (Sedelis
et al., 2001), or rats (Prediger et al., 2006). Our findings that Pdyn deletion produces a
relative sparing of MPTP-induced motor dysfunction may be explained by inhibitory
effects of dynorphin peptides on the striatal dopaminergic system, since dynorphins and
exogenous

agonists inhibit dopamine release in striatum and nucleus accumbens

(Mulder et al., 1984; Herrera-Marschitz et al., 1986; Di Chiara and Imperato, 1988; Reid
et al., 1988; Spanagel et al., 1992; Ronken et al., 1993; Schlosser et al., 1995), while
antagonists enhance dopamine release (Spanagel et al., 1992). A mild speed increase is
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observed in the MPTP-injected WT groups; however it is probable that this finding is
artifactual due to the significantly decreased movement time and the decreased accuracy
of distance measures in the setting of substantially depressed motor activity. It should be
recognized that the observed changes in open-field behavior may be related to altered
mechanisms of reward or arousal rather than motor impairment per se.
Object recognition tasks, which in contrast to the inhibitory avoidance assay or
water maze tasks permit evaluation of learning in the absence of an aversive stimulus,
were used to determine effects of aging and Pdyn deletion on recognition and passive
recall. In both protocols, average object recognition parameters in Pdyn KO mice are
slightly lower than their WT counterparts in most comparisons; however the most reliable
finding is that 24-hour recall in Pdyn KO mice is significantly impaired among 12-month
and 24-month mice. However, the proportion of time spent on novel object exploration
in these cases was substantially less than 50%, suggesting an altered response to novel
stimuli rather than a recognition memory failure may account for these observations. In
fact, despite spending a smaller percentage of time on the novel objects during retention
trials, the total of time spent exploring either object is substantially elevated in the Pdyn
KO mice.

The above conjecture is supported by our further findings that young Pdyn

KO mice show significantly greater total exploration times. While most groups show
declining total exploratory activity when presented with only familiar objects during the
acquisition phase of Protocol 1, the young adult Pdyn KO mice exhibited substantially
less habituation-related change, resulting in a sustained elevation in total exploratory
times across all trials. These findings are internally consistent with the results of our
open-field experiments showing markedly elevated exploratory indices in young Pdyn
KO mice.
The present findings demonstrate subtle changes in learning and memory and
motor function attributable to Pdyn deletion. While the improved performance of Pdyn
KO mice in the passive avoidance trial may appear on initial observation to conflict with
the minimally affected object recognition parameters, it has previously been proposed
that the role of dynorphins in memory may depend on the nature of the reinforcing
stimulus (Yakovleva et al., 2006a). The variation in the effects of Pdyn deletion on
performance in the different learning and memory paradigms may be related to the
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differing neuroanatomical substrates involved in each type of learning task. For instance,
a recent study found that subchronic exposure to phencyclidine, which increases striatal
dynorphin expression, causes impairment of novel object recognition without affecting
passive avoidance (Shirayama et al., 2007). Since dopamine mediates the reinforcement
of addictive behaviors (Bozarth and Wise, 1983) and since the

opioid system is

believed to modulate dopaminergic tone (Di Chiara and Imperato, 1988; Spanagel et al.,
1992; Kreek, 1996; Kreek et al., 2002), dynorphinergic dysregulation is likely to interfere
preferentially with tasks involving activation of dopamine-dependent reward pathways.
In the case of water maze and passive avoidance performance, it is conceivable that the
reward mechanisms associated with escape from the water maze and avoidance of an
electrical shock, respectively, are less subject to inhibition in Pdyn KO mice, resulting in
improved performance.
Given the fairly diverse pharmacological profile of the various Pdyn-derived
peptides and their potential roles in not only learning and memory, but also reward
mechanisms, motor activity, and nociception, further studies are need to clarify the
mechanisms by which Pdyn deletion produces the effects seen in the present study.
However, the effects of dynorphins on dopaminergic pathways represent a plausible site
of action of dynorphins in influencing performance in the behavioral assays discussed
above. The following chapter will discuss changes in dopamine with aging and Pdyn
deletion.

Copyright © Xuan V. Nguyen 2007
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CHAPTER 4:

Effects of prodynorphin deletion on striatal dopamine in mice
during normal aging and in response to MPTP

Introduction
Alterations in dopamine neurotransmission in basal ganglia pathways produce motor
deficits in normal aging (Ingram, 2000) and pathological states like Parkinson’s disease
(PD) (Hornykiewicz and Kish, 1987; Graybiel et al., 1990; Forno, 1996). Dopamine,
synthesized by substantia nigra (SN) neurons projecting to the striatum, has been strongly
implicated in aging (Carlsson and Winblad, 1976; Kish et al., 1992; Reeves et al., 2002;
Haycock et al., 2003). More severe dopaminergic neuronal loss is observed in idiopathic
Parkinson’s disease (PD), for which advanced age is the most identifiable risk factor.
However a causal link between aging and these processes is yet unclear. Accumulating
evidence of interactions between dynorphin and dopamine pathways in the basal ganglia
suggests that these endogenous neuropeptides may play important roles in age-related
dopamine regulation with relevance to mechanisms of age-related motor dysfunction or
susceptibility to PD.
Dynorphin peptides are obtained by proteolytic cleavage of a precursor encoded
by the prodynorphin (Pdyn) gene (Simonato and Romualdi, 1996) and are expressed in
striatum, hypothalamus, nucleus accumbens, dentate gyrus, hippocampus, cerebral
cortex, and spinal cord (Khachaturian et al., 1982; Watson et al., 1982a; Watson et al.,
1982b; Khachaturian et al., 1993; Hurd et al., 1999). Within striatum, dynorphin is
colocalized with substance P and GABA within dopamine D1-receptor-expressing
striatonigral projection neurons (Steiner and Gerfen, 1998). Though originally identified
as an opiate (Goldstein et al., 1979) with picomolar affinity for

opioid receptors

(Chavkin et al., 1982), dynorphin has a complex pharmacological profile and can
participate in

or

opioid (Mansour et al., 1995) and non-opioid mechanisms (Brauneis

et al., 1996; Caudle and Dubner, 1998; Tang et al., 1999; Tang et al., 2000; Woods and
Zangen, 2001).

Dynorphins and exogenous

agonists inhibit dopamine release in

striatum and nucleus accumbens (Mulder et al., 1984; Herrera-Marschitz et al., 1986; Di
Chiara and Imperato, 1988; Reid et al., 1988; Spanagel et al., 1992; Ronken et al., 1993;
Schlosser et al., 1995), while

antagonists result in enhanced dopamine release
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(Spanagel et al., 1992). Conversely, dopamine promotes dynorphin expression via the
D1-receptor (Li et al., 1986; Li et al., 1988; Li et al., 1990; Bordet et al., 1997; Wong et
al., 2003).
Aging has varied effects on dynorphin expression, with age-related elevations in
dynorphin noted in the hippocampus and frontal cortex (Jiang et al., 1989; Zhang et al.,
1991; Gallagher and Nicolle, 1993) and in spinal cord (Iadarola et al., 1986; Zhang et al.,
2004a).

The molecular and biochemical causes and consequences of altered Pdyn

expression are unclear, but given the inhibitory roles of dynorphins on dopaminergic
activity and reports of dynorphin-mediated neurotoxicity (Hauser et al., 1999; Tan-No et
al., 2001; Goody et al., 2003; Singh et al., 2003), we hypothesized that suppression of
Pdyn expression would mitigate effects of aging on striatal dopaminergic activity. In this
study, we examine the chronic effects of Pdyn deletion on dopamine biosynthesis in mice
during normal aging by quantitating striatal dopamine content in wild-type (WT) and
Pdyn knockout (KO) mice.

Methods
Animal subjects
Mice used in this study were mixed male and female WT or Pdyn KO mice that were
maintained in an approved animal facility at the University of Kentucky. WT mice were
derived from the 129SvEv-Tac line, and Pdyn KO mice, provided by Dr. Ute
Hochgeschwender (Oklahoma Medical Research Foundation, Oklahoma City, OK), were
obtained by targeted deletion of the coding exons of the Pdyn gene and maintained in a
129SvEv-Tac background (Sharifi et al., 2001). Animals were housed in groups of up to
4 per cage with food and water ad libitum in a well-ventilated room with a 12 h: 12 h
light:dark cycle. Prior to weaning, tail specimens were collected from each animal, and
DNA was extracted for subsequent genotyping to confirm the identity of the Pdyn locus
by the polymerase chain reaction (PCR) using primer pairs specific for each allele. For
experiments involving 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 3-month
(n = 3 - 5 per group) and 10-month (n = 5 - 8 per group) mice were injected with 0.9%
saline or MPTP (Sigma, St. Louis, MO) at a dose of 15 mg/kg intraperitoneally four
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times at 2-h intervals and euthanized at 7 days post-injection. A 20-month age point was
not selected in the MPTP experiments due to logistical reasons pertaining to availability
of mice of substantially advanced age. Striatal tissue specimens were dissected on ice
from CO2-asphyxiated mice, weighed, frozen in liquid nitrogen, and stored at -80°C until
needed for protein extraction or high-performance liquid chromatography (HPLC)
analysis. All procedures involving animals were approved by the Institutional Animal
Care and Use Committee at the University of Kentucky.

HPLC analysis
HPLC analysis was performed based on methods described previously (Hall et al., 1989).
Sensitive detection of 3,4-dihydroxyphenylacetic acid (DOPAC), dopamine (DA),
serotonin (5-HT), norepinephrine (NE), 5-hydroxyindole-3-acetic acid (5-HIAA), and 4hydroxy-3-methoxyphenylacetic acid (homovanillic acid; HVA) were performed using an
isocratic HPLC system (Beckman, Inc., Fullerton, CA) at a flow rate of 2 ml/min coupled
to a dual-channel electrochemical array detector (model 5100A, ESA, Inc., Chelmsford,
MA), E1 = +0.35 mV and E2 = -0.25 mV, using an ESA model 5011 dual analytical cell.
The compounds of interest were separated by reverse-phase chromatography, using a C18
column (4.6 mm x 75 mm, 3- m particle size, Shiseido CapCell Pak UG120, Shiseido
Co., LTD., Tokyo, Japan) with a pH 4.1 citrate-acetate mobile phase containing 4.0%
methanol and 0.341 mM 1-octane-sulfonic acid. By comparison to a set of analytical
standards, quantities of the species of interest were calculated as pmol per mg wet tissue,
and the results expressed as means ± standard errors of the mean (SEM). Samples
exhibiting aberrantly high quantities of degradation products consistent with post-mortem
degradation or poor tissue quality were identified and excluded from the analysis based
on the presence of one or more turnover ratios exceeding 5 standard deviations above the
sample mean. Results were pooled from multiple HPLC experiments after applying a
proportional scaling factor to normalize data to the mean of the 10-mo WT control group
in each experiment to minimize run-to-run variability in quantitation.
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Protein extraction and western blotting
Whole striatal specimens from a separate group of 3- (n = 6 per group) and 21-month (n
= 8 per group) WT and Pdyn KO mice were dissected and homogenized in lysis buffer
containing 10 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 1 mM Na
orthovanadate, and protease inhibitor cocktail (1:1000 dilution; Sigma, St. Louis, MO)
using a Brinkman Kinematic sonicator. Following a 30- to 60-minute incubation on ice,
samples were centrifuged to remove cell debris, and protein content was determined by a
modification of the Lowry assay using the DC Protein Assay kit (catalog #500-0115;
Bio-Rad Laboratories, Hercules, CA).
Prior to loading, samples were normalized to a concentration of 1.0 mg/ml and
subsequently diluted in loading buffer containing 5% 2-mercaptoethanol (BME; Sigma,
St. Louis, MO), boiled for 5 minutes, and cooled on ice. Samples containing 7 mg total
protein were subjected to electrophoresis in 12% polyacrylamide gels, followed by
transfer onto nitrocellulose membranes. Membranes were then washed in a Tris-buffered
saline wash buffer containing 0.05% Tween-20, blocked with 5% blotting-grade non-fat
milk, and incubated at room temperature with primary antibody for a minimum of 2 h.
The primary antibodies used are as follows: tyrosine hydroxylase (TH, 1:3000 dilution;
Pel-Freez Biologicals, Rogers, AK), phospho-Ser40-TH (1:2500 dilution; Chemicon),
phospho-Ser31-TH (1:2500 dilution; Chemicon, Billerica, MA), dopamine transporter
(DAT C-20, 1 g/ml; Santa Cruz Biotech, Santa Cruz, CA), synaptophysin (SY38, 1:200
dilution; Research Diagnostics, Inc., Flanders NJ), and actin (1:3000 dilution, Sigma, St.
Louis, MO).
Following repeated washes in wash buffer, membranes were then incubated for 2
h with horseradish peroxidase-conjugated secondary antibody.

After at least three

successive rinses in wash buffer, chemiluminescent detection by the ECL-plus system
(Amersham, Piscataway, NJ) was performed, with subsequent exposure on Amersham
Hypermax film. For multiple antibody probings on a single blot, membranes were
stripped by a 40-minute incubation in 0.7% BME at 55°C.
Film exposures were scanned using an Epson Expression 1640XL scanner under
transparency mode, and the resulting images were recorded as uncompressed 8-bit
grayscales at 300 dpi resolution. Optical densities (ODs) of the band of interest in each
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lane were measured using Scion Image software (release beta 4.0.2, Scion Corporation,
Houston, TX) by recording the average pixel grayscale value within rectangular areas of
a fixed size for a given image. Background ODs were obtained at multiple points along
the width of the image, and the average background value was subtracted from each band
OD prior to normalizing to the respective actin band OD and expressing the results
relative to the mean value for the image. Data were obtained by combining results from
two different gels containing samples from distinct sets of mice and are expressed as
mean relative ODs ± standard errors of the mean (SEM).

Statistical analysis
Statistical analyses were performed using Systat 10 software (SPSS, Inc., Chicago,
Illinois). Two-way ANOVA was used for evaluating effects of aging and Pdyn, and in
experiments involving an MPTP component, three-way ANOVA was applied. Individual
contrasts were obtained by the least significant difference method.

Results
Striatal dopamine is elevated in aged Pdyn KO mice
Quantitative HPLC analysis of dopamine from mouse striatal samples demonstrated that
dynorphin-deficient mice on average exhibited markedly higher dopamine concentrations
in striatum than WT mice, especially at increasing age (Figure 4.1). Two-way ANOVA
of dopamine levels revealed a significant main effect of age [F(2, 24) = 4.77, p<0.018]
and of Pdyn genotype [F(1, 24) = 5.42, p<0.029]. Striatal dopamine concentrations in
Pdyn KO mice were significantly higher at 10 months [F(1, 24) = 8.48, p<0.02] and 20
months [F(1, 24) = 6.44, p<0.008], when compared to 3-month Pdyn KO mice.
However, the Pdyn genotype effect on total striatal dopamine levels was only statistically
significant in the 20-month group [F(1, 24) = 4.50, p<0.045].

Notably, there was no

appreciable age-related decline in total striatal dopamine content in the WT mice of this
study.

64

No significant differences with age or Pdyn genotype were noted in the
metabolites DOPAC or HVA despite an increase in mean DOPAC levels with age.
However, two-way ANOVA of molar turnover ratios revealed subtle but statistically
significant differences (Figure 4.2). With increasing age, the mean DOPAC/DA ratio
exhibited an increasing trend whereas the mean HVA/DA ratio decreased. The increase
in the DOPAC/DA ratio was most prominent among the WT mice with an approximately
50% elevation at 20 months that was nonetheless short of significance [F(1, 24) = 3.76,
p<0.064 (NS)].

In contrast, the Pdyn KO mice showed minimal change in the

DOPAC/DA ratio with age, resulting in a significant Pdyn genotype effect at 20 months
when examining either DOPAC/DA [F(1, 24) = 4.51, p<0.044] or (DOPAC+HVA)/DA
[F(1, 24) = 4.91, p<0.036]. A statistically significant age effect was seen only in the
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20-mo.

HVA/DA ratio, with significant declines noted among WT mice at 10 months [F(1, 24) =
4.49, p<0.045] and among Pdyn KO mice at 10 months [F(1, 24) = 5.86, p<0.023] and at
20 months [F(1, 24) = 6.57, p<0.017]. Analysis of norepinephrine, serotonin, and the
serotonin metabolite HIAA resulted in no significant contrasts (Figure 4.3). The turnover
ratio HIAA/5HT also did not show significant age or Pdyn genotype effects (Figure 4.2).
Although the present study was not initially designed to optimally assess effects
of gender, inclusion of gender as an additional ANOVA factor reveals a main effect of
gender on dopamine quantities [F(1, 19) = 5.49, p<0.03] with males averaging 14%
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Figure 4.2. Dopamine and serotonin turnover ratios as a function of age and Pdyn
genotype.
These results were obtained by HPLC analysis of whole striatum homogenates of WT
and Pdyn KO mice aged 3, 10, and 20 months. Only mild decreases in dopamine
turnover ratios are seen in aged Pdyn KO mice, whereas no trends in serotonin turnover
were observed. Data represent means SEM. *p<0.05 relative to corresponding 3month mice; #p<0.05 relative to corresponding WT mice.
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Figure 4.3. HPLC analysis of norepinephrine (NE), serotonin (5-HT), and the serotonin
metabolite HIAA as a function of age and Pdyn genotype.
These results were obtained by HPLC analysis of whole striatum homogenates of WT
and Pdyn KO mice aged 3, 10, and 20 months. No significant effects were noted for
these variables. Data represent means SEM.

higher dopamine levels than females irrespective of Pdyn or age (males: 90.5
pmol/mg tissue; females: 79.3

5.9 pmol/mg tissue).

6.8

In addition, a Pdyn-gender

interaction was also significant [F(1, 19) = 5.47, p<0.03], as gender differences were less
apparent among Pdyn KO mice. A male gender effect on dopamine levels was observed
in WT mice [males: 84.5

7.9 pmol/mg tissue; females: 72.8

6.2 pmol/mg tissue; F(1,

19) = 7.49, p<0.013], but was smaller and not significant in Pdyn KO mice (males: 93.1
9.4 pmol/mg tissue; females: 88.5

11.0 pmol/mg tissue).

Significant gender effects

were not observed with other amines or any turnover ratios examined in this set of mice.

Pdyn deletion enhances TH phosphorylation at Ser40
Western blotting analyses were performed on young (3-month) and aged (21-month)
mice to detect TH, the rate-limiting enzyme in dopamine synthesis that catalyzes the
conversion of tyrosine to the dopamine precursor L-dopa (Figure 4.4).

Other

dopaminergic and neuronal markers were also examined, including DAT, SY38, and
actin (Figure 4.4). In addition, because TH activity can be modulated by phosphorylation
at specific serine sites (Haycock and Haycock, 1991; Sutherland et al., 1993; Harada et
al., 1996; Lindgren et al., 2000; Lindgren et al., 2001), phospho-Ser40-TH and phospho-
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3-mo WT

3-mo KO

21-mo WT

21-mo KO

TH
P-Ser40-TH
P-Ser31-TH
DAT
SY38
actin
Figure 4.4. Representative Western blot of mouse striatal homogenates.
Immunoblot analysis of whole striatum homogenates of WT and Pdyn KO mice aged 3
and 21 months was performed, and bands representing immunoreactivity to TH,
phospho-Ser40-TH (P-Ser40-TH), phosphor-Ser31-TH (P-Ser31-TH), dopamine
transporter (DAT), synaptophysin (SY38), and actin as a function of age and Pdyn
genotype are shown. Depicted are blots from a representative gel from one of two
separate experiments that are pooled for statistical analysis.

Ser31-TH immunoreactivity were also examined. Two-way ANOVA to evaluate for
effects of age and Pdyn genotype revealed significant main effects of age [F(1, 24) =
5.51, p<0.027] and Pdyn genotype [F(1, 24) = 10.40, p<0.004] on TH immunoreactivity
(Figure 4.5). A statistically significant age effect was noted only in the WT mice, with
21-month mice displaying approximately 50% greater TH immunoreactivity than 3month mice [F(1, 24) = 4.67, p<0.041]. In both age groups, mean TH immunoreactivity
in Pdyn KO mice was approximately 60% that of the corresponding WT mean; however
statistical significance was seen only among the aged mice [F(1, 24) = 9.03, p<0.006].
Phospho-Ser40-TH also exhibited a significant main effect of aging [F(1, 24) =
12.69, p<0.002], with aged Pdyn KO mice demonstrating an increase by a factor of 3.6
compared to young Pdyn KO mice [F(1, 24) = 10.97, p<0.003]. In contrast, phosphoSer31-TH showed a significant Pdyn effect [F(1, 24) = 4.76, p<0.039] similar to that
exhibited by total TH, but there was no statistically significant aging effect.
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A

significant main effect of age was also noted for the dopamine transporter [F(1, 24) =
5.41, p<0.029], although individual contrasts were not significant in this analysis.
Correlation analysis confirmed that DAT levels correlated very strongly with TH
(Pearson's correlation coefficient r = 0.889, Bonferroni-corrected p<0.0005).

No

significant differences were evident in synaptophysin levels in this study.
To assess the extent to which the above differences in immunoreactivity to
phosphorylated TH reflect posttranslational effects as opposed to changes in
dopaminergic neuron mass, a separate analysis was also performed on phospho-Ser40TH: total TH and phospho-Ser31-TH: total TH ratios (Figure 4.5). This analysis revealed
no age effect but demonstrated a significant main effect of Pdyn genotype on only the
phosphor-Ser40-TH: total TH ratio [F(1, 24) = 5.09, p<0.033], which was approximately
2-fold higher in Pdyn KO mice compared to the respective WT counterparts, with a
significant difference observed only among the aged groups [F(1, 24 = 4.55, p<0.043].

Table 4.1. ANOVA results from analysis of effects of MPTP, age, and Pdyn genotype on
dopamine and related monoamines.
Three-way ANOVA was performed on results of monoamine quantitation and their
respective turnover ratios. Only variables for which a statistically significant effect or
interaction is noted are listed below along with corresponding F statistics and p-values.
MPTP effect
DA
DOPAC
HVA
5HT
HVA / DA
DOPAC / DA
(DOPAC + HVA) / DA
HIAA / 5HT
Pdyn effect
5HT
MPTP x age
DA
DOPAC
HVA

F(1, 37) = 54.93
F(1, 37) = 9.88
F(1, 37) = 11.76
F(1, 37) = 22.93
F(1, 37) = 11.65
F(1, 37) = 12.15
F(1, 37) = 12.76
F(1, 37) = 9.13

p<0.0005
p<0.003
p<0.002
p<0.0005
p<0.002
p<0.001
p<0.001
p<0.005

F(1, 37) = 4.46

p<0.042

F(1, 37) = 9.72
F(1, 37) = 4.61
F(1, 37) = 4.86

p<0.004
p<0.038
p<0.034
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MPTP-induced dopamine loss is unaffected by Pdyn deletion
We also examined dopaminergic changes induced by systemic MPTP, which mimics in
mice many features of human parkinsonism via toxic degeneration of SN dopaminergic
neurons (Arai et al., 1990; Sundstrom et al., 1990).

Intraperitoneal MPTP was

administered to 3- or 10-month Pdyn KO or WT mice, with corresponding saline
controls. A 3-way ANOVA to evaluate the effects of MPTP administration, age, or Pdyn
genotype on dopamine and its metabolites found significant main effects of treatment and
an MPTP-age interaction but no main effect of age or genotype in this data set (Table
4.1).

Levels of dopamine in the striatum significantly decreased 7 days following

intraperitoneal MPTP administration (Figure 4.6).

Among 10-month mice, MPTP

resulted in a reduction of dopamine levels by 71% in WT mice [F(1, 37) = 34.64,
p<0.0005] and 73% in Pdyn KO mice [(F(1, 37) = 44.48, p<0.0005] when compared to
respective saline-injected controls. The MPTP-associated loss of dopamine among the 3month mice was less robust, with MPTP-injected WT mice exhibiting a nonsignificant
reduction of 40%, and Pdyn KO mice demonstrating a statistically significant 46%
reduction [(F(1, 37) = 5.66, p<0.023]. Consistent with the preceding analysis, salineinjected Pdyn KO mice at 10 months showed significantly higher dopamine levels
compared to 3-month Pdyn KO mice [(F(1, 37) = 8.96, p<0.005].
The dopamine metabolites DOPAC and HVA also showed significant MPTPinduced changes, most prominent at 10 months (Figure 4.6). DOPAC levels decreased
by over 50% following MPTP administration in 10-month WT [F(1, 37) = 9.98, p<0.003]
and 10-month Pdyn KO mice [F(1, 37) = 10.08, p<0.003]. Similarly, MPTP caused a
decrease in HVA by 33% and 44% in 10-month WT [F(1, 37) = 6.95, p<0.012] and 10month Pdyn KO mice [F(1, 37) = 16.15, p<0.0005], respectively.
Serotonin levels also responded significantly to MPTP (Figure 4.7).

MPTP

administration was associated with an approximately 25% decline in striatal serotonin
levels in each group with statistical significance noted in 3-month Pdyn KO [F(1, 37) =
5.70, p<0.022], 10-month WT [F(1, 37) = 12.45, p<0.001], and 10-month Pdyn KO mice
[F(1, 37) = 6.01, p<0.019]. No significant contrasts were observed in levels of HIAA or
NE.

However, the serotonin turnover ratio (HIAA / 5HT) was found to increase
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following MPTP administration in 10-month WT mice to 1.7 times that of saline controls
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[F(1, 37) = 7.40, p<0.01, Figure 4.8].

Figure 4.5. Densitometric quantitation of Western blot data.
Immunoreactivity to (a) tyrosine hydroxylase (TH), (b) phospho-Ser40-TH (pSer40-TH),
(c) phospho-Ser31-TH (pSer31-TH), (d) dopamine transporter (DAT), (e) phosphoSer40-TH: total TH ratio, (f) phospho-Ser31-TH: total TH ratio, (g) synaptophysin
(SY38), and (h) actin are shown as a function of age and Pdyn genotype. Pdyn KO mice
demonstrate increased phosphorylation of TH at Ser40 but not Ser31, an effect most
prominently seen at 21 months. However, total TH immunoreactivity was decreased in
Pdyn KO mice compared to WT mice. Data were pooled from two separate gels and
represent mean relative optical densities (ODs) SEM. *p<0.05, **p<0.01 relative to
corresponding 3-month mice; #p<0.05, ##p<0.01 relative to corresponding WT mice.
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Figure 4.6. Effect of MPTP on dopamine and its metabolites as a function of age and
Pdyn genotype.
These results reflect HLPC measurements of dopamine (DA) and its metabolites in
whole striatum from 3- and 10-month mice obtained 7 days post-injection of saline or
MPTP. Note the decreases in dopamine with milder reductions in DOPAC and HVA in
†
response to MPTP. Data represent means
SEM.
p<0.05, ‡p<0.01 relative to
corresponding saline controls; *p<0.05, **p<0.01 relative to corresponding 3-month
mice; #p<0.05 relative to corresponding WT mice.

Dopamine turnover ratios also increased upon MPTP administration, more
prominently among the 10-month mice (Figure 4.8). MPTP caused DOPAC/DA to
increase in 10-month WT and Pdyn KO mice to 2.5 [F(1, 37) = 9.57, p<0.004] and 3
times [F(1, 37) = 10.41, p<0.003] the saline control values, respectively, and HVA/DA
increased 3.6-fold [F(1, 37) = 9.03, p<0.005] and 3.9-fold [F(1, 37) = 7.89, p<0.008],
respectively. Consequently, the (HVA+DOPAC)/DA ratio was increased by a factor of
2.8 and 3.3 in 10-month WT [F(1, 37) = 9.98, p<0.003] and Pdyn KO mice [F(1, 37) =
9.99, p<0.003], respectively.

This analysis also revealed modest but statistically

significant elevations in HVA levels in saline-injected 10-month Pdyn KO mice
compared to saline-injected 10-month WT mice [F(1, 37) = 4.56, p<0.039] or 3-month
Pdyn KO mice [F(1, 37) = 5.57, p<0.024]. Inclusion of gender in the ANOVA analysis
found no significant main effects of gender in any of the monoamine levels examined in
the above MPTP experiment. However, a significant MPTP-sex interaction was evident
in dopamine [F(1, 29) = 10.22, p<0.003] and HVA levels [F(1, 29) = 4.17, p<0.05).
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Figure 4.7. Effect of MPTP on NE, 5-HT, and HIAA.
NE and HIAA show no significant changes in response to MPTP, but 5-HT shows mild
decreases 7 days after MPTP injection. Data represent means SEM. †p<0.05, ‡p<0.01
relative to corresponding saline controls.

MPTP-induced loss of dopamine in males averaged across all groups was 81% compared
to 41% in females. MPTP-sex interactions were also noted for the turnover ratios
HVA/DA [F(1, 29) = 5.69, p<0.024], DOPAC/DA [F(1, 29) = 4.47, p<0.043],
HIAA/5HT [F(1, 29) = 4.82, p<0.036], and (HVA+DOPAC)/DA [F(1, 29) = 5.55,
p<0.026], for which female turnover ratios averaged 40-60% less than the corresponding
male ratios. The gender discrepancy in turnover ratios was more pronounced among 10month mice, as manifested by significant age-MPTP-sex interactions for DOPAC/DA
[F(1, 29) = 5.46, p<0.027], HIAA/5HT [F(1, 29) = 8.11, p<0.008], and
(HVA+DOPAC)/DA [F(1, 29) = 4.56, p<0.041].

Discussion
In this study, quantitative HPLC was used to identify changes in dopamine, other
biogenic amines, and related metabolites in mouse striatum with aging, Pdyn deletion, or
MPTP. Interestingly, no decline in dopamine levels with aging alone was apparent
among WT mice. While several studies have documented declines in striatal dopamine
with aging in rats (Moretti et al., 1987; Marshall and Rosenstein, 1990), monkeys (Collier
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Figure 4.8. Effect of MPTP on dopamine and serotonin turnover ratios.
MPTP produces increases in dopamine turnover and serotonin turnover 7 days postinjection, findings which are statistically significant only among older (10-month) mice.
Data represent means SEM. †p<0.05, ‡p<0.01 relative to corresponding saline controls.
et al., 2007), and humans (Carlsson and Winblad, 1976; Kish et al., 1992; Haycock et al.,
2003), there have also been studies in rodents describing whole-striatum dopamine
content to demonstrate minimal or no decline with age (Friedemann and Gerhardt, 1992;
Burwell et al., 1995; Hebert and Gerhardt, 1998; Stanford et al., 2003).
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While the

relatively preserved dopamine content among WT mice in this study may be attributable
to species and strain differences, it also lends support to the view that normal aging alone
is unlikely to produce the pathological dopamine deficits seen in disorders such as
Parkinson's disease.
The use of Pdyn KO mice offers distinct advantages over studies employing
traditional pharmacologic antagonists as this study does not presume a specific receptor
interaction and permits evaluation of chronic changes in the presence of compensatory
effects, which would likely not be feasible when using only exogenously applied agents.
We show in this study that striatal dopamine is elevated in aging Pdyn KO mice
compared to aging WT mice. These findings could be interpreted as a chronic inhibitory
effect of dynorphin on dopamine biosynthetic activity, or alternatively, a harmful effect
of dynorphins on dopaminergic cell survival in the SN. Despite published evidence that
dynorphin peptides may exhibit toxic or pro-apoptotic effects in both neuronal and nonneuronal cells under various experimental conditions (Hu et al., 1996; Hauser et al.,
1999; Hu et al., 1999; Hu et al., 2000; Hauser et al., 2001; Tan-No et al., 2001; Goody et
al., 2003; Singh et al., 2003), the latter interpretation is less likely because in comparison
to their WT counterparts, 21-month Pdyn KO mice in this study show less
immunoreactivity to TH, a surrogate marker for dopaminergic neuron mass. Moreover, a
putative neurotoxic role of dynorphin is further challenged by reports that dynorphin
peptides can show neuroprotective properties in some situations (Kong et al., 1997; Liu et
al., 2001; Gabrilovac et al., 2003). Differences in total TH levels are therefore unlikely
to account for the altered dopamine levels seen with aging in Pdyn KO mice. One study
examining post-mortem human striata found an aging-associated decline in striatal
dopamine content without loss of TH (Haycock et al., 2003), suggesting that impaired
dopaminergic neuron function rather than cell death could account for the relative
dopamine depletion in aged WT mice relative to aged Pdyn KO mice in this study. This
assertion is supported by reports that infusion of dynorphin into the striatum decreases
dopamine levels by as much as 60% (Zhang et al., 2004b).
Consequently, we addressed the effect of aging and Pdyn deletion on the
enzymatic activity of TH, which is subject to physiological regulatory control via
phosphorylation at Ser31 or Ser40 by different kinase pathways, resulting in increases in
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the intrinsic rate of catalysis (Haycock and Haycock, 1991; Sutherland et al., 1993;
Harada et al., 1996; Lindgren et al., 2000; Lindgren et al., 2001). Other investigators, for
instance, have noted increased Ser31 phosphorylation of TH by neurotrophic factors
(Salvatore et al., 2004). Although we did not directly measure enzyme activity, our
results show that a greater proportion of TH molecules in aged Pdyn KO mice are
phosphorylated at the Ser40 site compared to aged WT mice. Because activation of
striatal dopamine D2 receptors selectively inhibits TH phosphorylation at Ser40 via
inhibition of adenylate cyclase (Lindgren et al., 2001), the increased phospho-Ser40-TH
in aged Pdyn KO mice may be attributable to decreased D2 receptor activity.
Alternatively, glutamate acting via NMDA receptors can also decrease TH
phosphorylation at Ser40 in striatum (Lindgren et al., 2000), and since dynorphin
peptides have been observed to potentiate NMDA receptor activation (Zhang et al., 1997;
Woods et al., 2006), the increased Ser40 phosphorylation in dynorphin-deficient mice in
the present study is consistent with the above observations.

While the precise

mechanisms underlying the age-associated increases in dopamine in Pdyn KO mice
remain to be elucidated, the available data suggest a role of dynorphin peptides in
suppressing dopaminergic neuron function via regulation of dopamine biosynthesis.
Other potential mechanisms include cellular or metabolic dysfunction caused by toxic
effects of specific dynorphin peptides as supported by evidence of dynorphin toxicity in
striatal neurons (Goody et al., 2003; Singh et al., 2003), spinal neurons (Caudle and
Isaac, 1987; Qu and Isaac, 1993; Hauser et al., 1999), and non-neuronal cells (Tan-No et
al., 2001), primarily via non-opioid mechanisms.
In the present study, the Pdyn-associated differences in dopamine levels are more
pronounced and are statistically significant at increased age. The findings that advanced
age unmasks these effects may reflect age-related alterations in the dynorphinergic
system. Increased dynorphin was observed in hippocampus of normal aged rats (Jiang et
al., 1989; Zhang et al., 1991; Gallagher and Nicolle, 1993; Kotz et al., 2004), the cortex
and hippocampus of amyloid precursor protein-overexpressing mice (Diez et al., 2000),
frontal cortex of Down’s syndrome patients (Risser et al., 1996), and frontal and parietal
cortex of Alzheimer’s disease patients (Risser et al., 1996; Yakovleva et al., 2006a), thus
implicating

dynorphin

in

age-related

pathophysiological
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processes.

Peripheral

inflammation also upregulates Pdyn in spinal cord (Iadarola et al., 1986), and aging
enhances this response (Zhang et al., 2004a). In striatum, Pdyn expression with aging has
been less well studied, with some studies showing no changes in aging rats (Zhang et al.,
1991; Kotz et al., 2004) and one study finding decreased Pdyn mRNA in striatum of
normal aged humans (Backman et al., 2007). In addition, dynorphin expression is also
markedly influenced by the dopaminergic system.

In models of PD, decreases in

dynorphin have been noted following experimental manipulations that lesion the
nigrostriatal dopaminergic pathway (Gerfen et al., 1991). Similarly, striatal dynorphin
expression is increased by dopamine, its biochemical precursors, or exogenous D1
agonists (Li et al., 1986; Li et al., 1988; Li et al., 1990; Bordet et al., 1997) and is reduced
in D1-receptor knockout mice (Wong et al., 2003). The above studies point to a possible
dysregulation of Pdyn expression with aging that may lead to or be caused by
perturbations in the dopaminergic system.

In this study, the potential effects of

dynorphin on the dopaminergic system are abolished in the Pdyn KO mice, permitting
evaluation of one component of this bidirectional interaction during the aging process.
However, the molecular and cellular events influencing Pdyn expression during aging
have not been fully identified and remain an interesting avenue for further research.
MPTP, in this study, produced declines in striatal dopamine content 7 days after
injection of a standard sublethal dose, consistent with prior studies using the C57BL6
strains (Arai et al., 1990; Sundstrom et al., 1990; Ali et al., 1993). Although the extent
of dopamine loss is less than the 80% originally reported (Arai et al., 1990; Sundstrom et
al., 1990), the lower magnitude observed in the present study may be attributed to
differential susceptibility among different mouse strains, which has previously been
noted (German et al., 1996). Dopamine turnover, as reflected in the ratio of levels of
dopamine metabolites to levels of dopamine, was elevated following MPTP, consistent
with activation of compensatory mechanisms to replenish dopamine following
dopaminergic neuronal loss (Zigmond, 1997), while aging alone yielded no changes in
turnover except for mild decreases with age in Pdyn KO mice that may reflect local
negative feedback mechanisms.

The MPTP-induced loss of dopamine was more

prominent among aged mice, suggesting that these compensatory mechanisms are less

77

effective with advanced age, consistent with other studies finding aged-associated
increases in susceptibility to MPTP (Faden, 1992).
The gender effects observed in the above MPTP experiment are consistent with
previous studies in mice. Attenuation of MPTP-induced dopamine depletion in females
compared to males has been previously reported in other mouse strains (Freyaldenhoven
et al., 1996; Miller et al., 1998), suggesting neuroprotective actions of estrogen. Also,
increased

opioid receptor sensitivity has been noted in females in human studies (Kreek

et al., 1999), which may explain the mild gender difference in basal striatal dopamine
present in the WT mice but absent in the Pdyn KO mice of this study.
Other neurotransmitters, such as norepinephrine and serotonin, were relatively
unaffected by age or Pdyn genotype in this study, signifying a relatively selective effect
on the dopaminergic system. However our data show mild reductions in striatal serotonin
content by MPTP, in contrast to prior studies documenting unchanged serotonin levels
following MPTP administration (Chang et al., 1993; Callier et al., 2000). This finding is
of uncertain significance but may be explained by strain-specific differences in MPTP
metabolism, since an MPTP analogue 2'-NH2-MPTP has been shown to produce
serotonergic deficits (Luellen et al., 2006).
Interestingly, there was no significant effect of Pdyn genotype on post-MPTP
dopamine levels, implying that Pdyn deletion confers no protection against MPTP
toxicity. This further supports the contention that the effect of Pdyn deletion on striatal
dopamine content is dependent on survival of MPTP-sensitive dopaminergic neurons,
consistent with a mechanism involving modulation of dopamine biosynthetic activity
rather than prevention of neurotoxicity.
In the context of aging and neurodegenerative disease, the results of this study
offer insight into one potential means by which striatal dopaminergic activity can be
modulated by dynorphin peptide neurotransmitters in physiological aging or
neurodegenerative disease.

Additional studies are needed to elucidate further the

mechanisms involved and to clarify the relevance of these findings to clinical entities
such as Parkinson's disease.
Copyright © Xuan V. Nguyen 2007
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CHAPTER 5:

Radioimmunological quantitation of prodynorphin-derived
peptides in mice in aging and an MPTP model

Introduction
Expression of endogenous dynorphin peptides during aging and age-related
disorders has received increased attention in the neurobiological literature.

Initial

localization studies have shown that dynorphins are widely distributed in the central
nervous system (Khachaturian et al., 1982; Watson et al., 1982a; Watson et al., 1982b;
Hurd et al., 1999), with high Pdyn mRNA levels in hypothalamus, nucleus accumbens,
neostriatum, dentate gyrus, hippocampus, cerebral cortex, and spinal cord (Khachaturian
et al., 1993). Within the striatum, dynorphins colocalize with substance P and GABA
within dopamine D1-receptor-expressing striatonigral projection neurons [reviewed in
(Steiner and Gerfen, 1998)], where they appear to regulate dopamine release and function
in a negative feedback manner.

Since dynorphins or exogenous

agonists inhibit

dopaminergic activity (Mulder et al., 1984; Herrera-Marschitz et al., 1986; Di Chiara and
Imperato, 1988; Reid et al., 1988; Spanagel et al., 1992; Ronken et al., 1993; Schlosser et
al., 1995), modulation of dynorphin expression by dopamine represents a biologically
plausible mechanism by which levels of this important neurotransmitter are regulated.
Lesioning of the nigrostriatal dopaminergic pathway as in some models of PD results in
decreases in dynorphin levels (Gerfen et al., 1991).

Similarly, striatal dynorphin

expression is increased by dopaminerigc activity at the D1-receptor (Li et al., 1986; Li et
al., 1988; Li et al., 1990; Bordet et al., 1997) and is reduced in mice lacking the D1receptor (Wong et al., 2003).
Given the intrinsic variability in the aging process and the diverse environmental
and species-dependent factors contributing to neuropeptide expression during aging, it is
not surprising that published reports show significantly varied effects on dynorphin
expression. Age-related elevations in dynorphin have been noted in hippocampus and
frontal cortex (Jiang et al., 1989; Zhang et al., 1991; Gallagher and Nicolle, 1993) and in
spinal cord (Iadarola et al., 1986; Zhang et al., 2004a). Pdyn mRNA expression with
aging in one study was decreased in arcuate nucleus and amygdala, increased in
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hippocampus, and unchanged in striatum or cortex of male rats (Kotz et al., 2004). We
previously noted no change in Dyn A with age in hippocampus but mild elevations in
frontal cortex (Nguyen et al., 2005).

Although the cellular events influencing Pdyn

expression during aging have not been fully identified, changes in CREB expression
(Collins-Hicok et al., 1994) or binding at the AP-1 site in the Pdyn promoter (Naranjo et
al., 1991; Collins-Hicok et al., 1994; Hunter et al., 1995; Kitamura et al., 1995) could
potentially increase transcription and thus represent feasible molecular mechanisms for
increased Pdyn with age.

Upregulation of Pdyn in spinal cord by peripheral

inflammation (Iadarola et al., 1986) is enhanced with advancing age (Zhang et al., 2004a)
by mechanisms that have not been fully elucidated. Recently, increased dynorphin levels
were observed in the cortex and hippocampus of amyloid precursor proteinoverexpressing mice (Diez et al., 2000) and in frontal cortex of Down’s syndrome or
Alzheimer’s disease patients (Risser et al., 1996), thus further implicating dynorphins in
pathophysiological neurological processes.

The above studies point to a possible

dysregulation of Pdyn expression with aging that may lead to pathological
manifestations.
Because of the relative abundance of dynorphin in striatum and the importance of
this region of the brain during aging, we measure in this study Dyn A and B in striatum
of mice with particular attention to changes associated with aging. In addition, we also
evaluate striatal expression of dynorphin peptides following systemic exposure to the
neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which produces
selective dopaminergic neuronal death in the nigrostriatal system (Arai et al., 1990;
Sundstrom et al., 1990; Ali et al., 1993). Since dynorphins have been found to be
upregulated during aging in frontal cortex of rats as discussed above, we also assess
dynorphin peptide expression in frontal cortical tissue of these mice.

Methods
Animal subjects
All animals in this study were wild-type (WT) or Pdyn KO mice that were maintained in
an approved animal facility at the University of Kentucky. WT mice were derived from
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the 129SvEv-Tac line, and Pdyn KO mice were originally obtained by targeted deletion
of the coding exons of the prodynorphin gene and bred into a 129SvEv-Tac background
as described previously (Sharifi et al., 2001). Animals were housed in groups of up to 4
per cage with food and water ad libitum in a well-ventilated room with a 12 h: 12 h light:
dark cycle. Prior to weaning, tail specimens were collected from each animal, and DNA
was extracted for subsequent genotyping to confirm the identity of the Pdyn locus by the
polymerase chain reaction (PCR) using primer pairs specific for each genotype. All
procedures involving animals are approved by the Institutional Animal Care and Use
Committee at the University of Kentucky.
The aging studies in frontal cortex used 3-month (n = 6), 10-month (n = 6), and
20-month (n = 6) male and female WT mice.

Striatal data were pooled from two

separate experiments such that sample sizes were as follows: 3-month (n = 15), 10-month
(n = 15), and 20-month (n = 10). Pdyn KO mice were included as qualitative controls
consisting of one mouse per group in each experiment. Pdyn-heterozygous (HET) mice
(n = 5) were included in the 3-month age group only. Group sizes listed above reflect
inclusion of mice pooled from saline control groups from the MPTP studies, as
preliminary analyses found no significant differences among the saline controls.
Two separate experimental MPTP protocols were used in this study.

In

experiments examining short-term post-MPTP effects, 3-month WT (n = 4) and 10month WT (n = 5) mice were injected intraperitoneally with a single dose of 30 mg/kg
MPTP, and striatal specimens were collected 6 hours later. The second MPTP protocol,
involving a standard MPTP regimen of four 15 mg/kg intraperitoneal injections at 2-hour
intervals with striatal tissue collection 7 days post-MPTP, used 3-month WT (n = 3), 3month HET (n = 4), 10-month WT (n = 8) mice, and 1-2 Pdyn KO mice per age point as
qualitative negative controls.

Dynorphin extraction and radioimmunoassay (RIA)
Frontal cortical and striatal tissue were isolated following rapid asphyxiation by CO2 and
were frozen in liquid nitrogen prior to being processed for radioimmunoassay as
previously described (Christensson-Nylander et al., 1985; Christensson-Nylander and
Terenius, 1985; Nylander et al., 1991). Briefly, tissues were incubated at 95°C in 1 M
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acetic acid containing 0.01% mercaptoethanol for 5 minutes, homogenized using a
Brinkman Kinematic sonicator, heated again to 95°C, and subsequently centrifuged at
20,000 x g. The supernatant was then stored at -80°C until chromatographic separation.
Ion exchange chromatography was performed on Sephadex C-25 columns.
Samples were diluted in Buffer I (0.1 M formic acid, 0.18 M pyridine, pH 3.0) in a 1:1
(v/v) ratio and applied onto the Sephadex column.

Elution fractions were obtained by

serial application of 3 ml of Buffer I, Buffer II (0.1 M formic acid, 0.1 M pyridine, pH
4.3), Buffer III (0.35 M formic acid, 0.35 mM pyridine, pH 4.3), and Buffer IV (1.6 M
formic acid, 1.6 M pyridine, pH 4.3). The eluent from Buffer III was used for Leu-EnkArg quantitation, and the eluent from Buffer IV was used for Dyn A and B.

The

fractions of interest were lyophilized and resuspended in a 1:1 (v/v) mixture of methanol
and 0.1 M HCl and subsequently stored at 4°C.
The radiolabeled peptide was generated by the chloramine T method.
Radioimmunoassays for Dyn A and B were performed by incubating 25 L aliquots of
each sample in duplicate or triplicate with 100 L of 125I-labeled Dyn A or Dyn B peptide
and 100

L of the primary antiserum for the peptide of interest at 4°C overnight,

followed by addition of 100 L of a secondary antibody, centrifugation at 1000 rpm, and
scintillation counting of the resultant pellet. A similar method was used in the case of
Leu-Enk-Arg, except that 200 L of charcoal solution was used instead of a secondary
antibody, and 200

L of the supernatant obtained after centrifugation was used for

scintillation counting to detect the 125I signal in each sample. Each experiment included a
set of standards for the peptide of interest in addition to positive and negative controls,
and sample values were confirmed to be within the linear range of the assay.

Peptide

concentrations were calculated based on the standard curve and expressed as fmol per mg
of wet tissue.

Statistical analysis
Using Systat 10 software (SPSS, Inc., Chicago, Illinois), effects of age, Pdyn genotype,
and MPTP were assessed by ANOVA, with individual contrasts obtained by the least
significant differences method. One Dyn B result in a 20-month cortical specimen was
excluded due to processing error.
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Results
Evaluation of gene dosage on Dyn A and B expression in young adult mice reveals
proportional declines in peptide levels in Pdyn HET and KO mice (Figure 5.1). The
Pdyn KO specimen, included in this data set as a qualitative negative control,
demonstrated absent or near-absent levels. HET mouse peptide levels are approximately
half the levels seen in WT mice, with a statistical significant difference observed in both
Dyn A [F(1, 9) = 6.20, p<0.034] and Dyn B [F(1, 9) = 6.26, p < 0.034]. The gene dosage
effects are not apparent in frontal cortex, where expression levels even in WT mice are
substantially lower than in striatum. The assay for Leu-Enk-Arg demonstrates some
nonspecificity as small amounts are detected in Pdyn KO mice. In addition, HET levels
of Leu-Enk-Arg are not significantly different from WT, suggesting the presence of
mechanisms to compensate for the decreased gene dosage.

Striatum

Cortex

35

3-mo HET

30

3-mo KO

25
20

25

fmol/mg tissue

fmol/mg tissue

3-mo WT

20
15

#
#

10

15
10
5

5
0

0
Dyn A

Dyn B

Leu EnkArg

Dyn A

Dyn B

Leu EnkArg

Figure 5.1. Evaluation of gene dosage on dynorphin peptide levels.
Radioimmunoassay was performed on young adult mouse striatum and frontal cortex.
The Pdyn KO group consists of only one specimen and is used only as a qualitative
control. Statistical analysis was performed only on WT and HET mice to evaluate
effects of gene dosage on peptide levels. HET mice show proportionately decreased
levels of Dyn A and Dyn B in striatum, but amounts of Leu-Enk-Arg are not
significantly changed. In cortex, peptide quantities are minimally altered in Pdyn HET
mice. #p<0.05 compared to WT mice.
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RIA analysis of dynorphin B shows a statistically significant main effect of age in
striatum [F(2, 15) = 7.93, p<0.004] and a tendency toward significance in an aging main
effect in cortex [F(2, 15) = 3.36, p<0.064], while Dyn A shows no significant change
(Figure 2.3). Dyn B declines progressively with advancing age with striatal levels in 10month and 20-month mice approaching approximately 50% [F(1, 15) = 6.24, p<0.025]
and 20% [F(1, 15) = 15.49, p<0.001] of 3-month values, respectively. In cortex, Dyn B
does not decrease significantly at 10 months, but by 20 months, levels are approximately
10% of 3-month controls [F(1, 14) = 6.72, p<0.021]. The Dyn A results contrast our
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Figure 5.2. RIA comparison of dynorphin peptides with age in striatum and cortex.
The Pdyn KO group consists of only one specimen and is used only as a qualitative
control. Dyn B showed a significant age-dependent decline with age in both striatum
and frontal cortex. Dyn A shows a trend toward an age-dependent increase in cortex that
was not statistically significant.
*p<0.05, ***p<0.001 compared to 3-month WT
controls.
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previous experimental finding of elevated Dyn A in striatum at 24 months that was
performed on a smaller sample size (n = 4). Upon pooling the previous experimental
results with the newer data, this effect was no longer significant. The Dyn KO control
specimen again shows near-undetectable levels of Dyn A and Dyn B.
To assess short-term changes in striatal dynorphin following neurotoxic injury,
Dyn A and B were quantified by RIA following a single 30 mg/kg dose of intraperitoneal
MPTP and found to increase in an age-dependent manner (Figure 5.3).

Two-way

ANOVA for Dyn A shows a significant main effect of MPTP [(F(1, 35) = 11.16,
p<0.002] but no age main effect or age-MPTP interaction. Post-MPTP Dyn A is higher
in both 3-month [F(1, 35) = 4.00, p<0.053] and 10-month mice [F(1, 35) = 7.64,
p<0.009], with relative increases of 58% and 85%, respectively, although the 3-month
difference is slightly short of significance. Dyn B showed absent main effects of age and
MPTP, but an age-MPTP interaction was noted trending toward significance [F(1, 17) =
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Figure 5.3. RIA measurement of dynorphin peptides 6 h after a single sublethal injection
of MPTP.
Mean Dyn A levels are increased in both young and aging mice following MPTP, but
Dyn B is increased only at 10 months. †p<0.05, ‡p<0.01 compared to corresponding
saline control.
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4.00, p<0.062]. MPTP produced an increase in Dyn B only among 10-month mice [F(1,
17) = 6.23, p<0.023], yielding an approximately 3.3-fold elevation compared to 10month saline controls.
RIA was also used to evaluate dynorphin peptide expression 7 days after a
standard intraperitoneal MPTP regimen (Figure 5.4) that has been previously noted to
produce significant dopamine depletion.

Pdyn KO mice, which were included in this

study only as qualitative controls and were not incorporated into the ANOVA model,
showed absent to near-absent levels of Dyn A and B. Three-month HET mice were also
used to evaluate the effect of gene dosage on dynorphin peptide levels post-MPTP.
Three-way ANOVA showed significant omnibus effects for both Dyn A [F(5, 44) = 3.09,
p<0.018] and Dyn B [F(5, 26) = 5.23, p<0.002]. WT mice showed a decrease in Dyn A
levels to approximately half that of saline controls, but the difference reached statistical
significance only among 3-month mice [F(1, 44) = 4.85, p<0.033], with only nearsignificant differences noted in 10-month mice [F(1, 44) = 3.94, p<0.053]. As noted in
the previous analysis, the gene dosage effect was also apparent when comparing 3-month
WT and HET saline controls, but no genotype or age effect was seen in Dyn A among
MPTP-injected mice.
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Figure 5.4. RIA quantitation of dynorphin peptides 7 days following intraperitoneal
MPTP.
Dyn A and B are decreased after MPTP. Age and Pdyn genotype effects among saline
controls in this analysis are consistent with findings noted in the preceding figures.
#
p<0.05, ##p<0.01 compared to WT mice; *p<0.05, **p<0.01 compared to 3-month
mice; †p<0.05, ‡p<0.01 compared to corresponding saline controls.
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Striatal Dyn B in WT mice also exhibited a substantial decline 7 days following
MPTP [F(1, 26) = 12.20, p<0.02], to levels approaching 24% of saline controls. Gene
dosage effects and age effects were also present among saline-injected mice and
consistent with the preceding analysis, with 3-month HET mice showing decreased Dyn
B compared to 3-month WT mice [F(1, 26) = 10.23, p<0.004] and 10-month WT
showing declines in Dyn B compared to 3-month controls [F(1, 26) = 8.26, p<0.008].
However, among MPTP-injected mice, no significant effects were observed.

Discussion
In this study, a radioimmunological assay was used to assess dynorphin peptide
expression in striatum and frontal cortex of mice. The internal validity of this study is
supported by our results confirming the analytical specificity of the assay and the
essentially linear quantitative relationship between gene dosage and peptide
concentration for the Dyn A and Dyn B peptides in striatum, although these properties
are less apparent in the data on Leu-Enk-Arg and the data in frontal cortical specimens.
In examining dynorphin peptide expression in striatum and frontal cortex with
aging, we find that aging produces progressive decline in Dyn B while Dyn A shows no
significant change. The existing literature on dynorphin alterations with aging contain
numerous reports of increased dynorphin in aging or aging-associated pathological
processes, including elevated mRNA or peptide concentrations in the hippocampus of
normal aged rats (Jiang et al., 1989; Zhang et al., 1991; Gallagher and Nicolle, 1993;
Kotz et al., 2004), the cortex and hippocampus of amyloid precursor proteinoverexpressing mice (Diez et al., 2000), the frontal cortex of Down’s syndrome patients
(Risser et al., 1996), and the frontal and parietal cortices of Alzheimer’s disease patients
(Risser et al., 1996; Yakovleva et al., 2006a). In striatum, Pdyn expression with aging
has been less well studied, with some studies showing no changes in aging rats (Zhang et
al., 1991; Kotz et al., 2004) and one study finding decreased Pdyn mRNA in striatum of
normal aged humans (Backman et al., 2007).

We previously had noted no significant

aging effect of Dyn A in hippocampus (Nguyen et al., 2005), but did observe an increase
in Dyn A in cerebral cortex in a small number of male aged WT mice (Nguyen et al.,
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2005). Our current results, which incorporated data pooled from the previous study and
which contain a larger sample size, show only a nonsignificant trend toward increasing
Dyn A with aging. Although complete characterization of dynorphin expression during
aging awaits further studies, our data and that of previous studies clearly implicate a
dysregulation of dynorphin expression during aging, the consequences of which remain
to be elucidated.
Numerous studies have found dynorphin to be elevated following acute and
chronic stressors such as inflammation (Millan et al., 1985; Sydbom and Terenius, 1985;
Chahl and Chahl, 1986; Iadarola et al., 1986; Noguchi et al., 1991; Gillardon et al., 1994;
Zhang et al., 2005) and neuronal injury (Faden et al., 1985a, b; Wang et al., 2001). It is
plausible that the age-related dynorphin elevations seen in other studies may be a
consequence of chronic subclinical episodes of neuronal injury or a manifestation of an
acute stress response during the period immediately prior to euthanasia. In the present
study, HPLC quantitation of dynorphin peptides after a single 30 mg/kg bolus of
intraperitoneal MPTP injection in WT mice showed increased dynorphin expression 6
hours following the neurotoxic insult. While Pdyn mRNA was not explicitly measured in
this study, one putative mechanism for the increased dynorphins would be upregulation
of Pdyn gene expression via activation of immediate-early genes and related transcription
factors (Naranjo et al., 1991; Collins-Hicok et al., 1994; Hunter et al., 1995; Kitamura et
al., 1995) during the initial phases of neuronal injury following MPTP. While Dyn A is
increased by MPTP in both young and middle-aged mice, the MPTP-induced increase in
Dyn B is seen only among 10-month mice, favoring an age-dependent mechanism in
which short-term dysregulation of Dyn B preferentially affecting aged individuals may
lead to impairments in dopaminergic function. These observations are corroborated by
existing literature showing that aging enhances Pdyn upregulation in response to
inflammation in spinal cord models (Zhang et al., 2004a).
The above findings remarkably contrast with the decreased expression of both
Dyn A and Dyn B seen at a longer time interval of 7 days post-MPTP. Since this MPTP
regimen in these mice produces substantial loss of striatal dopamine and because
dopamine promotes dynorphin expression via the D1-receptor (Li et al., 1986; Li et al.,
1988; Li et al., 1990; Bordet et al., 1997; Wong et al., 2003), the observed effects are
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likely a consequence of decreased dopamine D1-receptor activity in a manner analogous
to that seen in experimental nigrostriatal lesions (Gerfen et al., 1991) or in D1-receptor
knockout mice (Wong et al., 2003).
The significance of the observed changes in dynorphin peptide levels in aging is
still unclear.

While compensatory responses or changes in the enzymatic systems

responsible for preprodynorphin processing are likely contributing factors, further studies
are needed to elucidate the causes and consequences of the observed alterations in
dynorphin peptide levels.

Age-related patterns of gene expression, such as those

described in the following chapter, may help to explain why these neuropeptide
transmitters are altered by advanced age.

Copyright © Xuan V. Nguyen 2007
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CHAPTER 6:

Microarray analysis of hippocampal gene expression changes
with aging and prodynorphin deletion

Introduction
Endogenous dynorphins derived from the product of the prodynorphin (Pdyn) gene have
been found to have diverse functional roles in a variety of organ systems (Simonato and
Romualdi, 1996; Hauser et al., 2005). Dynorphin peptides present in the hypothalamus,
dentate gyrus, striatum, cortex, and hippocampus exert a multitude of diverse biological
actions, including effects on pain transmission, seizure activity, learning and memory,
endocrine function, excitotoxic injury, stress responses, and the immune system
[reviewed in (Smith and Lee, 1988)]. The mechanisms through which dynorphin and
related peptides exert many of their effects involve the

opioid receptor (Goldstein et al.,

1979; Chavkin et al., 1982) (Goldstein and Naidu, 1989) and other opioid (Garzon et al.,
1984) and non-opioid receptors (Chen et al., 1995a, b; Chen and Huang, 1998; Tang et
al., 1999).
However, the detailed mechanisms for many of the downstream mediators of
dynorphin activity have not been fully elucidated. The inhibitory actions of dynorphin
peptides on neurotransmission have been reported to be mediated by depressing calcium
entry into neurons (Cherubini and North, 1985) via inhibition of voltage-gated calcium
channels in a manner similar to
1995)].

and

opioid agonists [reviewed in (Satoh and Minami,

However dynorphins can increase calcium influx via interaction with the

bradykinin receptor in models of neuropathic pain (Lai et al., 2006).

There have also

been varying reports in the literature regarding the ability of dynorphins and
general to inhibit adenylate cyclase activity in a manner analogous to that of

agonists in
agonists

(Satoh and Minami, 1995). Other downstream effects of dynorphins include activation of
NMDA receptors and inflammatory signaling cascades in the case of spinal hyperalgesia
(Koetzner et al., 2004).

In addition, dynorphnis interact closely with multiple non-

neuronal cells and with the endocrine system (Sherman et al., 1986; Currie et al., 1994;
Ohnishi et al., 1994; Spampinato et al., 1995; Kreek et al., 1999; Goodman et al., 2004;
Foradori et al., 2005; Jacobson et al., 2006), suggesting that Pdyn deletion is likely to
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produce fairly broad gene expression changes, especially in a process as pervasive and
multifactorial as normal aging.
Early reports that prodynorphin is elevated in the hippocampus and frontal cortex
in cognitively impaired subpopulations of aged rats have implicated Pdyn-derived
peptides in various aspects of aging (Jiang et al., 1989; Zhang et al., 1991). In vivo
studies by other laboratories had demonstrated impaired cognitive function in response to
administration of various dynorphin peptides (Introini-Collison et al., 1987; Sandin et al.,
1998), but the mechanistic basis for this phenomenon is currently unclear and may range
from suppressive effects of dynorphin at the glutamatergic synapse to direct toxic effects
of some of the dynorphin peptides (Hauser et al., 2005). Based on our experimental
findings that aged knockout (KO) mice lacking the Pdyn gene perform relatively better
than comparably aged wild-type (WT) mice (Nguyen et al., 2005) and other observations
as noted in preceding chapters, we seek in this study to evaluate patterns of alterations in
hippocampal gene expression with aging and with Pdyn deletion to explore possible
mechanisms to explain the role of dynorphins in cognitive decline. Because of the broad
range of interactions of prodynorphin-derived peptides with a variety of cell types and
biochemical pathways, we initiated the current microarray study to enable systematic
characterization of patterns of differential gene expression without a priori assumptions
on any particular gene or set of genes. Microarray approaches have previously been used
to assess gene expression profiles with aging and cognitive impairment (Blalock et al.,
2003; Blalock et al., 2004). By comparing Pdyn KO mice to similarly aged wild-type
(WT) mice, we expect to identify the molecular mechanisms and intermediary processes
by which the chronic absence of Pdyn-derived peptides may contribute to the observed
functional manifestations in mice.

Methods
Animal subjects
Pdyn KO mice, generated by deletion of exons 3 and 4 of the Pdyn gene (Sharifi et al.,
2001), and wild-type (WT) 129SvEv-Tac were bred and housed in an approved animal
facility. After weaning, genotyping was performed by the polymerase chain reaction
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(PCR) from DNA isolated from mouse tail tissue using primer pairs specific for each
genotype. Microarray analyses were conducted in two separate experiments. Experiment
A included young adult (3-month) WT and Pdyn KO male mice in addition to a separate
set of 22-month WT and Pdyn KO male mice (n = 3 per group). In Experiment B, only
aged (22- to 26-month) WT (n = 3) and aged Pdyn KO (n = 3) mice were used, with each
group consisting of 2 females and 1 male.

In each experiment, fresh hippocampal

specimens were dissected from CO2-asphyxiated mice and stored at –80°C until
processing. All procedures involving animals are approved by the Institutional Animal
Care and Use Committee at the University of Kentucky.

Microarray processing
Total RNA was extracted using the Trizol reagent (Gibco BRL) and reconstituted in deionized water treated with diethyl pyrocarbonate (DEPC).

RNA specimens were

quantitated by optical density and normalized, followed by assessment of molecular
integrity by electrophoresis. Samples were then submitted to the University of Kentucky
Microarray Core Facility for labeling and hybridization onto individual microarray chips.
Murine MOE430A cDNA microarray chips, with 22,690 probe sets each, were used in
Experiment A, while murine whole-genome MG U74A version 2 chips, each containing
12,488 probe sets, were used for Experiment B. Automated detection of fluorescent
intensity using an Affymetrix GeneArray scanner was performed according to standard
manufacturer protocols, yielding a quantitative score for each probe set.

Probe set list selection
The automated detection system assigns each probe set in each chip a numerical signal
value and an absent-present designation of absent (A), present (P), or marginal (M). For
each probe set, the absent-present score for each group of 3 replicates was calculated by
first assigning a value of 0 for each A designation, 1 for each P designation, and 0.5 for
each M designation and summing the total for the group. Within a given experiment,
probe sets for which all groups have an absent-present score of less than 1.5 were deemed
to be absent in a majority of replicates in each group and were excluded from further
analysis. Next, lists of probe sets were generated to reflect increases or decreases in
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mean signal values in each of the planned comparisons. Experiment A includes the
following comparisons: young Pdyn KO vs. young WT, aged Pdyn KO vs. aged WT,
aged WT vs. young WT, and aged Pdyn KO vs. young Pdyn KO. In Experiment B, aged
Pdyn KO mice are compared to aged WT mice.

An ANOVA p-value was computed for

each comparison in Experiment A and a t-statistic p-value was computed for each
comparison in Experiment B. Probe set lists for each of the planned comparisons were
subsequently generated by selecting non-absent probe sets in which the p-value for the
associated comparison is less then 0.05.

Functional categorization of differentially regulated genes
A software program known as Expression Analysis Systematic Explorer (EASE) (Hosack
et al., 2003) was used to systematically identify functional categories of genes, based on
Biological Process and Molecular Function annotation data in existing Gene Ontology
(GO) databases (Ashburner et al., 2000), that are over-represented within a given list of
Affymetrix probe sets. The software program evaluates for each categorical grouping in
the GO classification system, the number of probe sets in the input list that under the
existing annotation database belong to the category being queried, thereby obtaining the
number of list hits. A similar process is applied to a reference population, in this case,
the entire list of probe sets available on the gene chip used, to calculate the number of
population hits. By comparing the proportion of list hits to that of population hits, the
program computes a conservative modification of the Fisher's exact statistic known as the
EASE score to quantify the probability that over-representation of the identified category
within the list might occur due to chance.
For each of the planned experimental comparisons, functional groupings that were
noted to be significantly over-represented based on an EASE score of less than 0.05 are
presented. Functional annotations and other descriptors for each probe set were obtained
using NetAffx Analysis Center software (Affymetrix) in conjunction with GenBank,
Swiss-Prot, and related databases, but only GO Biological Process and Molecular
Function annotations were used in the systematic over-representation analysis.

All p-

values reported in the Results section refer to the EASE score for each specified
categorical identifier.
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Results
Gene expression in WT and Pdyn KO mice were compared to identify genes that show
altered expression with either aging or Pdyn deletion. Table 6.1 describes the results of
the filtering process by which probe set lists were generated. The results of the overrepresentation analysis using biological process annotations are listed in Table 6.2
through Table 6.15, and the results of an analogous analysis applied to molecular
function identifiers are presented in Table 6.16 through Table 6.29.
Effects of aging
We first examined probe sets that show a significant main effect of age in Experiment A
and analyzed them initially without regard to Pdyn genotype using biological process
(Table 6.2 and Table 6.3) and molecular function identifiers (Table 6.16 and Table 6.17).
We find that 44 of the 251 genes downregulated with aging are involved in nervous
system development, which is significantly higher than the approximately 10%
prevalence of this identifier in the murine genomic background (p<0.0004). Similarly
other downregulated gene categories include those involved in neurogenesis (p<0.017),
mesenchymal cell differentiation and development (p<0.025), stem cell division
(p<0.042), cell growth (p<0.047), potassium transport (p<0.012), DNA binding
(p<0.003), and zinc-mediated transcription factor activity (p<0.034). The prevalence of
genes identified as involved in learning and memory is also disproportionately high in the
age-downregulated probe set list (p<0.004), as are processes such as action potential
regulation (p<0.026), synaptic transmission (p<0.026), and dopamine receptor signaling
(p<0.029).
In contrast, gene categories upregulated by aging include a number of processes
associated with immune response (p<0.00006), complement activation (p<0.002), acutephase response (p<0.024), response to pathogens (p<0.005), and antigen presentation or
processing (p<0.003). Cell development genes are also found to be over-represented
among age-upregulated probe sets (p<0.03).
Age effects, when evaluated among WT mice only, provide similar results with
regard to biological process identifiers (Table 6.4 and Table 6.5) and molecular function
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(Table 6.18 and Table 6.19). Downregulated gene categories include nervous system
development (p<0.004) and neurite morphogenesis (p<0.001), as observed in the
preceding analysis. In addition, we also find downregulation of genes involved in protein
phosphorylation (p<0.04), nucleosome assembly (p<0.038), cellular morphogenesis
(p<0.003), protein transporter activity (p<0.004), and phospho-protein binding (p<0.004).
Aging in WT mice is also associated with downregulation of numerous cellular processes
(p<0.026) that broadly include such functions as cell cycle control, protein transport,
exocytosis, and chromosome organization.

Genes upregulated in aged WT mice

compared to young WT mice include those involved in neuron development (p<0.023),
cell death (p<0.046), cell maturation (p<0.043), cell growth (p<0.021), protein transport
(p<0.007), and calcium binding (p<0.0001). In addition, upregulated genes also have a
disproportionately high prevalence of genes identified as being involved in negative
regulation of cellular processes (p<0.022).

There are relatively fewer genes

downregulated in aged Pdyn KO mice relative to young KO mice (Table 6.6 and Table
6.20), such as those involved enzyme-linked receptor signaling pathways (p<0.036) and
potassium binding (p<0.005), while age-upregulated genes in Pdyn KO mice (Table 6.7
and Table 6.21) are associated with MHC I-mediated endogenous antigen processing
(p<0.007), protein binding (p<0.019), RNA binding (p<0.016), and RNA splicing
(p<0.042).

Effects of Pdyn deletion
When Experiment A is analyzed without regard to age, main effects of Pdyn deletion are
present in multiple probe sets. Genes downregulated with Pdyn deletion (Table 6.8 and
Table 6.22) are involved in macromolecule metabolism (p<0.0006), including processes
related to RNA binding (p<0.0001), protein synthesis (p<0.015), protein folding
(p<0.019). Electron transport-related processes (p<0.04) and ubiquinol-cytochrome C
reductase activity (p<0.008) are also over-represented among genes downregulated by
Pdyn deletion. Biological process categories for genes upregulated by Pdyn deletion
(Table 6.9) include neuron differentiation (p<0.026) and regulation of action potential
(p<0.039), while upregulated molecular function categories (Table 6.23) include esterhydrolase activity (p<0.016) and phospho-transferase activity (p<0.036).
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When probe sets were selected based on significant group contrasts in Experiment
A, Pdyn deletion among young mice was associated with changes in expression of a
relatively small number of biological process (Table 6.10 and Table 6.11) and molecular
function categories (Table 6.24 and Table 6.25).

The only statistically significant

biological process category over-represented among genes downregulated by Pdyn
deletion is protein metabolism (p<0.043), but upregulated biological process identifiers
include cellular biosynthesis (p<0.044) and negative regulation of apoptosis (p<0.021).
Calmodulin-dependent protein kinase activity is also downregulated by Pdyn deletion in
young mice (p<0.010), whereas calcium ion binding (p<0.015) and tyrosine kinase
activity (p<0.043) are among the molecular function identifiers of upregulated genes.
Among the aged mice of Experiment A, Pdyn deletion is associated with
downregulation of genes associated with cell growth (p<0.038), vesicle-mediated
transport (p<0.038), cell differentiation (p<0.044), nervous system development
(p<0.050), calcium binding (p<0.0001), and potassium binding (p<0.013) (Table 6.12
and Table 6.26).

In addition, Pdyn deletion was also associated with decreased

expression of genes identified in the category of negative regulation of cellular processes
(p<0.046). Pdyn deletion among aged mice causes upregulation of genes involved in
neurite morphogenesis (p<0.002) (Table 6.13). In addition, aged Pdyn KO mice also
show increased expression of genes involved in positive regulation of transcription
(p<0.028), phosphoprotein binding (p<0.039), transcription coactivator activity
(p<0.044), and sequence-specific DNA binding (p<0.006) compared to aged WT mice
(Table 6.13 and Table 6.27).
Experiment B, which compares aged WT and Pdyn KO mice in a separate group
of animals, found upregulation by Pdyn deletion of genes involved in Golgi organization
and biogenesis (p<0.045) and organelle localization (p<0.025) (Table 6.15).
Furthermore, 14 of the 117 annotated genes upregulated by Pdyn deletion possess ion
channel activity (p<0.003), with a majority of these specifically noted to demonstrate
voltage-gated ion channel activity (p<0.021) (Table 6.29).

The only downregulated

biological process category was the proteasome activator complex (p<0.033) (Table
6.14), and molecular function identifiers among genes downregulated in Pdyn KO mice
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similarly include proteasome activator activity (p<0.031) and NADH dehydrogenase
activity (p<0.047) (Table 6.28).

Discussion
In this study, we implement a modification of the Fisher exact analysis to identify
functional categories of genes upregulated or downregulated by either aging or Pdyn
deletion using the EASE program. Analysis of microarray data often is problematic
because statistical concerns can hinder interpretation of individual results when obtained
among a very large number of potential comparisons (Blalock et al., 2003). However,
when co-regulated groups of genes are assessed, microarray data may yield abundant
information on patterns of altered gene expression, which tend to be more robust and less
dependent on individual gene alterations (Ashburner et al., 2000).
Our findings of increased immune response genes and decreased neurogenesis or
axonogenesis genes with age are corroborated by previously published microarray studies
in rats (Rowe et al., 2007). These observations may reflect impairments in regulation of
various pathways that may increase susceptibility to various pathological outcomes with
advancing age. Genes involved in dopamine receptor signaling are also downregulated
with aging, consistent with known functional declines in the dopaminergic system with
age (Kish et al., 1992; Ingram, 2000; Reeves et al., 2002).
In this study, we use two separate microarray experiments to evaluate effects of
Pdyn deletion on gene expression. While the biological process identifiers associated
with up- and downregulated genes vary between the two experiments, Pdyn-deletionassociated findings consistently seen in both experiments include a decrease in protein
metabolism genes, an increase in cellular organization and biogenesis genes, and an
increase in genes related to ion transport. The effects of Pdyn deletion in aged mice,
which include increased expression of genes associated with neurite development and
general cell metabolic processes such as transcription, suggest a more active and
functional neuronal environment in the aging hippocampus that may explain previously
noted amelioration of memory deficits by Pdyn deletion (Nguyen et al., 2005). Similar
changes were observed in young mice, in which Pdyn deletion produces upregulation of
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genes involved in a broad range of developmental processes, cellular physiological
processes, signal transduction, and suppression of apoptosis. These observations support
a generally suppressive effect of dynorphin peptides on cellular functioning in the
hippocampus.
One downstream consequence of dynorphin activity is opiate-receptor-mediated
inhibition of voltage-gated calcium channels (Satoh and Minami, 1995), resulting in
decreased intracellular calcium (Cherubini and North, 1985). Our findings in Experiment
B that Pdyn deletion increases expression of genes involved in ion channel activity, with
over half of these specifically listed as voltage-gated ion channel genes, suggest that
control of intracellular calcium may represent an important mechanism responsible for
tonic

opioid receptor-mediated suppression of calcium-dependent neurotransmitter

release by dynorphin peptides, consistent with electrophysiological studies (Spadoni et
al., 2004). Experiment A also reveals that, among genes downregulated by Pdyn deletion
in aged mice, close to 20% are involved in calcium ion binding. In young mice, Pdyn
deletion produces downregulation of genes with calcium-dependent protein kinase
activity. Altered calcium regulation therefore appears to be an important reproducible
consequence of Pdyn deletion.
This microarray analysis was performed on whole hippocampal homogenates.
Therefore, results are based on expression profiles of tissue specimens comprised of a
hetereogeneous cellular composition. Differences in the relative proportion of neurons or
glial cells within the hippocamps or variations in expression patterns among the different
subpopulations or cell types may potentially skew the resulting data. The sensitivity with
which gene expression differences may be detected may similarly be reduced for genes
whose expression is altered only in a small subpopulation of cells within the
hippocampus. Even with these limitations, we were able to detect a substantial number
of genes that, within a specified degree of statistical certainty, show altered expression
with either aging or Pdyn deletion.
Importantly, this analysis evaluates groups of genes with similar patterns of
changes in expression and circumvents the need to generate conclusions regarding
specific probe sets. Although identification of individual genes may prove helpful in
focused experiments with well-planned a priori hypotheses, attempts at independent
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validation of microarray results would be unlikely to yield a high concordance rate unless
very large numbers of replicates are tested and exceedingly stringent statistical criteria
are used in probe set selection. Therefore, in light of the statistical obstacles associated
with individual probe set data, we focused exclusively in this study on gene categories.
Furthermore, the results in the tables below contain all statistically significant annotation
groupings identified in an automated unbiased manner solely using existing annotation
categories within an established ontological database, thereby avoiding subjective biases
associated with manual data-mining approaches.
It should be emphasized that the accuracy of this type of analysis is limited by the
completeness of the available annotation systems and may be expected to improve as
bioinformatic databases evolve with further additions to existing knowledge on the
biochemical, molecular, and cellular processes associated with specific genes.
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Table 6.1. Summary of probe set filtering and selection results.
Probe sets were excluded based on insufficient presence-absence calls or inadequate
statistical significance of inter-group differences. Only non-absent probe sets with
significant inter-group differences by ANOVA (Experiment A) or t-test (Experiment B)
were included.
Experiment A – Aging effects
Total number of probe sets in chip
Non-absent probe sets
Non-absent probe sets with aged mice > young mice
Non-absent probe sets with aged mice < young mice
Non-absent probe sets with aged WT > young WT
Non-absent probe sets with aged WT < young WT
Non-absent probe sets with aged Pdyn KO > young Pdyn KO
Non-absent probe sets with aged Pdyn KO < young Pdyn KO
Non-absent probe sets with aged mice > young mice and p<0.05 by ANOVA
Non-absent probe sets with aged mice < young mice and p<0.05 by ANOVA
Non-absent probe sets with aged WT > young WT and p<0.05 by ANOVA
Non-absent probe sets with aged WT < young WT and p<0.05 by ANOVA
Non-absent probe sets with aged Pdyn KO > young Pdyn KO and p<0.05 by ANOVA
Non-absent probe sets with aged Pdyn KO < young Pdyn KO and p<0.05 by ANOVA

22690
14412
7374
7034
7428
6983
7372
7034
313
313
226
266
54
92

Experiment A – Pdyn effects
Total number of probe sets in chip
Non-absent probe sets
Non-absent probe sets with Pdyn KO > WT
Non-absent probe sets with Pdyn KO < WT
Non-absent probe sets with young Pdyn KO > young WT
Non-absent probe sets with young Pdyn KO < young WT
Non-absent probe sets with aged Pdyn KO > aged WT
Non-absent probe sets with aged Pdyn KO < aged WT
Non-absent probe sets with Pdyn KO > WT and p<0.05 by ANOVA
Non-absent probe sets with Pdyn KO < WT and p<0.05 by ANOVA
Non-absent probe sets with young Pdyn KO > young WT and p<0.05 by ANOVA
Non-absent probe sets with young Pdyn KO < young WT and p<0.05 by ANOVA
Non-absent probe sets with aged Pdyn KO > aged WT and p<0.05 by ANOVA
Non-absent probe sets with aged Pdyn KO < aged WT and p<0.05 by ANOVA

22690
14412
7510
6898
7291
7115
7472
6938
187
152
113
107
189
186

Experiment B – Pdyn effects in aged mice
Total number of probe sets in chip
Non-absent probe sets
Nonabsent probe sets upregulated in Pdyn KO
Nonabsent probe sets downregulated in Pdyn KO
Nonabsent probe sets upregulated in Pdyn KO and p<0.05 by t-test
Nonabsent probe sets downregulated in Pdyn KO and p<0.05 by t-test
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12488
7487
4064
3423
149
116

Table 6.2. Complete list of Biological Process identifiers over-represented among probe
sets significantly downregulated with aging in Experiment A.
Terms used in the following tables reflect those used in the Gene Ontology Biological
Process database. Arrows precede categories that are subsets of one or more categories
listed above them, with increasing numbers of arrows denoting more specific
categorizations. List hits and population hits are presented along with the corresponding
totals. Note that not all entries within a given probe set list are reflected in the total, since
some probe sets do not have a corresponding annotation in the ontological system.
Biological process category identifier
SYSTEM DEVELOPMENT
→ NERVOUS SYSTEM DEVELOPMENT
→→ CENTRAL NERVOUS SYSTEM DEVELOPMENT
ANATOMICAL STRUCTURE FORMATION
→ FORMATION OF PRIMARY GERM LAYER
MESODERM DEVELOPMENT
→ MESODERM MORPHOGENESIS
→→ MESODERM FORMATION
CELL DEVELOPMENT
→ NEUROGENESIS
→→ NEURON DIFFERENTIATION
→→→ NEURON MATURATION
→→ NEURON MIGRATION
→ GERM CELL DEVELOPMENT
MESENCHYMAL CELL DIFFERENTIATION
→ MESENCHYMAL CELL DEVELOPMENT
HINDLIMB MORPHOGENESIS
→ EMBRYONIC HINDLIMB MORPHOGENESIS
GROWTH
CELLULAR MORPHOGENESIS
REGULATION OF CELL SIZE
→ CELL GROWTH
CORTICAL CYTOSKELETON ORGANIZATION AND
BIOGENESIS
STEM CELL DIVISION
LOCALIZATION
→ ESTABLISHMENT OF LOCALIZATION
→→ TRANSPORT
→→→ ION TRANSPORT
→→→→ CATION TRANSPORT
→→→→→ METAL ION TRANSPORT
→→→→→ MONOVALENT INORGANIC CATION
TRANSPORT
→→→→→→ POTASSIUM ION TRANSPORT
COFACTOR BIOSYNTHESIS
→ COENZYME BIOSYNTHESIS
RIBONUCLEOTIDE BIOSYNTHESIS
→ PURINE NUCLEOTIDE BIOSYNTHESIS
PURINE NUCLEOTIDE METABOLISM
RIBONUCLEOTIDE METABOLISM
REGULATION OF GENE EXPRESSION, EPIGENETIC
NEUROPHYSIOLOGICAL PROCESS
→ TRANSMISSION OF NERVE IMPULSE
→→ REGULATION OF ACTION POTENTIAL
CELL COMMUNICATION
→ SIGNAL TRANSDUCTION
→ SYNAPTIC TRANSMISSION
→→ NEUROMUSCULAR SYNAPTIC TRANSMISSION
→ ENZYME LINKED RECEPTOR PROTEIN
SIGNALING PATHWAY
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List hits /
List total
44 / 251
44 / 251
19 / 251
10 / 251
10 / 251
10 / 251
10 / 251
10 / 251
25 / 251
24 / 251
22 / 251
11 / 251
5 / 251
11 / 251
9 / 251
9 / 251
8 / 251
8 / 251
19 / 251
28 / 251
16 / 251
16 / 251

Population hits /
Population total
1114 / 10541
1078 / 10541
468 / 10541
169 / 10541
167 / 10541
198 / 10541
167 / 10541
166 / 10541
628 / 10541
605 / 10541
562 / 10541
204 / 10541
51 / 10541
182 / 10541
149 / 10541
149 / 10541
139 / 10541
138 / 10541
494 / 10541
815 / 10541
396 / 10541
393 / 10541

EASE
score
0.0009
0.0004
0.0297
0.0193
0.0180
0.0463
0.0180
0.0174
0.0141
0.0170
0.0261
0.0235
0.0323
0.0114
0.0255
0.0255
0.0474
0.0459
0.0464
0.0478
0.0500
0.0473

3 / 251
8 / 251
99 / 251
98 / 251
84 / 251
32 / 251
25 / 251
24 / 251

11 / 10541
135 / 10541
3265 / 10541
3243 / 10541
2865 / 10541
864 / 10541
624 / 10541
504 / 10541

0.0268
0.0416
0.0032
0.0038
0.0196
0.0131
0.0131
0.0020

17 / 251
14 / 251
13 / 251
13 / 251
12 / 251
12 / 251
12 / 251
12 / 251
10 / 251
42 / 251
25 / 251
10 / 251
101 / 251
90 / 251
23 / 251
8 / 251

399 / 10541
269 / 10541
295 / 10541
278 / 10541
249 / 10541
245 / 10541
252 / 10541
260 / 10541
200 / 10541
1182 / 10541
653 / 10541
178 / 10541
3338 / 10541
3032 / 10541
597 / 10541
133 / 10541

0.0282
0.0118
0.0485
0.0332
0.0351
0.0318
0.0378
0.0456
0.0488
0.0078
0.0215
0.0259
0.0030
0.0105
0.0265
0.0389

21 / 251

558 / 10541

0.0427

Biological process category identifier
(continued from previous page)
→ DOPAMINE RECEPTOR SIGNALING PATHWAY
BEHAVIOR
→ LEARNING AND/OR MEMORY
RHYTHMIC PROCESS
→ CIRCADIAN RHYTHM

List hits /
List total

Population hits /
Population total

EASE
score

9 / 251
25 / 251
8 / 251
10 / 251
9 / 251

153 / 10541
567 / 10541
84 / 10541
200 / 10541
162 / 10541

0.0292
0.0042
0.0037
0.0488
0.0391

Table 6.3. Complete list of Biological Process identifiers over-represented among probe
sets significantly upregulated with aging in Experiment A.
Biological process category identifier
DEVELOPMENT
→ CELL DIFFERENTIATION
→→ CELL DEVELOPMENT
CELLULAR MACROMOLECULE METABOLISM
RESPONSE TO STIMULUS
→ RESPONSE TO STRESS
→ RESPONSE TO BIOTIC STIMULUS
→→ RESPONSE TO OTHER ORGANISM
→→→ RESPONSE TO PEST, PATHOGEN OR
PARASITE
→ IMMUNE RESPONSE
→→ HUMORAL IMMUNE RESPONSE
→→→ COMPLEMENT ACTIVATION
→→→→ COMPLEMENT ACTIVATION, CLASSICAL
PATHWAY
→ DEFENSE RESPONSE
→ RESPONSE TO EXTERNAL STIMULUS
→→ RESPONSE TO WOUNDING
→→→ ACUTE-PHASE RESPONSE
ANTIGEN PRESENTATION
→ ANTIGEN PRESENTATION, ENDOGENOUS
ANTIGEN
ANTIGEN PROCESSING
→ EXOGENOUS ANTIGEN PROCESSING VIA MHC
CLASS II
ORGANISMAL PHYSIOLOGICAL PROCESS
→ SMOOTH MUSCLE CONTRACTION
CELL-CELL SIGNALING
REPRODUCTION
→ SEXUAL REPRODUCTION

List hits /
List total
77 / 229
44 / 229
22 / 229
77 / 229
75 / 229
49 / 229
49 / 229
34 / 229

Population hits /
Population total
2974 / 10541
1382 / 10541
628 / 10541
2930 / 10541
2723 / 10541
1635 / 10541
1400 / 10541
984 / 10541

EASE
score
0.0499
0.0082
0.0310
0.0367
0.0142
0.0148
0.0007
0.0072

34 / 229
48 / 229
16 / 229
6 / 229

965 / 10541
1231 / 10541
409 / 10541
43 / 10541

0.0054
0.0001
0.0321
0.0022

4 / 229
48 / 229
32 / 229
25 / 229
5 / 229
7 / 229

31 / 10541
1346 / 10541
978 / 10541
774 / 10541
51 / 10541
65 / 10541

0.0288
0.0005
0.0194
0.0467
0.0241
0.0027

4 / 229
7 / 229

31 / 10541
52 / 10541

0.0288
0.0008

3 / 229
70 / 229
7 / 229
31 / 229
24 / 229
21 / 229

12 / 10541
2537 / 10541
106 / 10541
964 / 10541
733 / 10541
608 / 10541

0.0267
0.0181
0.0273
0.0266
0.0457
0.0402

Table 6.4. Complete list of Biological Process identifiers over-represented among probe
sets significantly downregulated in aged WT mice compared to young WT mice in
Experiment A.
Biological process category identifier
SYSTEM DEVELOPMENT
→ NERVOUS SYSTEM DEVELOPMENT
NEUROGENESIS
→NEURON DIFFERENTIATION
→ →NEURON DEVELOPMENT
→→→ NEURON MORPHOGENESIS DURING
DIFFERENTIATION
→→→→ NEURITE MORPHOGENESIS
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List hits /
List total
35 / 210
35 / 210
22 / 210
20 / 210
19 / 210

Population hits /
Population total
1114 / 10541
1078 / 10541
605 / 10541
562 / 10541
443 / 10541

EASE
score
0.0069
0.0042
0.0088
0.0160
0.0031

18 / 210
18 / 210

377 / 10541
377 / 10541

0.0013
0.0013

Biological process category identifier
(continued from previous page)
→→→→→ AXONOGENESIS
→→→→→ DENDRITE MORPHOGENESIS
CELLULAR PROCESS
→ REGULATION OF CELLULAR PROCESS
→→ POSITIVE REGULATION OF CELLULAR
PROCESS
→→ REGULATION OF TRANSPORT
→ REGULATION OF PROTEIN STABILITY
→→ PROTEIN STABILIZATION
→ MITOTIC CELL CYCLE
→ INTERPHASE
→→ INTERPHASE OF MITOTIC CELL CYCLE
→→→ G1/S TRANSITION OF MITOTIC CELL CYCLE
→ CELLULAR LOCALIZATION
→→ ESTABLISHMENT OF CELLULAR
LOCALIZATION
→→→ EXOCYTOSIS
→→→ INTRACELLULAR TRANSPORT
→→→ PROTEIN TRANSPORT
→→→→ INTRACELLULAR PROTEIN TRANSPORT
→→→ NUCLEOCYTOPLASMIC TRANSPORT
→→→→ REGULATION OF NUCLEOCYTOPLASMIC
TRANSPORT
→ PROTEIN LOCALIZATION
→→ ESTABLISHMENT OF PROTEIN LOCALIZATION
→ NUCLEOTIDE METABOLISM
→→ NUCLEOTIDE BIOSYNTHESIS
→ CHROMOSOME ORGANIZATION & BIOGENESIS
(SENSU EUKARYOTA)
→→ ESTABLISHMENT AND/OR MAINTENANCE OF
CHROMATIN ARCHITECTURE
→ CELL-CELL ADHESION
→ INTRACELLULAR SIGNALING CASCADE
→ PROTEIN COMPLEX ASSEMBLY
→ CELL ORGANIZATION AND BIOGENESIS
→→ CELLULAR MORPHOGENESIS
→ CELL DIFFERENTIATION
→→ CELL DEVELOPMENT
→→→CELLULAR MORPHOGENESIS DURING
DIFFERENTIATION
GAMETOGENESIS
PRIMARY METABOLISM
BIOPOLYMER METABOLISM
→ BIOPOLYMER MODIFICATION
→→ PROTEIN MODIFICATION
→→→ PROTEIN AMINO ACID PHOSPHORYLATION
→→ BIOPOLYMER METHYLATION
→ DNA PACKAGING
→→ CHROMATIN ASSEMBLY OR DISASSEMBLY
→→→ NUCLEOSOME ASSEMBLY
POSITIVE REGULATION OF PHYSIOLOGICAL
PROCESS
NEGATIVE REGULATION OF ENZYME ACTIVITY
→ NEGATIVE REGULATION OF TRANSFERASE
ACTIVITY
NEGATIVE REGULATION OF PROTEIN KINASE
ACTIVITY
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List hits /
List total

Population hits /
Population total

EASE
score

15 / 210
8 / 210
199 / 210
83 / 210

348 / 10541
157 / 10541
9577 / 10541
3535 / 10541

0.0094
0.0367
0.0261
0.0469

32 / 210
10 / 210
6 / 210
3 / 210
18 / 210
12 / 210
12 / 210
11 / 210
34 / 210

1111 / 10541
217 / 10541
52 / 10541
16 / 10541
549 / 10541
304 / 10541
303 / 10541
214 / 10541
1109 / 10541

0.0313
0.0289
0.0036
0.0391
0.0454
0.0397
0.0389
0.0102
0.0112

34 / 210
7 / 210
33 / 210
30 / 210
24 / 210
14 / 210

1102 / 10541
129 / 10541
1079 / 10541
1000 / 10541
788 / 10541
386 / 10541

0.0103
0.0432
0.0131
0.0236
0.0394
0.0436

5 / 210
30 / 210
30 / 210
15 / 210
13 / 210

62 / 10541
1063 / 10541
1034 / 10541
386 / 10541
309 / 10541

0.0343
0.0471
0.0347
0.0215
0.0202

16 / 210

467 / 10541

0.0448

15 / 210
10 / 210
43 / 210
15 / 210
69 / 210
28 / 210
38 / 210
24 / 210

381 / 10541
239 / 10541
1545 / 10541
410 / 10541
2289 / 10541
815 / 10541
1382 / 10541
628 / 10541

0.0195
0.0485
0.0188
0.0336
0.0002
0.0057
0.0336
0.0032

18 / 210
18 / 210
133 / 210
67 / 210
54 / 210
50 / 210
22 / 210
9 / 210
15 / 210
7 / 210
5 / 210

407 / 10541
555 / 10541
6037 / 10541
2737 / 10541
1800 / 10541
1728 / 10541
708 / 10541
197 / 10541
390 / 10541
112 / 10541
64 / 10541

0.0030
0.0494
0.0471
0.0387
0.0014
0.0049
0.0415
0.0424
0.0233
0.0239
0.0379

32 / 210
11 / 210

1150 / 10541
236 / 10541

0.0466
0.0192

10 / 210

220 / 10541

0.0312

10 / 210

216 / 10541

0.0282

Table 6.5. Complete list of Biological Process identifiers over-represented among probe
sets significantly upregulated in aged WT mice compared to young WT mice in
Experiment A.
Biological process category identifier
SYSTEM DEVELOPMENT
→ NERVOUS SYSTEM DEVELOPMENT
→→ BRAIN DEVELOPMENT
→→ NEURON DIFFERENTIATION
→→→ NEURON DEVELOPMENT
HEART DEVELOPMENT
DEATH
→ CELL DEATH
CELL MATURATION
LOCALIZATION
→ LOCALIZATION OF CELL
→→ CELL MOTILITY
CELL ORGANIZATION AND BIOGENESIS
→ CELLULAR LOCALIZATION
→ ESTABLISHMENT OF LOCALIZATION
→→ ESTABLISHMENT OF CELLULAR
LOCALIZATION
→ PROTEIN LOCALIZATION
→→ ESTABLISHMENT OF PROTEIN LOCALIZATION
→→ TRANSPORT
→→→ VESICLE-MEDIATED TRANSPORT
→→→→ EXOCYTOSIS
→→→ PROTEIN TRANSPORT
→→→ INTRACELLULAR TRANSPORT
→→→→ INTRACELLULAR PROTEIN TRANSPORT
→→→→→ PROTEIN TARGETING
→→ SECRETION
→→→ SECRETORY PATHWAY
GROWTH
MORPHOGENESIS
→ CELLULAR MORPHOGENESIS
→→ REGULATION OF CELL SIZE
→→→ CELL GROWTH
→ MORPHOGENESIS OF AN EPITHELIUM
→ EMBRYONIC MORPHOGENESIS
TUBE DEVELOPMENT
→ TUBE MORPHOGENESIS
DETECTION OF BIOTIC STIMULUS
CELL-CELL SIGNALING
FIBROBLAST GROWTH FACTOR RECEPTOR
SIGNALING PATHWAY
PROTEIN KINASE CASCADE
AROMATIC COMPOUND METABOLISM
SULFUR COMPOUND BIOSYNTHESIS
NEGATIVE REGULATION OF BIOLOGICAL
PROCESS
→ NEGATIVE REGULATION OF PHYSIOLOGICAL
PROCESS
→ NEGATIVE REGULATION OF CELLULAR
PROCESS
→→ NEGATIVE REGULATION OF CELLULAR
PHYSIOLOGICAL PROCESS
REGULATION OF DEVELOPMENT
CELL ION HOMEOSTASIS
SENSORY PERCEPTION OF MECHANICAL
STIMULUS
LOCOMOTION
MUSCLE CONTRACTION
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List hits /
List total
28 / 167
28 / 167
11 / 167
16 / 167
14 / 167
7 / 167
27 / 167
26 / 167
9 / 167
72 / 167
19 / 167
19 / 167
55 / 167
31 / 167
72 / 167

Population hits /
Population total
1114 / 10541
1078 / 10541
319 / 10541
562 / 10541
443 / 10541
154 / 10541
1131 / 10541
1121 / 10541
249 / 10541
3265 / 10541
717 / 10541
717 / 10541
2289 / 10541
1109 / 10541
3243 / 10541

EASE
score
0.0150
0.0100
0.0293
0.0316
0.0227
0.0348
0.0307
0.0461
0.0432
0.0008
0.0331
0.0331
0.0008
0.0021
0.0007

31 / 167
28 / 167
27 / 167
62 / 167
22 / 167
8 / 167
27 / 167
29 / 167
21 / 167
18 / 167
14 / 167
12 / 167
15 / 167
36 / 167
23 / 167
13 / 167
13 / 167
11 / 167
11 / 167
11 / 167
9 / 167
4 / 167
23 / 167

1102 / 10541
1063 / 10541
1034 / 10541
2865 / 10541
621 / 10541
129 / 10541
1000 / 10541
1079 / 10541
788 / 10541
544 / 10541
457 / 10541
343 / 10541
494 / 10541
1494 / 10541
815 / 10541
396 / 10541
393 / 10541
292 / 10541
311 / 10541
285 / 10541
235 / 10541
42 / 10541
964 / 10541

0.0019
0.0084
0.0109
0.0042
0.0007
0.0042
0.0072
0.0054
0.0228
0.0053
0.0283
0.0197
0.0240
0.0093
0.0089
0.0226
0.0214
0.0171
0.0252
0.0147
0.0324
0.0281
0.0486

4 / 167
18 / 167
8 / 167
4 / 167

33 / 10541
677 / 10541
181 / 10541
51 / 10541

0.0148
0.0378
0.0243
0.0461

33 / 167

1454 / 10541

0.0294

30 / 167

1297 / 10541

0.0316

31 / 167

1366 / 10541

0.0357

30 / 167
14 / 167
10 / 167

1259 / 10541
463 / 10541
284 / 10541

0.0222
0.0310
0.0356

8 / 167
19 / 167
11 / 167

208 / 10541
726 / 10541
317 / 10541

0.0462
0.0368
0.0283

Table 6.6. Complete list of Biological Process identifiers over-represented among probe
sets significantly downregulated in aged Pdyn KO mice compared to young Pdyn
KO mice in Experiment A.
Biological process category identifier
AROMATIC COMPOUND METABOLISM
ENZYME LINKED RECEPTOR PROTEIN SIGNALING
PATHWAY
COENZYME A METABOLISM
→ COENZYME A BIOSYNTHESIS

List hits /
List total
5 / 73

Population hits /
Population total
181 / 10541

EASE
score
0.0351

9 / 73
3 / 73
3 / 73

558 / 10541
47 / 10541
46 / 10541

0.0358
0.0408
0.0393

Table 6.7. Complete list of Biological Process identifiers over-represented among probe
sets significantly upregulated in aged Pdyn KO mice compared to young Pdyn
KO mice in Experiment A.
Biological process category identifier
ANTIGEN PROCESSING
ANTIGEN PRESENTATION
→ ANTIGEN PRESENTATION, ENDOGENOUS
ANTIGEN
→→ ANTIGEN PROCESSING, ENDOGENOUS
ANTIGEN VIA MHC CLASS I
METABOLISM
→ PRIMARY METABOLISM
→→ RNA METABOLISM
→→→ RNA SPLICING
RESPONSE TO STIMULUS

List hits /
List total
3 / 46
3 / 46

Population hits /
Population total
52 / 10541
65 / 10541

EASE
score
0.0206
0.0313

3 / 46

31 / 10541

0.0077

3 / 46
35 / 46
33 / 46
8 / 46
4 / 46
19 / 46

30 / 10541
6509 / 10541
6037 / 10541
653 / 10541
181 / 10541
2723 / 10541

0.0072
0.0367
0.0399
0.0197
0.0417
0.0260

Table 6.8. Complete list of Biological Process identifiers over-represented among probe
sets significantly downregulated with Pdyn deletion in Experiment A.
Biological process category identifier
METABOLISM
→ CELLULAR METABOLISM
→→ CELLULAR BIOSYNTHESIS
→ PRIMARY METABOLISM
→ MACROMOLECULE METABOLISM
→→MACROMOLECULE BIOSYNTHESIS
→→→ PROTEIN BIOSYNTHESIS
→→ PROTEIN METABOLISM
→→ CELLULAR MACROMOLECULE METABOLISM
→→→ CELLULAR PROTEIN METABOLISM
→→→→ PROTEIN FOLDING
CELLULAR PHYSIOLOGICAL PROCESS
→ ATP SYNTHESIS COUPLED ELECTRON
TRANSPORT
→ ATP SYNTHESIS COUPLED ELECTRON
TRANSPORT (SENSU EUKARYOTA)
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List hits /
List total
88 / 118
84 / 118
24 / 118
80 / 118
64 / 118
20 / 118
18 / 118
48 / 118
46 / 118
46 / 118
8 / 118
106 / 118

Population hits /
Population total
6509 / 10541
6194 / 10541
1439 / 10541
6037 / 10541
4082 / 10541
966 / 10541
865 / 10541
3122 / 10541
2930 / 10541
2888 / 10541
244 / 10541
8620 / 10541

EASE
score
0.0026
0.0041
0.0435
0.0145
0.0006
0.0098
0.0145
0.0092
0.0077
0.0058
0.0188
0.0126

3 / 118

30 / 10541

0.0434

3 / 118

29 / 10541

0.0408

Table 6.9. Complete list of Biological Process identifiers over-represented among probe
sets significantly upregulated with Pdyn deletion in Experiment A.
List hits /
List total
24 / 149
23 / 149
16 / 149
16 / 149
15 / 149
7 / 149
18 / 149
8 / 149
14 / 149

Biological process category identifier
SYSTEM DEVELOPMENT
→ NERVOUS SYSTEM DEVELOPMENT
→ CELL DEVELOPMENT
→→ NEUROGENESIS
→→→ NEURON DIFFERENTIATION
REGULATION OF ACTION POTENTIAL
RESPONSE TO WOUNDING
CIRCULATION
GAMETOGENESIS

Population hits /
Population total
1114 / 10541
1078 / 10541
628 / 10541
605 / 10541
562 / 10541
178 / 10541
774 / 10541
178 / 10541
555 / 10541

EASE
score
0.0376
0.0464
0.0303
0.0227
0.0264
0.0394
0.0434
0.0127
0.0482

Table 6.10. Complete list of Biological Process identifiers over-represented among probe
sets significantly downregulated in young Pdyn KO mice compared to young WT
mice in Experiment A.
List hits /
List total
36 / 92

Biological process category identifier
PROTEIN METABOLISM

Population hits /
Population total
3122 / 10541

EASE
score
0.0432

Table 6.11. Complete list of Biological Process identifiers over-represented among probe
sets significantly upregulated in young Pdyn KO mice compared to young WT
mice in Experiment A.
Biological process category identifier
SYSTEM DEVELOPMENT
→ ORGAN DEVELOPMENT
→ NERVOUS SYSTEM DEVELOPMENT
→→ CENTRAL NERVOUS SYSTEM DEVELOPMENT
→→→ BRAIN DEVELOPMENT
TUBE DEVELOPMENT
→ TUBE MORPHOGENESIS
MORPHOGENESIS
→ EMBRYONIC MORPHOGENESIS
→ CELLULAR MORPHOGENESIS
→ MORPHOGENESIS OF AN EPITHELIUM
→→ MORPHOGENESIS OF EMBRYONIC
EPITHELIUM
LOCALIZATION
CELL ORGANIZATION AND BIOGENESIS
→ MEMBRANE ORGANIZATION AND BIOGENESIS
→→ MEMBRANE FUSION
→ VESICLE ORGANIZATION AND BIOGENESIS
→ CELLULAR LOCALIZATION
→ ESTABLISHMENT OF LOCALIZATION
→→ SECRETION
→ PROTEIN LOCALIZATION
→→ ESTABLISHMENT OF PROTEIN LOCALIZATION
→→ ESTABLISHMENT OF CELLULAR
LOCALIZATION
→→→ SECRETORY PATHWAY
→→ TRANSPORT
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List hits /
List total
15 / 82
21 / 82
15 / 82
11 / 82
10 / 82
7 / 82
6 / 82
22 / 82
8 / 82
12 / 82
7 / 82

Population hits /
Population total
1114 / 10541
1489 / 10541
1078 / 10541
468 / 10541
319 / 10541
285 / 10541
235 / 10541
1494 / 10541
311 / 10541
815 / 10541
292 / 10541

EASE
score
0.0434
0.0078
0.0342
0.0030
0.0007
0.0222
0.0344
0.0037
0.0098
0.0466
0.0246

6 / 82
36 / 82
31 / 82
5 / 82
5 / 82
3 / 82
20 / 82
36 / 82
9 / 82
17 / 82
16 / 82

220 / 10541
3265 / 10541
2289 / 10541
174 / 10541
96 / 10541
39 / 10541
1109 / 10541
3243 / 10541
457 / 10541
1063 / 10541
1034 / 10541

0.0270
0.0132
0.0012
0.0448
0.0063
0.0360
0.0006
0.0118
0.0238
0.0063
0.0114

20 / 82
8 / 82
33 / 82

1102 / 10541
343 / 10541
2865 / 10541

0.0005
0.0161
0.0105

Biological process category identifier
(continued from previous page)
→→→ NUCLEOBASE, NUCLEOSIDE, NUCLEOTIDE
AND NUCLEIC ACID TRANSPORT
→→→→ NUCLEIC ACID TRANSPORT
→→→ INTRACELLULAR TRANSPORT
→→→→ NUCLEOCYTOPLASMIC TRANSPORT
→→→ REGULATION OF TRANSPORT
→→→ VESICLE-MEDIATED TRANSPORT
→→→→ VESICLE FUSION
→→→→ ENDOSOME TRANSPORT
→→→→ ENDOCYTOSIS
→→→→ RECEPTOR MEDIATED ENDOCYTOSIS
→→→→→ REGULATION OF ENDOCYTOSIS
→→→→ EXOCYTOSIS
→→→ PROTEIN TRANSPORT
→→→→ INTRACELLULAR PROTEIN TRANSPORT
→→→→→ PROTEIN TARGETING
→ RNA LOCALIZATION
→→ ESTABLISHMENT OF RNA LOCALIZATION
→→→ RNA TRANSPORT
→→→→ RNA EXPORT FROM NUCLEUS
→ ACTIN FILAMENT-BASED PROCESS
→→ ACTIN CYTOSKELETON ORGANIZATION AND
BIOGENESIS
→→→ ACTIN CYTOSKELETON REORGANIZATION
SIGNAL TRANSDUCTION
→ RHO PROTEIN SIGNAL TRANSDUCTION
→ ENZYME LINKED RECEPTOR PROTEIN
SIGNALING PATHWAY
→→ TRANSMEMBRANE RECEPTOR PROTEIN
TYROSINE KINASE SIGNALING PATHWAY
→→→ EPIDERMAL GROWTH FACTOR RECEPTOR
SIGNALING PATHWAY
→→→ FIBROBLAST GROWTH FACTOR RECEPTOR
SIGNALING PATHWAY
→→ TRANSMEMBRANE RECEPTOR PROTEIN
SERINE/THREONINE KINASE SIGNALING
PATHWAY
→→→ TRANSFORMING GROWTH FACTOR BETA
RECEPTOR SIGNALING PATHWAY
→ PROTEIN KINASE CASCADE
→→ POSITIVE REGULATION OF I- B KINASE/NFB CASCADE
CELLULAR BIOSYNTHESIS
PROTEIN MODIFICATION
→ PROTEIN UBIQUITINATION
VITAMIN METABOLISM
REGULATION OF NEUROTRANSMITTER LEVELS
MUSCLE CONTRACTION
→ SMOOTH MUSCLE CONTRACTION
TELOMERASE-DEPENDENT TELOMERE
MAINTENANCE
DEATH
→ NEGATIVE REGULATION OF PROGRAMMED
CELL DEATH
→→ NEGATIVE REGULATION OF APOPTOSIS
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List hits /
List total

Population hits /
Population total

EASE
score

4 / 82
4 / 82
19 / 82
8 / 82
6 / 82
16 / 82
4 / 82
5 / 82
10 / 82
4 / 82
5 / 82
5 / 82
16 / 82
14 / 82
10 / 82
4 / 82
4 / 82
4 / 82
4 / 82
7 / 82

85 / 10541
73 / 10541
1079 / 10541
386 / 10541
217 / 10541
621 / 10541
64 / 10541
105 / 10541
334 / 10541
85 / 10541
107 / 10541
129 / 10541
1000 / 10541
788 / 10541
544 / 10541
76 / 10541
73 / 10541
73 / 10541
72 / 10541
318 / 10541

0.0275
0.0185
0.0012
0.0286
0.0256
0.0001
0.0130
0.0086
0.0010
0.0275
0.0092
0.0173
0.0085
0.0067
0.0233
0.0206
0.0185
0.0185
0.0178
0.0353

7 / 82
3 / 82
32 / 82
4 / 82

291 / 10541
35 / 10541
3032 / 10541
69 / 10541

0.0243
0.0295
0.0406
0.0159

11 / 82

558 / 10541

0.0101

7 / 82

316 / 10541

0.0344

4 / 82

98 / 10541

0.0395

3 / 82

33 / 10541

0.0264

6 / 82

250 / 10541

0.0431

4 / 82
11 / 82

98 / 10541
677 / 10541

0.0395
0.0340

5 / 82
18 / 82
21 / 82
7 / 82
4 / 82
5 / 82
7 / 82
4 / 82

178 / 10541
1439 / 10541
1728 / 10541
319 / 10541
96 / 10541
173 / 10541
317 / 10541
106 / 10541

0.0480
0.0443
0.0353
0.0358
0.0375
0.0440
0.0348
0.0480

3 / 82
15 / 82

44 / 10541
1131 / 10541

0.0448
0.0483

8 / 82
8 / 82

364 / 10541
363 / 10541

0.0216
0.0213

Table 6.12. Complete list of Biological Process identifiers over-represented among probe
sets significantly downregulated in aged Pdyn KO mice compared to aged WT
mice in Experiment A.
Biological process category identifier
DEVELOPMENT
→ MORPHOGENESIS
→→ CELLULAR MORPHOGENESIS
→→→ REGULATION OF CELL SIZE
→→→→ CELL GROWTH
NERVOUS SYSTEM DEVELOPMENT
LOCALIZATION
→ ESTABLISHMENT OF LOCALIZATION
→→ VESICLE-MEDIATED TRANSPORT
ION HOMEOSTASIS
→ CELL ION HOMEOSTASIS
CELL DIFFERENTIATION
NEGATIVE REGULATION OF BIOLOGICAL
PROCESS
→ NEGATIVE REGULATION OF CELLULAR
PROCESS
→→ NEGATIVE REGULATION OF CELLULAR
PHYSIOLOGICAL PROCESS
NEGATIVE REGULATION OF PHYSIOLOGICAL
PROCESS
AROMATIC COMPOUND METABOLISM
INTERACTION BETWEEN ORGANISMS
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List hits /
List total
55 / 142
32 / 142
19 / 142
11 / 142
11 / 142
22 / 142
55 / 142
55 / 142
15 / 142
10 / 142
9 / 142
27 / 142

Population hits /
Population total
2974 / 10541
1494 / 10541
815 / 10541
396 / 10541
393 / 10541
1078 / 10541
3265 / 10541
3243 / 10541
621 / 10541
341 / 10541
284 / 10541
1382 / 10541

EASE
score
0.0058
0.0075
0.0238
0.0397
0.0380
0.0499
0.0375
0.0332
0.0381
0.0394
0.0368
0.0437

29 / 142

1454 / 10541

0.0281

27 / 142

1366 / 10541

0.0387

25 / 142

1259 / 10541

0.0458

26 / 142
7 / 142
9 / 142

1297 / 10541
181 / 10541
298 / 10541

0.0373
0.0345
0.0466

Table 6.13. Complete list of Biological Process identifiers over-represented among probe
sets significantly upregulated in aged Pdyn KO mice compared to aged WT mice
in Experiment A.
Biological process category identifier
CELL ORGANIZATION AND BIOGENESIS
→ CELLULAR MORPHOGENESIS
CELL DEVELOPMENT
→ CELLULAR MORPHOGENESIS DURING
DIFFERENTIATION
NERVOUS SYSTEM DEVELOPMENT
→ NEUROGENESIS
→→ NEURON DIFFERENTIATION
→→→ NEURON DEVELOPMENT
→→→→ NEURON MORPHOGENESIS DURING
DIFFERENTIATION
→→→→→ NEURITE MORPHOGENESIS
→→→→→→AXONOGENESIS
→→→→→→DENDRITE MORPHOGENESIS
BLOOD VESSEL MORPHOGENESIS
G1/S TRANSITION OF MITOTIC CELL CYCLE
REGULATION OF BIOLOGICAL PROCESS
REGULATION OF PHYSIOLOGICAL PROCESS
→ REGULATION OF CELLULAR PROCESS
→→ POSITIVE REGULATION OF CELLULAR
PROCESS
→ REGULATION OF CELLULAR PHYSIOLOGICAL
PROCESS
→→ POSITIVE REGULATION OF CELLULAR
PHYSIOLOGICAL PROCESS
→ POSITIVE REGULATION OF BIOLOGICAL
PROCESS
→ POSITIVE REGULATION OF PHYSIOLOGICAL
PROCESS
→→ POSITIVE REGULATION OF METABOLISM
→→→ POSITIVE REGULATION OF CELLULAR
METABOLISM
→→→→ POSITIVE REGULATION OF
GLUCONEOGENESIS
→→→→ POSITIVE REGULATION OF NUCLEOBASE,
NUCLEOSIDE, NUCLEOTIDE & NUCLEIC
ACID METABOLISM
→→→→→ POSITIVE REGULATION OF
TRANSCRIPTION
NEGATIVE REGULATION OF ENZYME ACTIVITY

List hits /
List total
48 / 147
22 / 147
16 / 147

Population hits /
Population total
2289 / 10541
815 / 10541
628 / 10541

EASE
score
0.0020
0.0041
0.0273

14 / 147
23 / 147
16 / 147
15 / 147
14 / 147

407 / 10541
1078 / 10541
605 / 10541
562 / 10541
443 / 10541

0.0042
0.0408
0.0203
0.0238
0.0085

14 / 147
14 / 147
11 / 147
7 / 147
10 / 147
8 / 147
67 / 147
62 / 147
63 / 147

377 / 10541
377 / 10541
348 / 10541
157 / 10541
333 / 10541
214 / 10541
3907 / 10541
3524 / 10541
3535 / 10541

0.0022
0.0022
0.0228
0.0219
0.0418
0.0292
0.0257
0.0207
0.0145

29 / 147

1254 / 10541

0.0069

59 / 147

3309 / 10541

0.0195

28 / 147

1111 / 10541

0.0025

31 / 147

1400 / 10541

0.0091

28 / 147
16 / 147

1150 / 10541
598 / 10541

0.0041
0.0185

16 / 147

575 / 10541

0.0134

2 / 147

3 / 10541

0.0410

13 / 147

469 / 10541

0.0295

13 / 147
8 / 147

465 / 10541
236 / 10541

0.0278
0.0457

Table 6.14. Complete list of Biological Process identifiers over-represented among probe
sets significantly downregulated in aged Pdyn KO mice compared to aged WT
mice in Experiment B.
List hits /
List total
2 / 79

Biological process category identifier
PROTEASOME ACTIVATOR COMPLEX
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Population hits /
Population total
3 / 7111

EASE
score
0.0326

Table 6.15. Complete list of Biological Process identifiers over-represented among probe
sets significantly upregulated in aged Pdyn KO mice compared to aged WT mice
in Experiment B.
Biological process category identifier
CELL ORGANIZATION AND BIOGENESIS
→ MICROTUBULE CYTOSKELETON
ORGANIZATION AND BIOGENESIS
→ GOLGI ORGANIZATION AND BIOGENESIS
LOCALIZATION
→ ORGANELLE LOCALIZATION
→ ESTABLISHMENT OF LOCALIZATION
→→ ION TRANSPORT
→→ ESTABLISHMENT OF ORGANELLE
LOCALIZATION
MUSCLE CONTRACTION

List hits /
List total
38 / 115

Population hits /
Population total
1667 / 7176

EASE
score
0.0148

6 / 115
4 / 115
48 / 115
4 / 115
47 / 115
16 / 115

123 / 7176
50 / 7176
2265 / 7176
41 / 7176
2250 / 7176
563 / 7176

0.0457
0.0446
0.0178
0.0269
0.0253
0.0323

4 / 115
9 / 115

40 / 7176
229 / 7176

0.0252
0.0289

Table 6.16. Complete list of Molecular Function identifiers over-represented among
probe sets significantly downregulated with aging in Experiment A.
Terms used in the following tables reflect those used in the Gene Ontology Molecular
Function database. Arrows precede categories that are subsets of one or more categories
listed above them, with increasing numbers of arrows denoting more specific
categorizations. List hits and population hits are presented along with the corresponding
totals. Note that not all entries within a given probe set list are reflected in the total, since
some probe sets do not have a corresponding annotation in the ontological system.
Molecular function category identifier
STRUCTURE-SPECIFIC DNA BINDING
→ DOUBLE-STRANDED DNA BINDING
ZINC-MEDIATED TRANSCRIPTIONAL ACTIVATOR
ACTIVITY
TRANSPORTER ACTIVITY
→ ION TRANSPORTER ACTIVITY
CYTOSKELETAL PROTEIN BINDING
METALLOEXOPEPTIDASE ACTIVITY
SULFURIC ESTER HYDROLASE ACTIVITY
NUTRIENT RESERVOIR ACTIVITY

List hits /
List total
14 / 247
12 / 247

Population hits /
Population total
240 / 11005
185 / 11005

EASE
score
0.0029
0.0029

8 / 247
55 / 247
30 / 247
23 / 247
9 / 247
8 / 247
8 / 247

137 / 11005
1853 / 11005
884 / 11005
641 / 11005
174 / 11005
137 / 11005
146 / 11005

0.0340
0.0212
0.0234
0.0297
0.0416
0.0340
0.0455

Table 6.17. Complete list of Molecular Function identifiers over-represented among
probe sets significantly upregulated with aging in Experiment A.
Molecular function category identifier
PROTEIN BINDING
ANTIGEN BINDING
ENZYME INHIBITOR ACTIVITY
STRUCTURAL CONSTITUENT OF RIBOSOME
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List hits /
List total
134 / 241
6 / 241
14 / 241
11 / 241

Population hits /
Population total
5244 / 11005
65 / 11005
287 / 11005
244 / 11005

EASE
score
0.0089
0.0135
0.0102
0.0413

Table 6.18. Complete list of Molecular Function identifiers over-represented among
probe sets significantly downregulated in aged WT mice compared to young WT
mice in Experiment A.
Molecular function category identifier
PROTEIN TRANSPORTER ACTIVITY
BINDING
→ PROTEIN BINDING
→→ PHOSPHOPROTEIN BINDING
→→→ PROTEIN PHOSPHORYLATED AMINO ACID
BINDING
→→ CYTOSKELETAL PROTEIN BINDING
→→ SNARE BINDING
→ SEQUENCE-SPECIFIC DNA BINDING
→ STRUCTURE-SPECIFIC DNA BINDING
→ ZINC ION BINDING
LIGASE ACTIVITY
→ LIGASE ACTIVITY, FORMING CARBONNITROGEN BONDS
→→ CTP SYNTHASE ACTIVITY
LYASE ACTIVITY
KINASE REGULATOR ACTIVITY
→ PROTEIN KINASE REGULATOR ACTIVITY
→→ CAMP-DEPENDENT PROTEIN KINASE
REGULATOR ACTIVITY

List hits /
List total
10 / 212
182 / 212
119 / 212
6 / 212

Population hits /
Population total
162 / 11005
8519 / 11005
5244 / 11005
56 / 11005

EASE
score
0.0040
0.0014
0.0092
0.0043

4 / 212
20 / 212
4 / 212
18 / 212
10 / 212
40 / 212
23 / 212

40 / 11005
641 / 11005
43 / 11005
544 / 11005
240 / 11005
1546 / 11005
652 / 11005

0.0408
0.0389
0.0490
0.0324
0.0417
0.0418
0.0070

15 / 212
2 / 212
9 / 212
8 / 212
7 / 212

403 / 11005
2 / 11005
205 / 11005
149 / 11005
102 / 11005

0.0232
0.0380
0.0438
0.0246
0.0136

3 / 212

17 / 11005

0.0412

Table 6.19. Complete list of Molecular Function identifiers over-represented among
probe sets significantly upregulated in aged WT mice compared to young WT
mice in Experiment A.
Molecular function category identifier
ION BINDING
→ METAL ION BINDING
→ CATION BINDING
→→ CALCIUM ION BINDING
ACTIN BINDING
RECEPTOR SIGNALING COMPLEX SCAFFOLD
ACTIVITY
RHO GTPASE BINDING
GUANYL-NUCLEOTIDE EXCHANGE FACTOR
ACTIVITY

List hits /
List total
63 / 177
63 / 177
59 / 177
35 / 177
11 / 177

Population hits /
Population total
2881 / 11005
2881 / 11005
2668 / 11005
988 / 11005
314 / 11005

EASE
score
0.0047
0.0047
0.0053
<0.0001
0.0294

5 / 177
4 / 177

65 / 11005
28 / 11005

0.0201
0.0098

6 / 177

122 / 11005

0.0460

Table 6.20. Complete list of Molecular Function identifiers over-represented among
probe sets significantly downregulated in aged Pdyn KO mice compared to young
Pdyn KO mice in Experiment A.
List hits /
List total
2 / 74
5 / 74
5 / 74
5 / 74

Molecular function category identifier
TRIPEPTIDYL-PEPTIDASE I ACTIVITY
PROTEIN TRANSPORTER ACTIVITY
ALKALI METAL ION BINDING
→ POTASSIUM ION BINDING
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Population hits /
Population total
2 / 11005
162 / 11005
168 / 11005
106 / 11005

EASE
score
0.0132
0.0225
0.0253
0.0053

Table 6.21. Complete list of Molecular Function identifiers over-represented among
probe sets significantly upregulated in aged Pdyn KO mice compared to young
Pdyn KO mice in Experiment A.
Molecular function category identifier
LIGASE ACTIVITY
→ LIGASE ACTIVITY, FORMING CARBONNITROGEN BONDS
MHC CLASS I RECEPTOR ACTIVITY
BINDING
→ PROTEIN BINDING
→ RNA BINDING

List hits /
List total
9 / 48

Population hits /
Population total
652 / 11005

EASE
score
0.0059

6 / 48
3 / 48
43 / 48
31 / 48
9 / 48

403 / 11005
30 / 11005
8519 / 11005
5244 / 11005
772 / 11005

0.0279
0.0072
0.0297
0.0186
0.0155

Table 6.22. Complete list of Molecular Function identifiers over-represented among
probe sets significantly downregulated with Pdyn deletion in Experiment A.
Molecular function category identifier
STRUCTURAL CONSTITUENT OF RIBOSOME
OXIDOREDUCTASE ACTIVITY, ACTING ON
DIPHENOLS AND RELATED SUBSTANCES
AS DONORS
→ OXIDOREDUCTASE ACTIVITY, ACTING ON
DIPHENOLS AND RELATED SUBSTANCES
AS DONORS, CYTOCHROME AS ACCEPTOR
MONOVALENT INORGANIC CATION
TRANSPORTER ACTIVITY
→ HYDROGEN ION TRANSPORTER ACTIVITY
→→ UBIQUINOL-CYTOCHROME-C REDUCTASE
ACTIVITY
NUCLEIC ACID BINDING
→ RNA BINDING
RAN GTPASE BINDING
UNFOLDED PROTEIN BINDING

List hits /
List total
12 / 123

Population hits /
Population total
244 / 11005

EASE
score
0.0001

3 / 123

12 / 11005

0.0075

3 / 123

12 / 11005

0.0075

8 / 123
8 / 123

280 / 11005
274 / 11005

0.0361
0.0327

3 / 123
42 / 123
22 / 123
3 / 123
8 / 123

12 / 11005
2711 / 11005
772 / 11005
20 / 11005
196 / 11005

0.0075
0.0157
0.0001
0.0203
0.0061

Table 6.23. Complete list of Molecular Function identifiers over-represented among
probe sets significantly upregulated with Pdyn deletion in Experiment A.
Molecular function category identifier
ANTIGEN BINDING
HYDROLASE ACTIVITY, ACTING ON ESTER BONDS
GUANYL NUCLEOTIDE BINDING
TRANSFERASE ACTIVITY, TRANSFERRING
PHOSPHORUS-CONTAINING GROUPS
CYSTEINE-TYPE ENDOPEPTIDASE ACTIVITY

List hits /
List total
5 / 151
19 / 151
11 / 151

Population hits /
Population total
65 / 11005
766 / 11005
375 / 11005

EASE
score
0.0118
0.0163
0.0324

24 / 151
9 / 151

1141 / 11005
289 / 11005

0.0357
0.0441

Table 6.24. Complete list of Molecular Function identifiers over-represented among
probe sets significantly downregulated in young Pdyn KO mice compared to
young WT mice in Experiment A.
Molecular function category identifier
CALCIUM- AND CALMODULIN-DEPENDENT
PROTEIN KINASE ACTIVITY
LIGASE ACTIVITY, FORMING CARBON-NITROGEN
BONDS
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List hits /
List total

Population hits /
Population total

EASE
score

3 / 91

19 / 11005

0.0103

8 / 91

403 / 11005

0.0467

Table 6.25. Complete list of Molecular Function identifiers over-represented among
probe sets significantly upregulated in young Pdyn KO mice compared to young
WT mice in Experiment A.
List hits /
List total
3 / 92
16 / 92
4 / 92
10 / 92
6 / 92
8 / 92
5 / 92
7 / 92
8 / 92
12 / 92
4 / 92

Molecular function category identifier
RHO GTPASE BINDING
CALCIUM ION BINDING
COPPER ION BINDING
CARBOHYDRATE BINDING
→ SUGAR BINDING
ACTIN BINDING
PROTEIN BINDING, BRIDGING
PATTERN BINDING
PROTEIN-TYROSINE KINASE ACTIVITY
OXIDOREDUCTASE ACTIVITY
EXONUCLEASE ACTIVITY

Population hits /
Population total
28 / 11005
988 / 11005
93 / 11005
468 / 11005
229 / 11005
314 / 11005
146 / 11005
301 / 11005
392 / 11005
752 / 11005
99 / 11005

EASE
score
0.0222
0.0150
0.0417
0.0151
0.0411
0.0151
0.0327
0.0383
0.0434
0.0453
0.0486

Table 6.26. Complete list of Molecular Function identifiers over-represented among
probe sets significantly downregulated in aged Pdyn KO mice compared to aged
WT mice in Experiment A.
Molecular function category identifier
ION BINDING
→ METAL ION BINDING
→ CATION BINDING
→→ CALCIUM ION BINDING
→→ POTASSIUM ION BINDING
RECEPTOR SIGNALING COMPLEX SCAFFOLD
ACTIVITY
GUANYL-NUCLEOTIDE EXCHANGE FACTOR
ACTIVITY
TRANSPORTER ACTIVITY
TRIPEPTIDYL-PEPTIDASE I ACTIVITY

List hits /
List total
52 / 147
52 / 147
48 / 147
29 / 147
6 / 147

Population hits /
Population total
2881 / 11005
2881 / 11005
2668 / 11005
988 / 11005
106 / 11005

EASE
score
0.0115
0.0115
0.0175
0.0001
0.0133

5 / 147

65 / 11005

0.0108

6 / 147
34 / 147
2 / 147

122 / 11005
1853 / 11005
2 / 11005

0.0231
0.0427
0.0264

Table 6.27. Complete list of Molecular Function identifiers over-represented among
probe sets significantly upregulated in aged Pdyn KO mice compared to aged WT
mice in Experiment A.
Molecular function category identifier
BINDING
→ PROTEIN BINDING
→→ CYTOSKELETAL PROTEIN BINDING
→→ PROTEIN DIMERIZATION ACTIVITY
→→ PHOSPHOPROTEIN BINDING
→→ TRANSCRIPTION COACTIVATOR ACTIVITY
→ PEPTIDE BINDING
→ SEQUENCE-SPECIFIC DNA BINDING
→ STRUCTURE-SPECIFIC DNA BINDING
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List hits /
List total
133 / 149
88 / 149
18 / 149
13 / 149
4 / 149
11 / 149
9 / 149
16 / 149
9 / 149

Population hits /
Population total
8519 / 11005
5244 / 11005
641 / 11005
523 / 11005
56 / 11005
401 / 11005
214 / 11005
544 / 11005
240 / 11005

EASE
score
0.0002
0.0040
0.0056
0.0493
0.0394
0.0441
0.0083
0.0064
0.0157

Table 6.28. Complete list of Molecular Function identifiers over-represented among
probe sets significantly downregulated in aged Pdyn KO mice compared to aged
WT mice in Experiment B.
Molecular function category identifier
PROTEIN KINASE C BINDING
PROTEASOME ACTIVATOR ACTIVITY
NADH DEHYDROGENASE ACTIVITY
→ NADH DEHYDROGENASE (QUINONE) ACTIVITY
→→ NADH DEHYDROGENASE (UBIQUINONE)
ACTIVITY
SODIUM ION TRANSPORTER ACTIVITY

List hits /
List total
3 / 79
2 / 79
3 / 79
3 / 79

Population hits /
Population total
26 / 7363
3 / 7363
33 / 7363
33 / 7363

EASE
score
0.0306
0.0314
0.0473
0.0473

3 / 79
3 / 79

33 / 7363
34 / 7363

0.0473
0.0500

Table 6.29. Complete list of Molecular Function identifiers over-represented among
probe sets significantly upregulated in aged Pdyn KO mice compared to aged WT
mice in Experiment B.
Molecular function category identifier
TRANSPORTER ACTIVITY
→ ION TRANSPORTER ACTIVITY
→ CHANNEL OR PORE CLASS TRANSPORTER
ACTIVITY
→→ ALPHA-TYPE CHANNEL ACTIVITY
→→→ ION CHANNEL ACTIVITY
→→→→ VOLTAGE-GATED ION CHANNEL
ACTIVITY
PROTEIN BINDING
→ PROTEIN DOMAIN SPECIFIC BINDING
→ DYNEIN BINDING

List hits /
List total
29 / 117
16 / 117

Population hits /
Population total
1277 / 7363
575 / 7363

EASE
score
0.0380
0.0357

14 / 117
14 / 117
14 / 117

377 / 7363
364 / 7363
346 / 7363

0.0062
0.0046
0.0030

8 / 117
70 / 117
8 / 117
4 / 117

176 / 7363
3732 / 7363
190 / 7363
41 / 7363

0.0208
0.0343
0.0301
0.0263

Copyright © Xuan V. Nguyen 2007

114

CHAPTER 7:

Discussion and Conclusions

Summary of effects of aging and Pdyn deletion
Behavioral effects
Aging produced a significant decrease in water maze performance, with mild decreases in
movement speed in both the water maze and open-field experiments and increased
stereotypical behavior in open-field analyses. The effects of Pdyn deletion on learning
and memory observed in this dissertation include relative sparing of age-related
impairment in spatial navigational memory and a subtle enhancement of passive
avoidance retention in young mice, with minimal effect on object recogntion.

No

significant age-associated deficits in performance were noted in the object recognition
and passive avoidance tasks of this study.
It is noteworthy that both of the learning and memory assays in which Pdyn
deletion confers a beneficial effect are tasks in which performance is driven in large part
by a response to an aversive stimulus in contrast to the relative neutral stimuli required
for object recognition. A likely interpretation of these findings is that Pdyn-derived
peptides alter the subject's reward or motivational response, possibly in addition to any
direct inhibitory effects of dynorphins on hippocampal neurotransmission previously
reported (Drake et al., 1994; Terman et al., 1994). Consistent with known effects of
dopamine and dynorphin in reward pathways (Carlezon et al., 1998; Hurd et al., 1999;
Zhang et al., 2004b), our data on dopamine alterations in Pdyn KO mice support such a
role of dynorphins. In the object recognition experiments, Pdyn deletion produces a
relative avoidance of novel objects, despite demonstrating slightly increased total
exploratory behavior following introduction of a new object. Spontaneous locomotor
activity in the open-field assay was also mildly elevated in male Pdyn KO mice in
relation to the average activity of other groups of mice tested, arguing in favor of
differentially regulated arousal or motivational processes in these mice. These behavioral
changes are likely influenced by significant elevations in striatal dopamine content, such
as those noted in aged Pdyn KO mice.
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Molecular changes
A major finding of this dissertation was the markedly enhanced striatal dopamine in aged
Pdyn KO mice, while aging alone in WT mice produced no significant changes in
dopamine. With evidence of increased phosphorylation of TH at Ser40 in Pdyn KO
mice, it is reasonable to conclude that dynorphin peptides, through mechanisms that have
not yet been fully delineated, suppress dopamine synthesis via modulation of TH activity.
Aging also was associated with altered dynorphin expression, with declines in Dyn B in
striatum and frontal cortex, while Dyn A showed a tendency to increase with age in
frontal cortex. These findings may account for some of the age dependence noted in the
behavioral functional comparisons between WT and Pdyn KO mice.
Moreover, the patterns of hippocampal gene expression from the microarray
experiments suggest that aged Pdyn KO mice are metabolically and transcriptionally
more active than aged WT mice, with increased expression of genes involved in neuronal
development and basic cellular processes. Furthermore, calcium binding and transport
appears to be an important downstream consequence of Pdyn deletion based on
microarray gene expression results.

This observation leads to the conclusion that

prolonged suppression of dynorphin may induce significant changes in calcium
regulation and other neuronal processes, including dopamine synthesis, which may
significantly enhance neurotransmission within the parts of the brain where dynorphin is
prevalent, such as striatum and hippocampus.

Role of dynorphins in MPTP neurotoxicity
In the data reported in the preceding chapters, MPTP induced decreases in locomotor
activity that was ameliorated by Pdyn deletion or heterozygosity, but in a separate
experiment on dopamine quantitation, Pdyn deletion conferred no protection against
MPTP-induced dopamine depletion despite the finding that dopamine was elevated in
Pdyn KO mice in an age-dependent manner. These results suggest that although certain
Pdyn-derived peptides can demonstrate direct neurotoxicty in various experimental
situations (Hauser et al., 1999; Goody et al., 2003; Singh et al., 2003), their absence does
not protect against striatal neurotoxicity by MPTP. Interestingly, in the acute phase of
MPTP injury, striatal dynorphin peptides are increased but eventually return to below
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pre-injection levels, likely as a consequence of subsequently decreased dopaminergic
tone. Our results showing improved post-MPTP open-field activity in Pdyn KO mice in
the absence of elevated dopamine are consistent with presumed effects of residual
dynorphins on dopaminergic activity beyond that of maintaining total striatal dopamine
content.

A working model for the role of dynorphins in aging
Early observations on the ability of dynorphins to antagonize morphine-induced analgesia
in opiate-dependent subjects while potentiating it in opiate-naïve subjects have led to the
proposal that dynorphins act in a modulatory capacity (Smith and Lee, 1988). The results
of the preceding chapters support such a role of physiological quantities of dynorphins,
and, in an attempt to establish a working model to explain our findings, we propose the
following framework to explain the role of dynorphins. In the proposed model, basal
dynorphinergic input is needed to maintain striatal dopaminergic activity within normal
functional levels (Steiner and Gerfen, 1998) and to prevent excessive synaptic excitability
in hippocampus (Simonato and Romualdi, 1996; Loacker et al., 2007), physiological
functions which are necessary for homeostasis and have ample evolutionary advantages.
In the Pdyn KO mice characterized in this dissertation, the absence of these basal
regulatory functions of dynorphins may be offset by appropriate counter-regulatory
elements. In young adult mice, these compensatory mechanisms may be sufficient to
mask functional effects of Pdyn deletion.

However, with advanced age, these

mechanisms may be inadequate, resulting, for instance, in elevations in dopamine as
noted in the preceding chapters.
The elevated dopamine may be sufficient to produce increased motivational drive,
increased alertness, or increased learning and memory functioning as manifested in the
relative amelioration of age-related water maze performance impairment in the aged
Pdyn KO relative to aged WT mice. The absence of similar Pdyn effects among aged
mice in the other learning and memory paradigms could be explained by the relatively
greater reward and motivational component present in the water maze task. Dynorphin
peptides are an important component in the biological mechanisms of reward, as
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supported by studies in which upregulation of prodynorphin by overexpressing CREB
substantially decreases the rewarding effects of cocaine (Carlezon et al., 1998).
In addition to the tonic dynorphinergic effect, there is likely another role of
dynorphins in which Pdyn expression is inducible following various types of neuronal
injury (Iadarola et al., 1986; Thai et al., 1996; Simpson et al., 1997; Zhang et al., 2004a).
The short-term increases in dynorphin expression following a neurotoxic injury by MPTP
in our studies raise the possibility that immediate-early genes activated during various
neurologic stressors (Naranjo et al., 1991; Noguchi et al., 1991; Bronstein et al., 1994;
Hunter et al., 1995) could induce episodic expression of supraphysiological levels of
dynorphins. Our findings that aging increases the amount of Dyn A relative to Dyn B
may indicate alterations in prodynorphin processing that favor the more neurotoxic Dyn
A product (Hauser et al., 2005). While the episodic dynorphin upregulation may provide
protective effects under some circumstances (Przewlocka et al., 1983; Simonato and
Romualdi, 1996; Liu et al., 2001; Loacker et al., 2007), such as anticonvulsant activity
during seizures or traumatic injury, the increased likelihood of direct neurotoxic or proexcitotoxic effects, mostly mediated by non-opioid mechanisms (Hauser et al., 2005),
may over time lead to repetitive injury that may manifest as worsening of cognitive
impairment.

Potential areas of further inquiry
One topic that was not directly addressed by this series of experiments is the potential
differences in activity and mechanisms of action among the prodynorphin-derived
peptides.

The knockout model, while effectively suppressing expression of the

preprodynorphin precursor, does not address the potential differences between Dyn A,
Dyn B, Dyn-32, and multiple other peptide derivatives of prodynorphin. Previous studies
have demonstrated significant variations in the biological effects and relative
concentrations of the different Pdyn-derived peptides in various physiological and
pathological states [reviewed in (Hauser et al., 2005)]. Given the discordant expression
profiles of Dyn A and B during aging seen in the WT mice of this study, further
characterization of the mechanisms controlling post-translational processing of the Pdyn
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gene product would be needed to supplement existing data on dynorphin peptide and
mRNA quantitation.
While the experiments described in this dissertation require no assumption
regarding the type of receptor through which any of the observed findings are mediated,
it would be interesting to assess whether similar observations may be made in

opioid

receptor knockout mice. Such studies, in conjunction with the results presented here,
may help elucidate the extent to which the observed Pdyn deletion effects are due to
opioid-mediated mechanisms.

Additional mechanistic studies will also be needed to

dissect the components of the cellular pathways in which dynorphins interact during
aging or neurotoxic injury.

Extrapolation to human disease
The findings of this dissertation may also be evaluated in the context of existing evidence
of dynorphins in specific human disorders. Information of potential clinical relevance to
human disease has been obtained by laboratory or pathological investigations in patients
with specific neurological disorders such as Alzheimer's disease (AD) or Parkinson's
disease (PD). One of the earliest studies of dynorphins in AD reported a 40% decline in
Dyn A(1-8) levels in cerebrospinal fluid (CSF) compared to age-matched controls
(Sunderland et al., 1991).

However, increased levels of Dyn A were later reported in

frontal cortex (Risser et al., 1996) and parietal cortex (Yakovleva et al., 2006a) in AD
patients post-mortem, with no similar increase observed for Dyn B (Yakovleva et al.,
2006a). Another study reported that Pdyn mRNA expression is decreased with aging, but
no differences were noted between normally aged subjects and PD patients (Backman et
al., 2007). Dynorphin peptide levels in most studies were similarly unchanged in various
brain regions and in CSF of Parkinson's disease patients compared to controls (Taquet et
al., 1985; Baronti et al., 1991; Yakovleva et al., 2006a), although one study of PD
patients reported a decline in dynorphin-like immunoreactivity in substantia nigra but not
basal ganglia (Waters et al., 1988). In addition, neither aging alone nor L-dopa therapy
induced any change in Dyn A in CSF in one clinical study (Baronti et al., 1991).
The complexity of the aging process and the heterogeneity of subject populations,
in addition to published reports of inconsistencies between animal and human studies
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(Baronti et al., 1991), make it challenging to identify consistent trends in dynorphin
expression. The studies presented in this dissertation involve exclusively the 129SvEv
mouse strain. As presented in the preceding chapters, Dyn A shows some evidence of
upward trend with age in striatum and frontal cortex of WT mice, but Dyn B exhibits an
age-dependent decline. Strain- and species-specific differences may render it difficult to
generalize these findings to other rodents or to primates.
Nonetheless, many results from animal studies have been replicated in the few
clinical trials involving direct administration of dynorphins or related agents. Although
few studies directly address the effects of pharmacologically applied dynorphins in
cognition or motor function in human subjects, dynorphins have been evaluated with a
broad array of other endpoints. Intravenous Dyn A(1-13) infusion in healthy human
subjects produces mild, transient mood and euphoric effects (King et al., 1999) and has
varying efficacy in opiate withdrawal (Greenwald et al., 1997; Specker et al., 1998). A
dynorphin A derivative has also been found to be effective in treatment of post-herpetic
neuralgia (Wallace et al., 2006).

In addition, an earlier trial reported dose-limiting

adverse behavioral effects when administering the

agonist spiradoline to Parkinson’s

disease patients (Giuffra et al., 1993) without effects on motor symptoms. Prodynorphinderived peptides have also been noted to exhibit endocrine effects in healthy humans.
Dyn A(1-13) was found to increase prolactin (Kreek et al., 1999; Bart et al., 2003), and a
dynorphin analogue was noted to inhibit vasopressin (Ohnishi et al., 1994), consistent
with findings in rodent studies. These studies support the contention that many of the
major properties of dynorphin peptides discovered in animal studies will likely be
generalizable to humans. However, the existing clinical literature unfortunately offers
little data on effects of dynorphinergic activity or suppression during normal aging in
humans.
While the results of this dissertation addressing memory and motor effects of
Pdyn deletion are felt to be relevant to disorders such as Alzheimer’s and Parkinson’s
disease, the potential applicability of further research on dynorphins is clearly not limited
to aging-associated disorders. The role of dynorphinergic input on dopamine levels and
its potential effects on reward pathways have significant implications for the
pathophysiology of addiction, which has been aptly described as a maladaptive
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interaction of reward pathways and learning mechanisms (Hyman, 2005).

The

prevalence of addictive behavior and its effect of health care costs confirm the potential
significance of the reward-mediating actions of dynorphins in human disease. While
further research is needed to address the mechanisms involved and to further characterize
the effects of dynorphins on human disease, the results of this dissertation support an
important role of dynorphins in age-related memory impairment and in modulation of the
nigrostriatal dopaminergic system. Further research into the roles dynorphins play in the
processes discussed in this dissertation would be helpful in assessing the applicability and
appropriateness of potential clinical interventions.

Copyright © Xuan V. Nguyen 2007
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